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The Relationship between Vertigo,Vestibular
System Disorders, and Therapy
Etta Rubin
Etta Rubin graduated in june 2018 with a b.s. degree in biology and is currently attending the physical therapy
program at Hunter College

Abstract
The relationship between vertigo and vestibular system disorders has been the subject of much research in recent years.The aim
of this study is to review and analyze the relevant literature regarding this relationship, with emphasis on determining what causes
the dizziness, how to test for vertigo, and specifically how to treat it. Additionally, while there may be many ways to prevent vertigo,
the focus will be on how the role of therapy is vital in the future of healthcare, serving as prevention of anxiety and reoccurring
vestibular disorders.
Introduction
About forty percent of Americans, will at some point of their
lives have a balance problem that is disturbing enough that they
consult a doctor, according to the National Institute of Health
(Better Balance, 2017). Symptoms of dizziness from seasickness,
fear of heights, or alcohol consumption were mentioned as
early as 730 BC in Roman, Greek, and Chinese texts. However,
due to the lack of scientific evidence at that time, an explanation for this dizziness was not present until mid-19th century
scientists began to study the somewhat camouflaged vestibular
system and research its possible correlations to vertigo. There
are different forms of treatment available for vertigo and vestibular disorders. This review will investigate and determine which
form of treatment is the most effective for treating vertigo and
vestibular disorders.

Methods
The information gathered in this paper has been collected
from numerous sources including databases such as PUBMED,
Google Scholar,Touro Library, and Nature.com.The information
was read, analyzed and compared to determine each study’s validity and standpoint.

Discussion: Defining the Vestibular System
One’s balance system helps one stand, walk, run, and move without falling.The eyes, inner ear, and body’s muscles and tendons coordinate with the brain, which help one control balance (Tamaki,
2016). Together the organs that control or sense the signals
throughout the body are known as the vestibular system. The
vestibular apparatus found in the inner ear of humans, provides a
sense of balance and awareness of spatial orientation. It is made
up of three semicircular canals, anterior, posterior, and lateral, that
are sensitive to angular accelerations (head rotations: up-down,
side to side, and tilting movements). It also includes two labyrinth
organs, the utricle and the saccule, that are sensitive to linear
(or straight-line) accelerations by sensing gravity (Tamaki, 2016).
Information from the vestibular organs of each ear, the eyes, and
the rest of the body are then integrated in the brain.
The semicircular canals originate from the utricle and are
positioned at a 90° angle from one another, with the horizontal canal tipped backwards 20-30 degrees (Figure 2). They are
filled with endolymphatic fluid which exerts pressure against
the 10–50 micrometer stereocilia, the canal’s sensory hair cell

receptors (Better Balance, 2017). Calcium carbonate crystals
called otoconia are attached to both the medial wall of the
saccule and floor of the utricle. Thus, under the influence of
acceleration of a car, for example, it can cause stimulation of the
hair cells by their movement relative to the endolymphatic fluid.
The receptors respond by sending impulses to the brain about
movement from the specific canal that was stimulated. When
the vestibular organs on both sides of the head are functioning
properly, they send symmetrical impulses to the brain and let
the brain know that the car has accelerated.
Additionally, the Vestibulocochlear Nerve, also known as
Cranial Nerve VIII, is responsible for a human’s sense of hearing
and equilibrium (Patel et. al., 2017). It transmits balance-related information from the semicircular canals and the labyrinth
organs to the central nervous system. The superior portion of
the nerve innervates anterior and horizontal canals and utricle,
while the inferior portion innervates posterior canal and saccule. When, for example, a rotational head movement occurs, it
causes the fluid in the semicircular canals to move which causes
the stereocilia in the saccule, utricle, and the cristae of the semicircular canals to bend. When the hair cells bend, they exert a
mechanical force into electrical nerve action potentials stimulating cranial nerve VIII. However, if one is jumping up and down,
descending in an elevator, or accelerating on the highway, the
two labyrinth organs of each ear are activated. Consequently, it
causes the fluid in the labyrinth organs to move, while otoconia,
the calcium carbonate crystals, lag behind. The lagging behind of
the otoconia causes hair cells in the labyrinth organs to bend,
and the bending of the hair cells stimulates cranial nerve VIII as
well. Through the help of the cochlea and the vestibular apparatus, cranial nerve VIII sends messages from the inner ear to
the central nervous system to empower the body’s sensation of
hearing and balance (Gill-Body, 2001).

History of Vertigo
Descriptions of vertigo and dizziness as a result of seasickness,
fear of heights, and alcohol consumption were found in Roman,
Greek, and Chinese texts as early as 730BC –600CE (Huppert
et al, 2018). One of the earliest references to vertigo and the
idea of dizziness in relation to fear of heights is found from
the 5th century BC in the Hippocratic Corpus. In a collection
of around 60 early Ancient Greek medical works strongly associated with the physician Hippocrates and his teachings, the
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Hippocratic Corpus uses Latin keywords of vertigo such as
caligo, caligare, altitudo, magnitudo, and celsitudo, describing relationship between heights and dizziness (Huppert et al, 2013).
During the sixteenth century the middle ear was described
in detail and further progress was made between the sixteenth
and eighteenth century in describing the inner ear.
Knowledge of the vestibular system and its functions began to
grow with nineteenth century scientists such as Jan Evangelista
Purkinje, Ernst Mach, Josef Breuer, Hermann Helmholtz, and
Alexander Crum-Brown (Huppert et al, 2018). The first textbook on neurology (Lehrbuch der Nervenkrankheiten des
Menschen, 1840) by Moritz Romberg contained general descriptions of signs and symptoms of various conditions with the
key symptom of vertigo, but lacked a definition of vestibular
disorders. However, in the nineteenth century technological advancement permitted a description of the cells and structures
that constituted the cochlea. Von Helmholtz made progress in
hearing physiology when he postulated his resonance theory,
and later Von Békésy made progress as well when he observed
a traveling wave within the cochlea of human cadavers. Brownell
later made a major advance when he discovered that the ear
has a mechanism for sound amplification, via outer hair cell electromotility (Hachmeister, 2003).

Vertigo as a Symptom
Vertigo and dizziness are among the most common complaints
in neurology clinics. They account for about 13% of patients entering emergency units and are reported as the third most common major medical symptom in general medical clinics (Brandt,
Dieterich, 2017).
Dizziness and vertigo are complex neurological symptoms,
traditionally categorized as one of four “types” based on symptom quality: (1) vertigo, an illusion of spinning or motion, (2)
presyncope, feeling faint, (3) disequilibrium, a loss of balance or
equilibrium when walking, and (4) lightheadedness, wooziness,
and giddiness, etc. (Newman-Toker, 2007).
Vertigo is a symptom, not necessarily a disease, but it is an
outcome of a physiological or uncontrolled processes, characterized by sudden dizzy spells causing a lot of discomfort (Srinivasan,
Jebasingh, 2007).Vertigo is often caused by an inner ear problem.
The sensations from the inner ear, eyes, and throughout the body
(somatosensory) are mismatched. Humans need the above three
to regulate their balance (Better Balance, 2012). Any abnormality
in one or more of these can trigger vertigo.
Vertigo can also be caused by decreased blood supply to certain
areas of the brain. This can follow mini-strokes called transient
ischemic attacks (TIAs) or can happen as a result of a permanent
stroke (Seiden, 1989). Similarly, head trauma, even a minor blow
to the head, is a risk factor to cause vertigo (Naguib et al, 2012).
There are different types of vertigo. Rotatory vertigo mimics
the sensation of being on a merry-go-round, like in vestibular
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neuritis and other disorders, while postural vertigo resembles
the sensation of riding in a boat.Yet many patients use the term
“dizziness” for lightheadedness without any sensation of movement (e.g., in drug intoxication). Lightheadedness is the most
common type of vertigo; it mainly affects older patients and it is
characterized by brief attacks of rotational vertigo, accompanied
by vertical positioning nystagmus that rotates toward the lower
of the two ears and beats toward the forehead. The attacks are
triggered by reclining the head, or by lateral positioning of the
head or body, with the affected ear downward. After a change in
position of one of these types, rotational vertigo and nystagmus
arise after a latency of a few seconds and last a total of 30 to 60
seconds (Strupp, Brandt, 2008).

Importance of Treating Vertigo
According to news from Munich, Germany by NewsRx editors,
research states, “Vertigo and dizziness are among the most
common complaints in neurology clinics, and they account for
about 13% of the patients entering emergency units (Nervous
system diseases and conditions, 2017). “Some vertigo is so violent a person can’t get out of bed, sometimes for several days at
a time.They can’t hold a job or take care of the family or just be
with the family. Some balance problems can be very debilitating,”
says Browning, a certified clinical audiologist at Rocky Mountain
Hearing and Balance in Salt Lake City (Collins, 2007)
The NIH also reports that balance-related falls cause more
than half of the accidental deaths among the elderly. About forty
percent of people over age sixty five fall each year, totaling more
than thirteen million falls a year, resulting in at least 1,600 senior
citizens’ deaths as a direct or indirect result of falls (Collins, 2007).
Dysfunction of the vestibular system in humans can be severe
and extremely debilitating, leading one to become housebound
and lead a very restricted life, with high rates of anxiety disorders and depression. In the United States of America, approximately 35% of people aged 40 and over have suffered from
some form of vestibular dysfunction [based on a sample of
5,086] (Smith, 2017).

Vestibular Disorders and Vertigo
Humans can become disoriented if different sensory input received from their eyes, muscles, tendons, or vestibular organs
conflict (Brennan, 2012). For example, Physiological vertigo is
Vertigo while in moving vehicles, colloquially known as motion
sickness. This is due to a “sensory conflict” between one’s vision and the actual movement sensation. In motion sickness,
it is caused by multi-sensory motions that do not correlate to
the expected pattern of movement. Many feel better sitting in
the front seat of the car or bus as it gives them more visual
input than at the back seat. These individuals are encouraged
to keep their eyes open as this will let the brain gain more
information of the movement of the vehicle and decrease the
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vertigo. Additionally, signal conflicts may occur when a person is
standing next to a bus that is pulling away from the sidewalk.The
visual image of the large moving bus may create an illusion for
the pedestrian that he, rather than the bus, is moving. However,
at the same time the information from his muscles and joints indicates that he is not actually moving. Sensory information provided by the vestibular organs helps override sensory conflicts
(Bedford, 2012). In addition, higher level thinking and memory
might suggest the person to glance away from the moving bus
to look down in order to seek visual confirmation that his body
is not moving relative to the pavement.
One of the most commonly diagnosed vestibular disorders
is Benign Paroxysmal Positional Vertigo, also known as BPPV
(Smith, 2017). BPPV is a mechanical problem in the inner ear
that is the most frequent cause of dizziness. It occurs when a
tiny crystal of calcium breaks free from the wall of one of the
semi cicular canals and moves into the canal of the inner ear,
causing disruptions in the inner ear signals that are eventually
sent to the brain about head and body movements (Najeeb,
2016). Typically, the crystals fall into the posterior semicircular
canal every time the patient lies down with the affected ear
down. As a result, the crystals move the fluids of the inner ear,
activating the sensor of the semicircular canal inappropriately. This is perceived as vertigo or spinning by the patient and
lasts less than a minute until the crystals settle down and stop
moving (Vestibular.org). It can occur suddenly while the sleeping
person gets into a particular position, yet, the after effects of
uneasiness and unsteadiness are even more disturbing than the
original pain (Baloh, 1998). BPPV is called “benign” because it
usually resolves spontaneously within a few weeks or months;
in some cases, however, it can last for years. If left untreated, it
persists in about 30% of patients (Strupp et al, 2008).
The treating physician will perform a simple maneuver called
the Dix Hallpike to test for the condition. The doctor will ask
the patient to sit on the exam table and he’ll turn the patient’s
head 45 degrees to one side and then will help him or her lie
back quickly so his or her head hangs slightly over the edge of
the table. This movement may make the loose crystals move
within the semicircular canals. The doctor will then ask if the
patient feels symptoms of vertigo and watch his or her eyes
to see how they move, checking for nystagmus, an involuntary
movement of the eyeballs, which is a major symptom of vertigo.
Once vertigo is proven, the follow-through procedure would
be either an Epley maneuver involving rotation of the patient in
the reclining position with their head hanging down, or Semonts
or Brandt Daroff maneuvers, which are all equally effective.
The cure rate for these procedures is more than 95% within a
few days, as shown by multiple controlled studies (Strupp et al,
2008).The purpose of these procedures is to displace abnormal
calcium deposits within the inner ear to an area which prevents
them from stimulating the nerve cells, which causes vertigo.

Canalith Repositioning Maneuvers, also known as Epley maneuvers, can be used to treat vertigo. It is a repositioning maneuver involving sequential movement of the head into four positions, staying in each position for approximately thirty seconds
to subsequently move the displaced crystals out of the affected
area (American-hearing.org).
With a series of specific head and body movements for BPPV
recommended by the American Academy of Neurology, the
movements are done to move the calcium deposits out of the
canal into an inner ear chamber so they can be absorbed by the
body. One will likely have vertigo symptoms during the procedure as the canaliths move. The movements are safe and often
effective. Commonly, this will be followed by Brandt-Daroff exercises, which will consist of shaking the crystals within the fluids by alternating body positions and ultimately dissolving them.
The treatment of benign paroxysmal positioning vertigo with
the Semont maneuver is as follows: In the initial sitting position, the head is turned forty five degrees to the side of the
unaffected “healthy” ear. Then the patient is laid on the right
side, i.e., on the side of the affected ear, while the head is kept
in forty five degrees of rotation to the other side. This induces
movement of the particulate matter in the posterior semicircular canal by gravity, leading to rotatory nystagmus toward the
lower ear that stops after a brief interval. The patient should
maintain this position for about one minute. While the head
is still kept in forty five degree of rotation toward the side of
the healthy ear, the patient is rapidly swung over to the side of
the unaffected ear, so that the nose now points downward. The
particulate matter in the semicircular canal now moves toward
the exit from the canal. This position, too, should be maintained
for at least one minute. The patient returns slowly to the initial,
sitting position.The particles settle in the utricular space, where
it can no longer induce rotatory vertigo. The above sequence
should be performed three times in a row three times per day,
in the morning, at noon, and at night. Most patients are free of
symptoms after doing this for three days (Strupp et al, 2008).
If one is diagnosed with BPPV, one should get treatment from
a physical therapist. Physical therapy has a success rate with the
symptoms usually resolving within one or two treatments. The
physical therapist guides the patient through a series of movements that will relocate the crystals to their place of origin
or to an area of the ear that is not affected by their presence
(Kelowna Capital News, 2008).
Another kind of vertigo is vestibular vertigo.Vestibular vertigo
is the leaking of inner ear fluid, vestibular failure, infection of
the vestibule, and tumors. Vestibules are sensitive to the movement of the head, and any type of irritation or damage to the
vestibules can cause confusion in the brain, resulting in vertigo.
Vestibular nerve inflammation, which is mostly viral in nature, is
self- limiting and almost always resolves by itself.
Similarly, Labyrinthitis and Vestibular Neuritis are vestibular
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disorders resulting from an infection that inflames the inner
ear or the nerves connecting the inner ear to the brain. This
inflammation disrupts the transmission of sensory information
from the ear to the brain. Vertigo, dizziness, and difficulties with
balance, vision, or hearing may result. This is explained from the
inner ear organs and the balance signals sent through the vestibulocochlear nerve. When one ear is infected, it sends faulty
signals and thus the brain receives mismatched information, resulting in dizziness or vertigo.
Lastly, Meniere’s disease is a chronic, incurable vestibular
disorder defined in 1995 by the Committee on Hearing and
Equilibrium of the American Academy of Otolaryngology. It produces a recurring set of symptoms as a result of abnormally large
amounts of endolymph fluid collecting in the inner ear. Meniere’s
disease can develop at any age, but it is more likely to happen to
adults between 40 and 60 years of age (Agrup Et. Al., 2007).
Vertigo is often triggered by a change in the position of one’s
head. Within seconds, one can experience an awful sensation,
as if the entire environment has begun to spin or that one is
spinning against a stationary environment. One may feel nauseated, have a headache, and have abnormal jerky eye movements
(Brandt, 2000). Ringing in the ears or hearing loss symptoms can
last a few minutes to a few hours or more and may come and
go. Another symptom may be nystagmus, which is involuntary
movement of the eyeballs. One will not see it in the mirror
because once one fixes their vision in the mirror, nystagmus
disappears. Additionally, hemi spatial neglect (failure to be aware
of one side of space), room tilt illusion, loss of spatial memory,
and ultimately pusher syndrome, a loss of postural balance are
all symptoms of vertigo. It is important to note that most of
the peripheral vestibular disorders have a clinical diagnosis, and
therefore medical history is important.

deviation is caused by abnormal prenuclear vestibular input to
the ocular motor nuclei, most commonly due to brainstem or
cerebellar stroke.
Frenzel goggles are extremely useful in evaluation of patients
with vestibular disorders. They were termed by the German
otolaryngologist Herman Frenzel from Gottingen, Germany in
the 1950’s, and have been used as an examination tool to disable
the patient’s ability to visually fixate on an object while at the
same time allowing the examiner to adequately visualize the
eye. In essence, they consist of the combination of magnifying
glasses and a lighting system. When Frenzel goggles are placed
on the patient and the room lights darkened, nystagmus can
easily be seen because the patient’s eyes are well illuminated
and magnified, and because fixation is removed as the patient
can hardly focus through magnifying glasses on a dark room.The
Frenzel goggles reduce visual fixation by means of the magnification glasses of about sixteen diopters (a unit of measurement
of the optical power of a lens or curved mirror), and also allow
a better examination of the eye movements, specifically nystagmus (Strupp, et. Al., 2014).
Despite these tests, sometimes one may feel dizzy or
light-headed but it’s not truly vertigo. This is common in people
with panic disorders or low blood sugar count, or when one
suddenly stands up from a lying or seated position or is intoxicated with drugs or alcohol. Alcohol interferes with the communication between nerve cells and cell receptors that send
messages between the body and the brain. As a result, the cerebellum, the part of the brain that usually creates nerve impulses
that control an individual’s balance and other fine movements
for balance, cannot function properly due to the uncoordinated
nerve signals. Ultimately, the muscle movements become uncoordinated and one can lose his or her balance (Susanto, 2014).

Testing for Vertigo

Treatment

The Head Impulse Test (HIT) is one of the many tests to do to find
the possible cause of vertigo. During the Head Impulse Test, the patient is asked to fix his or her eyes on a target (e.g. the examiner’s
nose).The examiner will then generate a rapid head impulse while
monitoring the patient’s eyes for a corrective or compensatory
saccade (CS) response. Individuals with normal vestibular function
should not generate a compensatory saccade after a head impulse,
rather the eyes should stay fixed on the target.
Ocular Motor Testing looks at the systems responsible for
integrating balance, vision, and movement. Four categories of
ocular motor functions: stability of gaze; smooth pursuit eye
movements,optokinetic nystagmus; and saccadic eye movements are used to determine spontaneous and gaze-evoked
nystagmus. Nystagmus often results in reduced vision and depth
perception and can affect balance and coordination. This testing
can also be used to determine skew deviation- wherein the eyes
move upward (hypertropia), but in opposite directions. Skew

Vertigo is a symptom, so finding its cause is the key to treating
it. For some, treatment from an audiologist, physical therapist,
or occupational therapist for balance treatment is needed. In
many cases, vertigo goes away without any treatment. This is
because one’s brain is able to adapt, at least in part, to the inner
ear changes, relying on other mechanisms (Phillips, 2011). For
example, if one is at a very loud concert, the brain adapts and
contracts the inner ear muscles to protect the inner ear from
damage. Similarly, the brain relies on sight as well as the musculoskeletal system to help with balance when one is walking along
a beach. Stepping on sand may not be as sturdy as pavement, but
with the help of the eyes and muscles, one can maintain his or
her balance even on uneven surfaces.
“Vestibular Rehabilitation” may be recommended if one has
recurrent bouts of vertigo. This is a type of physical therapy
aimed at helping strengthen the vestibular system. It helps train
the other senses to compensate for vertigo or learn ways to
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turn one’s head or move without getting dizzy. It includes improving balance and stability while in motion, improving neuromuscular coordination and decreasing anxiety due to vestibular
disorientation, and minimizing falls (Merlingolda, 2013).
Medicine can be another treatment towards vertigo discomfort. In some cases, medication may be given to relieve symptoms such as nausea or motion sickness associated with vertigo.
Antihistamines such as meclizine (Antivert) may offer shortterm relief from vertigo in addition to anti-nausea medications
(Donaldson et al, 2008). If vertigo is caused by an infection or
inflammation, antibiotics or steroids may reduce swelling and
cure the infection.
In a few cases when medical treatment is not effective in
controlling vertigo, surgery may be considered to repair or
stabilize the inner ear function (Strupp et al, 2008). There are
destructive treatments that are designed to eliminate vertigo,
possibly sacrificing hearing. These procedures are appropriate
for consideration when medical treatment and vestibular rehabilitation has failed to control vertigo symptoms. For example,
labyrinthectomy is a destructive procedure used for Ménière’s
disease. Labyrinthectomy is appropriate for patients in whom
there is no hearing in the ear which is causing vertigo and thus
offers excellent control of vertigo (Hain 2012). The balance end
organs, namely the semicircular canals and two otolith organs,
are removed so that the brain no longer receives signals from
the parts of the inner ear that sense gravity and motion changes.
It is important to note the hearing organ, the cochlea, is also
sacrificed with this procedure. Ultrasound surgery at times may
also be used to destroy the balance end organs so that the brain
no longer receives signals from the parts of the ear that sense
gravity and motion changes (vestibular.org).
After an estimated half a million people have received cochlear
implants by 2016, several decades since the first cochlear implant
was performed in 1961 (Smith, 2017), the success of cochlear
implant technology has naturally encouraged researchers to
consider other forms of bionic implants that can substitute for
lost sensory function. The development of the ‘vestibular implant
or prosthesis’, which aims to replace a missing or dysfunctional
vestibular system, has been given to groups of patients since 2007
and considerable progress has been made in this area.
It is important to note, if vertigo is caused by a more serious
underlying problem, such as a brain tumor or injury to the brain
or neck, initial treatment for those conditions may help to alleviate its chain reaction vertigo as well.

Conclusion
Through the analysis and research shown throughout the paper,
it leaves one empowered by what may be the best future healthcare treatment for one who has vertigo and other vestibular
disorders. There are many types of treatment for vestibular disorders, but where does the future for best healthcare treatment

of vertigo and vestibular disorders lie? According to the above
research discussed, doctors and healthcare providers should be
weary of surgery and medication as solutions to vertigo, for
many times the vertigo symptoms may prove to be invalid or
subside over time and these treatments are short term and
destructive to nearby organs in the body. As a healthier and
longer lasting alternative, Vestibular Rehabilitation via Epley,
Sermont, or Brandt Daroff Maneuvers will not only help control
the dizziness, but also strengthen other senses in the body to
compensate for vertigo. As a result of the therapy, it will not
only prove strengthening of the vestibular system, but will also
decrease the anxiety and the symptoms of disorientation that
occur as a result of vestibular disorders.

References
Agrup, C., Gleeson, M., & Rudge, P. (2007). The inner ear
and the neurologist. Journal of Neurology, Neurosurgery
and Psychiatry, 78(2), 114. doi:http://dx.doi.org/10.1136/
jnnp.2006.092064
Baloh, R. W. (1998).Vertigo. The Lancet, 352(9143),
1841-6. Retrieved from https://search.proquest.com/
docview/199022045
Bedford, F. L. (2012). A perception theory in mind-body
medicine: Guided imagery and mindful meditation as
cross-modal adaptation. Psychonomic Bulletin & Review,
19(1), 24-45. Retrieved from https://search.proquest.com/
docview/1021977739
Brandt, T., & Dieterich, M. (2017). The dizzy patient: Don’t
forget disorders of the central vestibular system. Nature
Reviews. Neurology, 13(6), 352-362. http://dx.doi.org/10.1038/
nrneurol.2017.58 Retrieved from https://search.proquest.com/
docview/1903441252
Brandt, T. (2000). Management of vestibular disorders. Journal
of Neurology, 247(7), 491-9. http://dx.doi.org/10.1007/
s004150070146
Brennan, M. (2012).Visual-vestibular interaction and treatment
of dizziness: A case report. Journal of Behavioral Optometry,
23(3), 68-72. Retrieved from https://search.proquest.com/
docview/1032813340
Collins LM. (Sep 24 2007) Balancing Act. Deseret News:
C01. Available from: https://search.proquest.com/
docview/351548677
Donaldson, Mark, BScPhm,R.Ph, PharmD., Gizzarelli, Gino,
BScPhm,D.D.S., M.Sc, & Chanpong, Brian,D.D.S., M.Sc. (2008).
Oral sedation: A primer on anxiolysis for the adult patient.
Oral Health, 98(2), 11-14, 17-18, 21-22, 24, 82-83. Retrieved
from https://search.proquest.com/docview/210822891
Gill-Body, K. (2001). Current concepts in the management of
patients with vestibular dysfunction. Pt, 9(12), 40. Retrieved
from https://search.proquest.com/docview/216835628

9

Etta Rubin

Hachmeister JE. An abbreviated history of the ear: from
Renaissance to present. The Yale Journal of Biology and
Medicine. 2003; 76(2):81-86

Strupp M, Fischer C, Hanß L, Bayer O. The takeaway Frenzel
goggles: A Fresnel-based device. Neurology. 2014; 83(14):12411245. doi:10.1212/WNL.0000000000000838

Hain, T.C. (2012) Surgical Treatments of Vertigo Americanhearing.org/disorders/surgical-treatments-of-vertigo/

Strupp M, Brandt T. Diagnosis and Treatment of Vertigo
and Dizziness. Deutsches Ärzteblatt International. 2008;
105(10):173-180. doi:10.3238/arztebl.2008.0173.

Huppert, D., & Brandt, T. (2018). Dizziness and vertigo syndromes viewed with a historical eye. Journal of Neurology, 1-7.
doi:http://dx.doi.org/10.1007/s00415-018-8807-x
Huppert, D., Benson, J., Krammling, B., & Brandt, T. (2013).
Fear of heights in roman antiquity and mythology. Journal
of Neurology, 260(9), 2430-2. doi:http://dx.doi.org/10.1007/
s00415-013-7073-1
Kelowna Capital News Vertigo responds well to physiotherapy
treatments. (2008, Jan 27). Retrieved from https://search.
proquest.com/docview/375944147
Merlingolda,V. (2013).Vestibular rehabilitation: Rehabilitation
options for patients with dizziness and imbalance. Nursing
Journal of India, 104(1), 18-20. Retrieved from https://search.
proquest.com/docview/1536919971
Najeeb (2016, Apr 28).Vertigo can be daunting, but it often
can be treated. Saudi Gazette Retrieved from https://search.
proquest.com/docview/1784866004
Naguib, M. B., Madian,Y., Refaat, M., Mohsen, O., El Tabakh, M., &
Abo-Setta, A. (2012). Characterization and objective monitoring of balance disorders following head trauma, using videonystagmography. The Journal of Laryngology and Otology, 126(1),
26-33. doi:http://dx.doi.org/10.1017/S002221511100291X
Newman-Toker, D. (2007). Diagnosing dizziness in the
emergency department: Why “What do you mean by ‘dizzy’?”
should not be the first question you ask (Order No. 3267879).
Available from ProQuest Central. (304856716). Retrieved from
https://search.proquest.com/docview/304856716
Patel,V. A., Zacharia, T. T., Goldenberg, D., & McGinn, J. D. (2017).
End-organ radiographic manifestations of cranial neuropathies:
A concise review. Clinical Imaging, 44, 5-11. doi:http://dx.doi.
org/10.1016/j.clinimag.2017.03.014
Phillips, J. O., PhD. (2011, fall). Find your balance. Deafness
Research Foundation (U.S.).Hearing Health, 27, 2020, 22. Retrieved from https://search.proquest.com/
docview/906279595
Seiden, H. (1989, Aug 17). Causes of vertigo enough to leave
your head spinning. Toronto Star Retrieved from https://search.
proquest.com/docview/436012454
Smith, P. F. (2017). Bionic balance organs: Progress in the development of vestibular prostheses. The New Zealand Medical
Journal (Online), 130(1461), 56-65. Retrieved from https://
search.proquest.com/docview/1938125164
Srinivasan, A.V., Jebasingh, K. (2007, Dec 02). When your world
spins. The Hindu Retrieved from https://search.proquest.com/
docview/287326340

10

Susanto, M. (2014). Dizziness: If not vertigo could it be cardiac
disease? Australian Family Physician, 43(5), 264-9. Retrieved
from https://search.proquest.com/docview/1528598666
Tamaki, C. (2016, Jan). Ears and balance. Hearing Loss Magazine,
37, 26-31. Retrieved from https://search.proquest.com/
docview/1897260786
Better balance: Easy exercises to improve stability and prevent
falls. (2012). Boston: Harvard Health Publications. Retrieved
from ProQuest Central Retrieved from https://search.proquest.com/docview/1370724289
Better balance. (2017). Boston: Harvard Health Publications.
Retrieved from ProQuest Central Retrieved from https://
search.proquest.com/docview/1992936732
Nervous system diseases and conditions - vertigo; investigators from Ludwig Maximilian university report new data
on vertigo (the dizzy patient: Don’t forget disorders of the
central vestibular system). Health & Medicine Week. Jun
23 2017:3036. Available from: https://search.proquest.com/
docview/1910227481
www.american-hearing.org
www.vestibular.org

New Medical Indications for Thalidomide
and its Derivatives
Chaya Newfield
Chaya Newfield will graduate in June 2019 with a B.S. degree in Biology and minor in Psychology.

Abstract
Thalidomide is an anti-inflammatory and an anti-angiogenesis drug that is being used around the world for a variety of malignant and inflammatory diseases. Is it justified to continue prescribing and developing thalidomide given the discovery of many
well-known side effects including catastrophic birth defects? To answer this question, this paper will discuss the pharmacology
and history of thalidomide, as well as many of its proposed mechanisms of action. The medical indications for the current use of
thalidomide as well as for several newer and more potent derivatives are mentioned for their therapeutic results, as well as their
adverse side effects.
Introduction to Thalidomide
“Thalidomide remains, arguably, the greatest disaster in medical
history” (Greener, 2011). Thalidomide was introduced in 1957
by a German pharmaceutical company as a sedative and hypnotic drug. It was also widely used in several countries to alleviate
morning sickness in early pregnancy. It was sold in more than
forty-six countries without any testing for teratogenicity, as was
common practice for new drugs at that time. More than 10,000
children around the world developed severe birth defects, especially shortening or absence of limbs. There was also an increase
in miscarriages and infant mortality. Remarkably, the United States
Food and Drug Administration did not approve sale of thalidomide despite five requests from manufacturers. As a result, only
seventeen babies were affected in the United States, probably
from thalidomide purchased in Canada (Huang, et. al. 2008).
By 1961 production and distribution of thalidomide were
banned worldwide. Due to the risk of teratogenicity, almost no
research into the use of thalidomide took place for the next
decade. The first new indication for thalidomide was in treating
a complication of leprosy known as erythema nodosum leprosum (ENL) (Sharma, et. al. 2007). Beginning in 1967, anecdotal
reports of the use of thalidomide in cancer treatment began to
be published. Some of the diseases treated were astrocytoma,
multiple-myeloma, chronic lymphocytic leukemia, and malignant
melanoma. New research is being done to investigate the mechanism of action of this class of immunomodulatory drugs in various
malignancies and in non-malignant conditions such as Alzheimer’s
Disease and persistent erythema multiforme (He, et. al. 2013).

Methods
Articles and studies researched in this paper were obtained
through the EBSCO and ProQuest databases with access provided by the Touro College Library. Additional research articles
were obtained through the National Center for Biotechnology
Information (NCBI) website and the Jackson Laboratory website. Images and diagrams that are used throughout the paper
were obtained from the research articles cited.

Chemical Analysis
Thalidomide is a racemic glutamic acid analogue also known as
[+] alpha-[N-phthalidimo]-glutarimide. It consists of two linked
rings: a glutamic ring and a phthalic ring. Because it contains a
chiral carbon the molecule is unstable and can switch back and

forth between two enantiomers which are mirror images of
each other. This reaction takes place rapidly in water or body
fluids. While only one state, the S-enantiomer is thought to be
teratogenic, the safer state, the R-enantiomer, is not stable and
cannot be preserved in the body. (Bartlett, et. al. 2004)
Thalidomide has traditionally been synthesized by a multistep process which uses expensive ingredients and produces a
very low yield. A recent research study by chemists at Stockton
University in New Jersey reports on a new rapid synthesis of
thalidomide and its analogs using easily obtained reagents which
rapidly interact with the assistance of a microwave. It produces
relatively high yields. The reaction of the corresponding anhydrides using DMAP (4-N, N- dimethylaminopyridine) as a base
catalyst takes place in ten minutes at 150 degrees Celsius. The
chemists developing this new method of production describe
their innovation as a, “novel green one-pot synthetic technique.”
(Benjamin, et. al. 2017)

Pharmacology
Thalidomide has an active half-life of 8 to 12 hours. It is broken down by hydrolysis in tissue fluids and metabolized by the
liver using the cytochrome p450 system. Although it is absorbed
slowly, it has a high oral bioavailability.The plasma concentration
peaks after at least two hours. Little drug is bound to protein in
the plasma.The average elimination half-life of both enantiomers
is five hours. (Vargesson, et. al. 2015)
According the British Columbia Cancer Drug Manual accessed online, high fat meals increase the time to peak concentration. Thalidomide is distributed mostly in the internal
organs such as the gastro-intestinal tract, liver and kidneys. It
is found to cross the blood brain barrier and is also found in
the ejaculate.
In 2004, a new derivative of thalidomide was introduced for
treatment of multiple myeloma. Lenalidomide, under the trade
name Revlimid is considerably more potent than thalidomide.
It has an added amino group at position 4 of the phthaloyl
ring and removal of a carbonyl group from the phthaloyl ring.
Pomalidomide (3-aminothalidomide) was the second thalidomide analog to be used in treating multiple myeloma. It is even
more potent than the analogs before it. A third thalidomide
analog, Apremilast is now showing effectiveness as an oral treatment for psoriasis and psoriatic arthritis. (Bartlett, et. al. 2004)
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Mechanism of Action: Innate immunity: Effects
on Epidermal Regeneration, Soluble Mediators,
and Natural Killer Cells
Studies of epidermal regeneration have shown that thalidomide
increases human keratinocytes migration and propagation.
Testing was done with a motility assay and thymidine incorporation assays to better understand how thalidomide promotes
this proliferation. In addition, the chemokine IL-8 that promotes
migration of neutrophils and keratinocytes significantly increases with thalidomide treatment. Because of this, researchers have
theorized that the mechanism with which thalidomide aids in
wound healing is by promoting keratinocyte production and
movement. This may be useful in explaining its ability to treat
ulcerative diseases, such as Behcet’s (a rare disorder causing inflammation in blood vessels with symptoms that include mouth
and genital sores, inflamed eyes, and rashes) and aphthous stomatitis (shallow sores inside the mouth or at the base of the
gums that make it hard to eat or talk) (Paravar & Lee, 2008).
The exact mechanism of thalidomide’s anti-inflammatory
action via soluble immune mediators is still being investigated.
However, researchers have linked thalidomide’s anti-inflammatory action to its ability to speed up the degradation of messenger RNA in blood cells.These effects have been analyzed in both
human monocytes and mouse macrophages (Paravar, Lee, 2008).
By reducing the half-life of the messenger RNA coding for
TNF-alpha, (Tumor Necrosis Factor) it in turn reduces the
blood serum level of TNF-alpha.TNF-alpha is a cell signaling protein (cytokine) involved in systemic inflammation. By reducing
TNF-alpha, thalidomide is an effective treatment for inflammatory diseases such as erythema nodosum leprosum (ENL) and
lupus erythematosus (LE). Many studies have been performed
that confirm this reduction of TNF-alpha. For example, 48-68%
of patients with ENL have a reduction of TNF-alpha in the
serum from their pretreatment levels.Tuberculosis patients also
show reduced levels in in-vitro and in-vivo studies and patients
gained a significant amount of weight while on the medication.
HIV-1 patients also had reduced TNF-alpha levels while under
treatment with thalidomide. A further confirmation comes from
studies using rodent models of pancreatitis in which thalidomide was seen to have similar effects (He, et. al. 2013).
Another proposed mechanism of action involves thalidomide’s effects on Natural Killer (NK) cells which are vital in
destroying tumor cells, intracellular pathogens, and cells infected by viruses. Using in-vitro studies, thalidomide has been
observed to enhance NK-cell-mediated lysis of cancerous cells.
This was demonstrated in a study that co-cultured NK cells
with the same patient’s cancerous cells. Additionally, thalidomide
increases the secretion of NK cell activators such as IL-12 and
specifically induces NK cell antitumor responses. In an in vivo
study, the number of NK cells in a multiple myeloma patient
were increased with thalidomide therapy. The results of these
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studies indicate that thalidomide’s ability to enhance NK-cells
is the mechanism by which it aids in the treatment of multiple
myeloma (Paravar, Lee, 2008).

Adaptive immunity: B Cell Antibody Suppression,
T Cell Stimulation
Thalidomide suppresses B cell antibody formation in studies
primarily using New Zealand Black (NZB) and Murphy Roths
Large (MRL) mice.These strains were chosen because they have
a genetic predisposition to autoimmune disorders (The Jackson
Laboratory Website, updated 2018). Thalidomide inhibits the
usually increased production of splenic IgM in NZB mice and
splenic and lymph node IgG1 in MRL mice. In clinical studies,
leprosy patients receiving thalidomide and dapsone treatment
had lower serum IgM levels than patients receiving dapsone
alone. The combination of these studies suggests that thalidomide’s action may be based on its downregulatory effects on
antibody production (Paravar & Lee, 2008).
Thalidomide was shown to be able to co-stimulate T cells
once they were already partially activated by the T cell receptor.
Co-stimulation is an important mechanism for immune defense.
A second signal is sent to naïve T cells which facilitates their initiation and further generation of an antigen-specific effector response. The co-stimulatory effect of thalidomide can be used as
an immunological adjuvant, that is, it can enhance the response
to tumor antigens in cancer patients (Bartlett, et. al. 2004).

Reduction of Tumorigenesis: Apoptosis and
Restriction of Tumor Growth, and Antiangiogenic
Activity
Tumors grow and expand due to their ability to evade apoptosis. In studies, thalidomide has induced apoptosis (G1 growth
arrest) in human cancerous cells. It has also been shown to
decrease the expression of the apoptosis-suppressing protein
Bcl-2 in blood and bone marrow of patients with multiple myeloma. Another mechanism proposed is thalidomide’s ability to
induce monocyte apoptosis by involving the cytochrome c-dependent pathway. (Cytochrome c is known for its role in the
mitochondria as a key contributor in ATP synthesis. In our case,
we are more interested in thalidomide’s stimulation of cytochrome c’s other effect which is triggered when a cell receives
an apoptotic stimulus. The cytochrome c is then released into
the cytosol and triggers programmed cell death through apoptosis) (Paravar & Lee, 2008).
In 1971, Dr. Judah Folkman of Harvard Medical School formulated his hypothesis that tumor growth depends on angiogenesis, the formation of new blood cells in the malignant tissue.
Thalidomide, as mentioned above, inhibits limb bud formation
in the embryo. This led to the idea that the teratogenic and
antiangiogenic actions may be related.
Dr. Folkman made the groundbreaking discovery that tumor
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growth and angiogenesis were related when he was working on
testing the efficacy of hemoglobin solutions as a substitute for
blood transfusions. As a part of this study he injected isolated
organs with mouse melanoma cells. He found that the tumors
could not grow and spread in the isolated perfused organs, but
when they transplanted these same tumor cells into mice, they
were quickly vascularized and grew larger. After conducting
more research trials to prove his hypothesis, Dr. Folkman published an article in the New England Journal of Medicine that
stated that tumor growth depends on angiogenesis and that inhibiting angiogenesis can be used to treat certain cancers. From
1980 to 2005 Dr. Folkman’s lab worked on testing twelve angiogenic inhibitors including interferon alpha, fumagillin, endostatin
and, notably, thalidomide (Ribatti, 2008).
Angiogenesis, the development of new blood vessels, is vital to
the growth and spreading of cancerous tumors. The cancer degrades basement membranes and extracellular matrix and brings
endothelial cells towards an angiogenic stimulus. It also involves
pericytes and smooth muscles cells as well. Various growth factors are also needed to form new blood vessels from preexisting
micro vessels. These growth factors include vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF), and
platelet-derived growth factor (PDGF) (Fialho, et. al. 2013).
One proposed mechanism for thalidomide’s antiangiogenic
effect is its ability to inhibit VEGF and bFGF production, which
thereby inhibits vessel growth. Studies using human endothelial
cells showed that thalidomide inhibits VEFG secretion and cell
migration and lowers the total number of capillaries. In studies
using chicken embryonic chorioallantoic membrane (CAM) thalidomide inhibited VEGF and bFGF induced vessel growth. In one
trial done by the Department of Cellular and Molecular Biology
and Pathogenic Agents of the University of Sao Paulo, twelve
CAMs from chicken eggs were incubated with thalidomide implants and analyzed after two days to review the percentage of
vessel deterioration. The results showed significant regression
of vessels in CAM that had thalidomide or thalidomide-loaded
implants as compared to the negative control (NC) group and
an implant not containing any drug (Fialho, et. al. 2013).
Another study proposed that thalidomide inhibits endothelial
cell proliferation by inhibiting the binding of the SP-1 transcription factor, which has many binding sites on the VEGF promoter.
This protein usually binds to the VEGF promoter to initiate and
activate the transcription of the gene directly. When its binding
is inhibited, it causes less VEGF to be produced and therefore
limits the cells’ growth (Yabu, et. al. 2005).
A third mechanism of action being researched is thalidomide’s
ability to suppress the VEGF gene by downregulating the VEGF
receptors Flk-1 and neuropilin-1. By reducing the productivity of the VEGF receptors, thalidomide lessens the effects of
the vascular endothelial growth factor in general. This causes
less signals for angiogenesis to be sent, so the body forms less

vasculature. With a smaller supply of blood, the growing limbs
do not receive enough oxygen and nutrients, and they subsequently do not grow properly and result in under developed or
malformed limbs (Yabu, et. al. 2005).
A study done using zebrafish embryos and Human Umbilical
Vein Cells (HUVEC) showed promising results in this area. The
thalidomide treated embryo was shorter in length than the control. In addition, the lumens of the dorsal artery and posterior
cardinal vein were clearly seen (with hematoxylin and eosin
staining) in the control but were so reduced in the embryo
treated with thalidomide that they were barely visible (Yabu,
et. al. 2005).

Teratogenesis
Over the past fifty years, many separate models for thalidomide
embryopathy have been proposed, however a full understanding of its mechanism of action is still incomplete. The proposed
theories are not necessarily mutually exclusive.And it is possible
that multiple mechanisms of action are each involved to some
extent. Additional theories include nerve toxicity, inhibition of
cell adhesion molecules and effects on chondrogenesis.
One breakthrough discovery revealed that Cereblon (CRBN),
a protein encoded by the CRBN gene, may be the primary target for binding by thalidomide. The authors found that thalidomide binds directly to CRBN, a substrate receptor for the
CUL4A-DDB1 E3 ubiquitin ligase, a protein that employs an E2
ubiquitin-conjugating enzyme that carries ubiquitin, recognizes a
protein substrate, and assists the transfer of ubiquitin from the
E2 to the protein substrate. The ubiquitin is used to tag specific
proteins to be broken down by proteasomes. This binding inhibits the activity of the assembled E3 ubiquitin ligase complex
so that it does not tag the specific proteins, and an unknown
substrate is allowed to accumulate. This in turn effects the expression of the fibroblast growth factor eight (FGF8) and causes
growth defects. Thus, the action of the E3 ubiquitin ligase complex is necessary for limb outgrowth (particularly in zebrafish)
and by disrupting this complex, thalidomide induces teratogenic
effects. Consequently, they demonstrated that the deformities
caused by thalidomide were directly mediated through stopping
its inhibition of CRBN. In zebrafish and chickens, when they
used an overexpression of a CRBN mutant that does not bind
thalidomide, they did not notice the defects usually caused by
this drug, proving that it is the binding of the drug to CRBN that
is responsible for the embryopathy effect (Ito. et. al. 2010).
Following this discovery, CRBN was also shown to be crucial for the mechanism of action of thalidomide’s anti-myeloma
properties, as well as other immune-modulatory drugs (IMiDs).
One of the downstream targets of CRBN was shown to be interferon regulatory factor 4 (IRF4).This protein which regulates
the transcription of interferons is essential for myeloma cell
survival and is downregulated by IMiD therapy (Zhu, et. al. 2013).
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Figure 1. Depiction of the downstream targets of thalidomide that
may lead to its teratogenic properties (Zhu, et. al. 2013).
A recent series of experiments supported in part by the
National Cancer Institute further confirmed the hypothesis
that antiangiogenesis and teratogenesis are related. The researches tested a variety of angiogenesis inhibitors, including
thalidomide and its analog CPS49, using zebrafish and chicken
embryo models. They focused on assessing the developmental
defects and teratogenic effects that the drugs caused. They
concluded that different classes of angiogenesis inhibitors,
regardless of the molecular target or specific mechanism of
action, are teratogenic to chicken embryos. This study also
proved that using chicken embryos and zebrafish embryos is
a valid way to screen new drugs for teratogenic effects before
they are used in clinical trials on women of childbearing age
(Beedie, et. al. 2016).

New Research in Treatments Using Thalidomide
and Its Derivatives: Multiple Myeloma (MM)
Multiple Myeloma is a type of blood cancer that affects plasma
cells. In multiple myeloma, malignant plasma cells amass in the
bone marrow crowding out the normal plasma cells that help
fight infection. This disease can damage the bones, immune system, kidneys, and cause anemia. A randomized trial compared
the costs and benefits of using a melphalan (chemotherapy) and
prednisone (steroid) treatment in conjunction with thalidomide
(MPT) as opposed to melphalan and prednisone (MP) alone.The
testing was done on 135 elderly patients over the age of 65 with
MM who were ineligible for stem-cell transplants. The results
showed a significant increase in the median progression-free
survival (PFS) of patients using a combination of drugs that included thalidomide. PFS is the length of time during and after
the treatment of a disease that a patient lives with the disease
but it does not get worse. Also, the overall survival (OS) rate
was 52 months as opposed to only 32 months for patients using
only melphalan and prednisone. The following graph compares
the progression-free survival rate of patients using MPT versus
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MP treatment.The MPT group has a significantly higher PFS rate.
The Y axis is the fraction of living patients who began in the
study. Both the MPT and MP groups start at 1.00, meaning that
100% of participants are alive. The X axis is the months of the
treatment.The MPT group has a higher PFS rate during the forty
months of the trial. The P value is 0.02, meaning the results are
statistically significant (Sacchi, et. al. 2011).
One downside of adding thalidomide to the treatment regiment is the adverse side-effects that were more frequent in
patients using thalidomide, which will be discussed in more detail in the “Adverse Effects of Thalidomide” section of this paper.
Researchers observed a significant increase in neutropenia,
deep venous thrombosis, infection, and peripheral neuropathy.
The incidence of toxicity correlates with the drug dosage. The
study concluded that while including thalidomide in the therapy
showed an increase in activity against MM, it came with a substantial cost, which will be discussed later.
Trials have also been conducted using the second-generation
thalidomide derivate, lenalidomide. In a randomized, controlled
clinical trial, lenalidomide therapy (in combination with dexamethasone, a corticosteroid, or with melphalan and prednisone)
significantly improved PFS in patients with newly diagnosed MM
who were not eligible for stem-cell transplants as compared to
MP treatment alone. These improvements in progression-free
survival were also reflected in patients’ health-related quality of
life (McCormack, 2015).
In general, the analog was found to have improved efficacy and
increased tolerability as compared to thalidomide. Although the
treatment regiments had similar efficacy results, lenalidomide was
observed to have fewer toxic side-effects than its parent drug.The
continuous use of lenalidomide did not have a negative impact on
the drug’s tolerability. It also did not increase the cases of neutropenia as compared with shorter-term use of the drug. With new
analogs, melphalan and prednisone plus a thalidomide-type drug
could be considered the new standard of care for the treatment
of patients with MM over age 65 years and for younger patients
who are transplant-ineligible (McCormack, 2015).
Recent studies are working on understanding lenalidomide’s
mechanism of action. They propose that it affects signal transduction, also known as cell signaling, which leads to the suppression of COX-2 but not COX-1. This can partly explain its
selective efficacy on cells. Meaning, it is able to be more selective
in the cells it targets so it can have a greater potency with less
side effects. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of
conditions highlights the possibility of multiple target sites of
action (Kotla, et. al. 2009).

Malignant Melanoma
Malignant melanoma is the most aggressive and life-threatening
skin cancer. It develops in the melanocytes and has a very high
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tendency to spread to other parts of the body. Symptoms can
include a new, unusual growth or a change in an existing mole.
Brain metastases will develop in almost half of the patients with
advanced melanoma and in 15-20% of these patients, the central
nervous system is the first site of relapse.The overall survival rate
is very short, only two to four months (Vestermark, et. al. 2008).
In one study, the antitumor activity and toxicity of thalidomide
was evaluated in patients with phase II brain metastases related
to metastatic melanoma. Thalidomide was administered orally
to patients, with the dose increasing over a one-month period
from 100 mg per day to 400 mg per day. Twenty-five men and
eleven women with a median age of forty-eight years were enrolled in the study.The average survival rate for the study group
was unchanged from historical data. Median PFS was 1.7 months
and OS was 3.1 months. Although thalidomide showed limited
activity against the metastatic melanoma in the central nervous
system, minor effects on peripheral tumor manifestation were
noted. This led researchers to conclude that thalidomide may
one day be part of the treatment plan for patients with that
form of metastasis in the future. Researchers also concluded
that more investigation should be done using thalidomide in
combination with Temozolomide, a cytotoxic chemotherapy
drug (Vestermark, et. al. 2008).

Persistent Erythema Multiforme
Erythema multiforme is a common, usually self-limited disease
which predominantly affects patients in their 20s and 30s. Its
symptoms include target shaped lesions (circular red patches
with central clearing) on the skin and mucous membranes.
There are three clinical subgroups of erythema multiforme:
classical, recurrent, and persistent erythema multiforme. The
most severe form is the persistent erythema multiforme
which can leave a patient stricken with continuous lesions. No
potential cause has been found yet, so this subgroup is defined
as idiopathic.
Thalidomide can be effectively used as a treatment for this
skin condition. It was initially introduced as a treatment for
persistent erythema multiforme as early as the 1980’s because
of its immunomodulatory and anti-inflammatory effects. The
following case report in the recent literature illustrates its
effectiveness. A fifteen-year-old boy in the Republic of China
experienced a sudden onset of target-like lesions on his trunk
and limbs. Although the wounds healed within two weeks, new
eruptions continued to appear. After unsuccessful treatment
attempts with oral corticosteroids and topical agents as well
as the antiviral drug valaciclovir, thalidomide was prescribed
to the patient. After two weeks of administering 100 mg per
day, the lesions gradually healed, and no new ones developed.
After two months of slowly reducing the dosage, there was no
recurrence of disorder. The researchers noted that because of
the risk of neuropathy associated with taking daily doses of this

medication, clinical vigilance and regular neurological exams are
advised (Chia-Wei, et. al. 2008).

Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus is an autoimmune disease,
which affects multiple organ systems in the body. In this disease
an individual’s own immune system attacks various cells causing a
wide variety of symptoms.Typically, it causes extensive, disfiguring
lesions. Although these lesions are not life threatening, they can
be very itchy or painful. Many patients respond to standard treatment methods such as sunscreen, topical corticosteroids, or oral
antimalarial drugs. However, for cases in which these treatments
did not prove useful, or if the CLE was severe, thalidomide can be
an important therapeutic option (Sharma, et. al. 2007).
In a study done by the Department of Dermatology at the
University Hospital of Leuven, Belgium, thirty patients received
thalidomide treatment for refractory CLE over fifteen years
(from February 1998 to August 2013.) Each of these patients
had previously tried at least two different drug treatments
with no success. All of them were required to follow vigorous
contraceptive methods because of thalidomide’s known teratogenic properties. Patients received an initial dose of 50 mg per
day, which was increased to 100 mg if the CLE was extensive.
Although six patients prematurely stopped treatment due to
the negative side-effects, all patients who continued in the study
experienced improvements within 1-9 weeks after beginning
treatment. A high rate of relapse (73%) was observed in patients
who stopped thalidomide treatment. In addition, five patients
were not able to be weaned off the drug due to flare-ups of
CLE when they attempted to taper off the doses. The researchers concluded that while thalidomide treatment for CLE does
have strong efficacy, because of its considerable risk of polyneuropathy, it should only be considered as a possible therapy for
severe cases of CLE or for patients who have exhausted other
treatment options without significant relief (Baret, et. al. 2015).
In another study done on twenty-five patients in India suffering
from various inflammatory skin diseases, including discoid lupus
erythematosus, thalidomide was found to be an effective treatment. Of the seven patients with LE, four had excellent response,
two had partial response and one discontinued treatment due
to deep vein thrombosis (DVT). The authors recommended thalidomide as an effective treatment but advised physicians to be
watchful of thrombo-embolic events (Sharma, et. al. 2007).

Erythema Nodosum Leprosum (ENL)
When the author’s father, Stanley Newfield MD, was a young
dermatology resident training at the United States Public Health
Service Hospital in Staten Island, New York he was involved in
diagnosing and treating many cases of leprosy, also known as
Hansen’s disease. This research interest was perhaps especially
appropriate since he is a kohen, the traditional caretaker for
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people suffering from tzoras (leprosy) in the Torah.
As a federal institution, his hospital was responsible for caring for patients with transmissible infectious diseases. Leprosy
patients were referred from a large area of the north-eastern United States for treatment. One of the complications of
leprosy is the immune-system reaction known as Erythema
Nodosum Leprosum. ENL is characterized by the presence of
many inflammatory skin nodules and symptoms such as fever,
arthritis, eye inflammation, neuritis, and swollen lymph nodes. It
was observed that many patients suffered from ENL, which was
even more distressing to them than some of the other leprosy
symptoms such as loss of sensation in the extremities and/or
exaggerated skin folds on the face.
Dr. Newfield explained that he was surprised, back in 1979, to
find that the infamous drug, thalidomide, was the miraculously
effective treatment for ENL. He was well-aware of the teratogenic effects of the drug which he learned about in detail in
medical school. Now this same drug was resurrected for a new
use, albeit with strong precautions to avoid administration to
pregnant women. Due to his involvement in leprosy treatment,
he was coauthor of a research report on the epidemiology of
leprosy in New York City, which was published in the prestigious Journal of the American Medical Association.
Many people have a fear of leprosy since it is transmissible
through contact with an infected patient. However, this seems
to require prolonged exposure, usually in a household setting.
The research verified that very few leprosy patients acquire the
disease in the continental United States, rather they brought
the disease with them when they immigrated to this country.
The average latent period from entering the United States until
onset of symptoms was 4.8 years, with a range of 0 to 38 years
(Levis, et. al. 1982).
Almost forty years have passed since thalidomide was first
used for ENL treatment, and it remains the drug of choice for this
condition, as evidenced by two current research reports originating from India, a country with a large number of leprosy patients.
The first paper reports on eleven patients with ENL. Six of those
patients had excellent response to thalidomide and five had to
stop treatment prematurely due to side-effects (most commonly
DVT but also rashes and tremors.) (Sharma, et. al. 2007) In the
second study following one hundred patients diagnosed with
ENL, the group of fifty patients treated with thalidomide had a
faster and longer lasting clinical response than the control group
of fifty patients treated with prednisolone, a strong steroid medication. Patients on thalidomide also experienced fewer relapses
of their cutaneous symptoms (Kaur, et. al. 2009).

Animal Models of Alzheimer’s Disease (AD)
Alzheimer’s Disease is a degenerative disease that destroys
memory and other important mental functions. This is an incurable condition that afflicts an estimated 5.7 million people
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in the United States, mostly over the age of sixty-five. Research
studies are currently being performed on a mouse model of AD.
In one study, healthy mice were injected with streptozotocin
(STZ), a chemical that causes AD-like cognitive deficits. In this
study, one group of mice were pre-treated with thalidomide.
Learning and memory behaviors were evaluated on the seventeenth, eighteenth and nineteenth days of the study using the
Morris water maze test. In this test, a mouse is placed in the
center of a circular pool and must find the hidden platform that
allows it to escape. Mice that are not treated with the drug will
improve their time to escape after doing the test multiple times.
The SZT injections caused a significant decrease in the mice’s
improvement in their performance on the test. In comparison,
the learning and memory behaviors of the thalidomide treated
mice were significantly better preserved and they were able to
complete the tests with improved timing, although they were
not as improved as the mice who did not receive any drugs.
This positive result appears to be due to the anti-inflammatory
effect of TNF-alpha inhibition (Elçioğlu, et. al. 2013).
A second study used a strain of mice with the human
APPswedish transgenic (APP23) mutation. This mutation is associated with Alzheimer’s Disease. These mutated mice show
deficits in spatial memory which become severe with age. (The
Jackson Laboratory Website. 2018) This report showed that
thalidomide treatment improved memory and learning ability
in the mutated mice. The level of TNF-alpha in the thalidomide
treated mice was decreased.This in turn reduced the amount of
amyloid (A beta 1-42,) a harmful protein, which accumulated in
their brain tissue.The control group mice treated with the inactive vehicle had 750 units of harmful amyloid, while the thalidomide group had only approximately 100 units (He, et. al. 2013).
In mice brain tissue, the control group (treated with the vehicle) developed a large number of harmful senile plaques but the
thalidomide treated group showed very few.

Adverse Effects of Thalidomide
This section summarizes the adverse effects of thalidomide, some
of which have also been mentioned previously. Thalidomide was
withdrawn from widespread use shortly after the devastating
effects on developing embryos was discovered. The drug came
back into limited use for malignant and inflammatory diseases
in non-pregnant women. It can still have serious harmful effects:
peripheral neuropathy (pain and tingling in the hands and feet),
venous thrombosis (blood clots in the veins), skin rashes, constipation, somnolence (excessive daytime sleepiness), weakness, and
bradycardia (BC Cancer Drug Index. updated 2018).
Peripheral neuropathy is a common side effect that is associated with prolonged use of the drug, but there is no clear mechanism of action that explains its correlation with a cumulative
dose. The risk for nerve damage is highest after 6 months or
more of therapy. The symptoms are usually reversible when the
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patient stops thalidomide treatment, although some patients do
suffer long term nerve damage (Rajkumar, et. al. 2002).
Constipation caused by thalidomide can vary from mild to severe. As many as 90% of patients can develop mild constipation.
This effect is thought to be secondary to thalidomide’s action
on the autonomic nerve endings in the gut. Severe constipation
usually occurs in patients who are taking high doses of thalidomide. It is especially prevalent among patients who are already
prone to developing constipation, such as those who lead an
inactive lifestyle. Change of diet and exercise can help alleviate
this side effect (Hall, 2003).
Deep vein thrombosis and pulmonary embolisms only occur
in one to three percent of the patients receiving thalidomide
as treatment for myeloma. There is not enough research done
yet to determine whether the risk of DVT in these patients is
higher than usual for patients receiving other types of treatment
for this severe malignancy, due to the nature of the disease or
the side effect of immobility that it can cause. Patients confined
to bed rest tend to have higher rates of DVT. The risk is also
elevated when patients receive thalidomide treatment in combination with dexamethasone or other chemotherapy drugs, have
an inherited thrombotic predisposition, or are over the age of
sixty-five (Hall, 2003).
A recent case report documents a thirty-eight-year-old female from Puerto Rico with a history of prenatal thalidomide
exposure. She suffered from phocomelia, the dramatic birth
defect in which the hands or feet are attached close to the
trunk. An MRI scan revealed that the uterus and vagina were
also absent.These internal anomalies have been less appreciated
by physicians because they are not noticeable without special
imaging, however they can cause serious symptoms such as pain
and malignancy (Dotters-Katz, et. al. 2013).
The analog drug, lenalidomide, has not been found to be
teratogenic in rabbits, a sensitive species used to detect birth
defects. However, it may still have adverse effects such as morbilliform rashes (Huang, et. al. 2008). In a study done at Mount
Sinai Medical Center in New York City, doctors found that 7.2%
of the 806 patients receiving IMiD treatment developed rashes.
In almost all cases, the rashes could be managed without having to discontinue treatment. Thus, it appears that lenalidomide
may lack some of the adverse effects of thalidomide, while still
having superior immunomodulatory and antiangiogenic efficacy
than its parent drug (Barley, et. al. 2016).
An additional analog, Pomalidomide, is now an approved
drug for MM. A research study conducted in Aberdeen, United
Kingdom analyzed its effect on zebrafish and chicken embryos.
The tests showed no detectable teratogenic, antiangiogenic or
neurotoxic effects. Despite having less side effects, it has more
anti-inflammatory properties than either thalidomide or lenalidomide (Mahony, et. al. 2013).

Conclusion
The psalmist wrote, “The stone that the builders rejected became
a cornerstone.” (Psalm 118:22) This report illustrates this concept
as it pertains to the drug, thalidomide. This drug was universally
banned due to its harmful side-effects. Years later it was found to
have unique healing properties in several serious diseases.
It appears that the continued use and development of thalidomide treatments is justified. Although it can have many serious
side effects, specifically crippling teratogenesis, it is often the
last resort as treatment for patients suffering serious diseases.
Care should be taken to prevent pregnant women from using
this drug to avoid causing birth defects. Given the significance of
these effects, the future of thalidomide is not in the drug itself
but in the derivatives that are now being tested. Lenalidomide
and pomalidomide are more effective and have less toxic effects.
As scientists continue to discover their specific mechanisms of
action they will be able to alter the drug to have even less adverse effects and help more patients worldwide. The prognosis
for PFS and OS for patients with MM and other forms of cancer will decrease even more and give the people suffering with
these diseases hope for their future. With this new and exciting
research thalidomide and its analogs have justly become important medical treatments.
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Abstract
Due to the sensitivity of location, brain cancer is one of the most difficult and deadly known cancers. There are various forms of
cancer in the brain with many shared characteristics as well as unique manifestations in each. While cancers originating in the
central nervous system present in several ways, the most common forms are high grade gliomas generally, and glioblastoma or
anaplastic astrocytomas specifically. With the advent of technology, researchers have been able to propose and refine extensive
profiles of these relentless tumors, enabling greater and more successful treatment profiles to be developed. Where treatments
used to consist primarily of chemotherapy and surgery, research has enabled the development of immunotherapy and gene
therapy techniques as well as alternative treatments to take on the caustic disease.
Introduction
The foremost distinction of brain tumors is between primary;
those that originated within the brain itself, and secondary; those
that developed beyond the blood brain barrier and migrated to
the brain under metastatic conditions. Secondary tumors account for the majority of all brain cancers and approximately
50% of these tumors metastasize from lung cancers (Gallego,
2015). According to the 2014 World Cancer Report, patients
diagnosed with glioblastomas were measured to have a median
survival time of 12-15 months post diagnosis with fewer than
5% of patients living beyond 3 years (Patchell, 2003).Under the
World Health Organization’s grading protocol for central nervous system (CNS) cancers, glioblastomas (GBM) are a grade
IV glioma (Bleeker, et al., 2011). This is the most common form
of primary brain tumor and the most fatal found in humans,
accounting for 15% of all intracranial neoplasms (Bleeker, et al.,
2011;Young, et al., 2015).The average age at diagnosis is 64 years
old and the approximate annual incidence of GBM per 100,000
population is 3.19 cases, making an understanding of the disease and its treatment of paramount importance (Ostrom et
al., 2017). GBMs develop rapidly de novo in astrocytes, starshaped neuroglial cells suspected to play a role in blood brain
barrier maintenance and neurotransmitter management (Kolb
& Whishaw, 2009). This swift development occurs without any
previous primary or lower grade lesion development that may
indicate or preclude the GBM onset, making early diagnosis and
adequate treatment more difficult.
Since 2005, the first-line standard of care has been established as surgery followed by chemotherapy, most often with
temozolomide (TMZ), and radiotherapy. Despite the established
longevity of this standard, its efficacy is highly questionable and
there is still recurrence in the majority of cases (Patchell, 2003).
To complicate matters further, there is no second-line standard
of care for glioblastomas and recurrence is consistently fatal
(Roy, et al., 2015).

Discussion: Difficulties with Conventional
Treatments
One of the significant factors contributing to the aggressive
character of GBMs is their infiltrative nature. Astrocytes have
extensive networks of processes forming from their cell bodies,
creating an intricately branched structure extending throughout the nervous system. Where some cancers merely invade
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their host tissue, the cells of grade IV astrocytomas penetrate
their host with protrusions. These processes weave a complex
margin with host tissue that blurs the border between invasive
and host cells. This makes complete surgical resection nearly
impossible as practitioners are unable to differentiate between,
and separate, the healthy and malignant tissue. As a result, recurrence is extremely high in GBMs and alternative treatments
must often be considered post-surgery when complete resection is not achieved (Patchell, 2003).
Beyond the inability to properly remove gliomas, the benefit
of surgery is questionable. In a study of recurrent brain tumors,
researchers found no significant benefit to a second resection,
though a first resection did confer an increased overall survival
(Suchorska et al., 2015). Nonetheless, the nature of the neurosurgical procedure lends itself to various complications. Along with
the wound and postsurgical medical complications, brain surgery
runs the risk of systemic and cortical injuries, damaging physical
and mental health with the most common risk of neurological
impairment (Jackson, et al., 2016). Research also found that the
acquisition of motor and language deficits post-surgery is linked
to decreased survival rates compared to patients without surgical
brain damage (McGirt et al., 2009). The results of these studies
indicate that the benefit of surgery is questionable.
Chemotherapy treatments generally follow the attempted resection procedures but have limited success due to the impermeability of the blood brain barrier to foreign chemicals (Deeken &
Loscher, 2007).TMZ is a common chemotherapy drug for gliomas
and has demonstrated mild success against GBM and anaplastic
astrocytoma but its overall effectiveness is slim and is accompanied by a cocktail of undesirable side effects (Friedman, et al,
2000).The established first-line standard of care is precarious and
insufficient. As a result, research has turned to alternative methods by which to treat and manage this deadly.

Genetic Analysis
In order to purposefully theorize and discuss possible solutions
and treatments, GBM manifestation must first be understood.
Occurring primarily in older patients, GBM progresses quickly
and with low survival rates. A minority of cases have been seen in
younger patients with a history of epilepsy connected to progressive low-grade gliomas (Ostrom et al., 2015). To address the lack
of understanding, research continues to look for commonalities
in tumor onset.As genomic instability is an enabling characteristic
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of cancer, efforts have been made in the field to source a primary effector with genetic basis. As of yet, there is only one confirmed molecular predictive factor for GBM - methylation of the
O6-methylguanine-DNA methyltransferase (MGMT) promoter
(Bleeker, et al, 2011). The relative dearth of information on the
molecular basis for GBM requires additional research.
Whole-genome single nucleotide polymorphism (SNP)-based
array analysis of gene expression in GBM patients has indicated
several genetic changes that shed some light on the nature of
the illness. Notably, loss of heterozygosity frequently occurs on
the 17p gene, which contains the tumor protein 53 (p53) (The
Cancer Genome Atlas (TCGA), Research Network, 2008). Loss
of heterozygosity refers to the deletion of a chromosome portion with the corresponding homologous segment being duplicated to compensate for the loss of gene neutrality (Bleeker, et
al, 2011).The significance of this mutation is reflected in the loss
of genetic code for p53. p53 encodes a nuclear phosphoprotein involved in regulation of cell proliferation. In other words,
wild type p53 is a tumor suppressor gene. Mutations in p53 not
only cause loss of tumor suppression, they can activate p53 to
an oncogene in a negatively dominant fashion implicating these
mutations in a number of cancers (Finlay, et al., 1989). Further,
loss of heterozygosity of chromosome 10q is associated with
poor rates of survival and is the most common genetic alteration found in primary and secondary GBM’s.This chromosome
contains various tumor suppression codes, most notably the
region containing ANXA7, an epidermal growth factor receptor (EGFR) inhibitor, and deletions contribute to a proliferation
of cell growth; a distinguishing behavior of cancerous tumors
(Yadav et al., 2009).
Additional research focuses on genetic amplifications associated with GBM. Specifically, amplification of the gene for EGFR
on chromosome 7 has been shown to be a consistent characteristic in glioblastomas (Finlay, et al, 1989; Bleeker, et al, 2011).
Focal amplifications (amplifications containing a small concentration of genes) correlate with overexpression or mutation
of EGFR, leading to subsequent activation of the PI3K/AKT
pathway, another indicator of poor prognosis (Beroukhim et al.,
2007; Phillips et al., 2006). General amplification of entire chromosomes, specifically chromosome 7, has shown correlation
with the activation of the Met axis, a codependent cycle with
Hepatocyte Growth Factor (HGF) which furthers the occurrence of cell proliferation (The Cancer Genome Atlas (TCGA),
Research Network, 2008).
Another genetic component considers IDH1 mutations.
The IDH1 gene codes for isocitrate dehydrogenase 1, a critical
component of the citric acid cycle, catalyzing the conversion of
isocitrate to α-ketoglutarate. Mutations of this gene have been
discovered in 12% of glioblastomas (Watanabe, et al., 2008).
Mutations of this enzyme do not appear to cause loss of function, rather, cancer-associated IDH1 mutations alter the reaction

of the enzyme, enabling it to catalyze the NADPH-dependent
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG).
As many humans have a reduced capacity to dispose of 2HG
in an efficient manner, overaccumulation of the metabolite has
been implicated in the formation of malignant brain tumors
(Dang et al., 2009). 2HG also has a penchant to activate NF-κB,
a prominent protein complex that controls cytokine production, cell survival, and DNA transcription, implicating it in many
cancers, including various leukemias (Chen et al., 2016).
Ultimately, the strongest evidence of a genetic aspect to GBM
is that of the MGMT promoter.While TMZ treatment in general
has shown some benefit, much of its effectiveness is diminished
by this molecular occurrence. TMZ acts by modifying the O6position in guanines. This translates to DNA lesions leading to
DNA cross-links preventing cell replication. MGMT can remove
the alkyl groups and contribute to TMZ resistance but not
when methylated. Because about 50% of patients exhibit MGMT
methylation, the effectiveness of TMZ is considerably lessened
in approximately half of all cases (Bleeker, et al., 2011). Research
is being done particularly in this area to better understand the
environment surrounding methylation and prospectively harnessing the power of methylation to increase TMZ effectiveness
(Lee et al., 2018).
Additional aberrations in genetic behavior exist in GBM with
varying degrees of frequency. With more tools becoming available, it is apparent that the picture of GBM is not clear and
further genetic research is required. Nonetheless, these tools
enable researchers to identify the most prevalent deviations
from typical behavior. For example, many alterations occur
within three primary pathways; the p53, RB, and PI3K/AKT
pathways, and appear to occur in a mutually exclusive fashion
(The Cancer Genome Atlas (TCGA), Research Network, 2008).
This defines a narrower scope of application, hopefully resulting
in the development of rational therapeutic techniques and drug
design. These genomic approaches may ultimately contribute to
more individualized therapies for greater patient longevity.

Immune Evasion and Immunotherapy
In addition to the complications involved with gene aberrations
in malignant gliomas, the impressive rate at which GBMs evade
natural immune response opens another point of study for
prospective treatments. Avoidance of the immune system was
added as a defining characteristic of cancer in 2011 and an examination of the natural immune response has helped develop
vaccinations and treatments for various diseases (Hanahan &
Weinberg, 2011). Nonetheless, the ability of tumors to dodge
these receptors requires a better understanding, specifically in
the brain. In line with original theories, the CNS is immunologically privileged. Unfortunately, it is not quite as privileged
as once suspected. While early theories assumed this privilege
was a result of isolation of the brain by the blood brain barrier,
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newer research refutes this. Peripheral immune cells do in fact
cross the barrier, but CNS neurons and glia regulate immune
responses in a different fashion than other cells (Carson, et
al., 2006). Researchers have demonstrated this deviance from
the standard immune system using experimental foreign grafts
to rabbit brain. These grafts were rejected at a much slower
rate than grafts to less unique locations (Medawar, 1948). An
additional indication of CNS immune system inadequacy is the
immune response of the brain in multiple sclerosis patients. The
immune system of affected individuals appears to contribute
directly to the proliferation of the disease rather than fighting it
(Hemmer, et al., 2015). Despite these deficiencies, analysis suggests proper manipulation of the immune system can assist in
the fight against brain cancers, achieved through understanding
the mechanism by which tumors evade it.
ICT-107 is a multiple-antigen-pulsed dendritic cell vaccine
containing multiple tumor-associated antigens (HER2, TRP-2,
gp100, MAGE-1, IL13Rα2, and AIM-2) known to interact with
glioma stem cells. These antigens may be ideal for vaccination
as their introduction to the dendritic cell tumor environment
stimulates T-cells to generate glioblastoma specific cytotoxicity
(Huang et al., 2017). This immunotherapy was the first such trial
to reflect significant results in terms of overall, progression-free
survival in newly diagnosed GBM (McGranahan, et al., 2017).
A phase III trial is awaiting additional funds to further investigate the effectiveness of this vaccine (Phuphanich et al., 2012).
Another vaccine in phase II trials is Gliovac. This vaccine utilizes
autologous antigens from the patient subjects combined with
allogeneic antigens (antigens with a dissimilar genetic makeup
from that of the patient) derived from other GBM patients.
Beyond using tumor lysate, the Gliovac vaccine is designed
similarly to ICT-107 to encourage the development of cytotoxic T-cells to enhance the struggling immunological response
(Schijns,Virgil E J C et al., 2015). Further studies examine the link
between the CTLA-4 receptor, a constitutively active receptor
on the Treg gene, and its downregulation of the immunologic
response in active T cells (Leach, et al., 1996). By blocking CTLA4, researchers have seen considerable success with enhancing
antitumor immunity, rejecting both artificially introduced and
pre-established tumors. The rapid growth of immunotherapeutic treatments stresses the importance of a more comprehensive understanding of the immune system and its reactions
to foreign in vivo developments. More specific information on
marker antibodies will go a long way in furthering treatments,
not only for GBM but also for other immuno-evasive diseases.

Treatment with Infection
A seemingly counterproductive method of treatment has been
considered to address incomplete resection of glioblastoma
tumors. While the actual number of surgical site infections
after malignant brain tumor resection is not well established,
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data indicates the rate to be about 3.4% (Uzuka et al., 2017). A
speculative theory supported with anecdotal evidence presented the idea that patients who developed postoperative bacterial
infections and survived had a radically increased overall survival.
A study reported four cases of patients with surgical site infections living well beyond the expected range of survival for
glioblastoma (Bowles, et al., 1999). This theory has been subjected to several trials and though not statistically significant, results showed that many infected patients live longer on average
though reverse logic may be cloud results. Infection may correlate with increased life span because patients that live longer
are more likely to develop an infection, not because infection
lengthens survival (De Bonis et al., 2011).

Antiangiogenic Treatments
Antiangiogenic treatments have shown a lot of promise in cancers management and particularly in that of GBM as second-line
treatments. The rationale for antiangiogenics is strong; as cancers
are highly vascular, preventing the growth of blood vessels to supply the tumor should help deplete tumor resources and severely
retard malignancy. Tumors are known to exploit the body’s nutrient and oxygen supplies and require enhanced networks of blood
and lymphatic vessels to facilitate this resource abuse (Nishida,
et al., 2006). Vascular endothelial growth factor (VEGF) is a signaling protein that stimulates the creation of blood vessels and
has received increased attention as an indicator of oncogenesis
(Pavlova & Thompson, 2016). To address this, researchers developed Bevacizumab, a monoclonal antibody that counters the
effects of VEGF and has been approved for trials in the United
States for some time. Dosed intravenously, Bevacizumab has been
used independently as a monotherapy and in pairs or groups of
antiangiogenics for a multi therapeutic approach in various cancer
types. In early trials, a statistically significant number of patients
demonstrated an improvement in overall survival, but randomized phase III trials have been unable to demonstrate an appreciable improvement in overall survival required to move this form of
therapy forward (Bleeker, et al., 2011).

Retroviral Delivery
A promising treatment technique addresses issues with alternative treatments. Retroviral replicating viruses (RRVs), are a novel
way of treatment delivery and contain a wide variety of unique
characteristics that allow for highly specific gene transfer in an
efficient manner. Pharmaceutical companies are combining many
of the above therapies into a single, comprehensive treatment
method for recurrent high-grade gliomas with the goal of extending these concepts to further treatments.
Retroviruses are positive-sense RNA viruses. These obligate
parasites cannot reproduce or complete their life cycle without
a host cell. Once within a host, these viruses use the enzyme
reverse transcriptase to produce DNA from the viral RNA
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sequences. This DNA strand is then incorporated into the host
cell genome with an integrase enzyme. By transferring it’s genetic data into the host, the virus ensures it will be reproduced
when the host reproduces. The applications of these viruses
can allow scientists to produce desired proteins and genetic
products for treatment purposes. These viruses confer many
advantages to the treatment of cancers and in particular, of
glioblastoma. One such benefit of RRVs is the selective acceptance within cells. It has previously been established that tumors
exhibit a distinct loss of immunity and that a central aspect of
cancer development is the evasion of the immune system. Cell
populations naturally assess tissue to prevent proliferative, uncontrolled growth, and cancers evolve to avoid the anti-tumor
response. This evolution evades immune checkpoints and regulators but also enables immunoediting, the process by which
cancers read, react, and adapt to immune processes. By disabling
the anti-tumor response, cancer cells can replicate continuously
unchecked (Butt, et al., 2004). The lack of immunity that permits cancers to exist also creates an opportunity for medical
intervention. RRVs are generally recognized by healthy cells and
dealt with accordingly by the normal immune system, but the
reduced defense mechanism of cancer cells allows the RRV to
incorporate genetic components into the cancer gene pool.This
selective acceptance safeguards healthy tissue while priming
cancer cells. Another key feature of RRVs is the ability to spread
non-lytically and without an exceptional inflammatory response.
Gene products are not produced until the virus is activated
and this avoids an inflammatory response from the innate immune system (which is not heavily compromised). Coupled
with a nonlytic retroviral infection, this delivery system enables
researchers to target specifically cancerous or immunocompromised cells (Logg, et al., 2012).
The Tocagen therapy relies on an engineered retrovirus known
as Toca 511 (vocimagene amiretrorepvec) for delivery. Toca 511
is a murine leukemia virus that infects dividing cells, preferentially
integrating into cells that are immune-deficient — in this case
GBM cells. In addition, the retrovirus has no trouble crossing the
blood brain barrier, an issue that arises with other treatments.
The virus contains the genetic code for an altered cytosine
deaminase (CD), a protein enzyme that catalyzes the reaction
converting cytosine residues to uracil (Ostertag et al., 2011). In
trials, after several cycles of RRV treatment, researchers found
a high concentration of CD present in tumor cells, but none or
insignificant levels expressed in quiescent cells. The retrovirus
delivery method efficiently targets tumor cells and integrates its
genetic contents into the DNA of the host cell without affecting
the genetic integrity of healthy cells in the body.
While the success of the genetic transfer is significant, the
expression of optimized CD within tumor cells is of little consequence. Further action is required to have an impact on cancerous cells. 5-fluorocytosine (5-FC) is subsequently administered

as a prodrug, a drug in an inactive form. Despite widespread uptake of 5-FC by the majority of cell types, this inactivity prevents
any notable response from quiescent or typical cells. However,
in the Toca-511 pretreated tumor cells, 5-FC is converted by
CD to 5-fluorouracil (5-FU), a potent antineoplastic cancer
drug used as the drug of choice for colorectal, esophageal, gastric, and many other cancers. While the precise mechanism of
5-FU is unknown, it is suspected to interfere with DNA synthesis, protein synthesis, and RNA processing (Pinedo & Peters,
1988). Collectively, these contribute to an incompatible state
for the tumor cell leading to apoptosis and subsequent removal
by the immune system. Furthermore, 5-FU has also been shown
to destroy myeloid-derived suppressor cells. These cells help
evade the immune system and elimination of these suppressor
cells allows the patient’s natural immunity to assist in tumor
destruction (Cloughesy et al., 2016). An additional advantage
of the engineered 5-FU produced in Toca-511 allows the active
drug to diffuse through the cell membrane, giving the potential
to have therapeutic effects reaching beyond the cytosol of the
parent cell (Hemmer, et al., 2015). There is strong evidence to
suggest this phenomenon, called the bystander effect, occurred
in preliminary trials and it resulted in an improved overall survival rate as well as an improved recurrence free outcome. The
Tocagen drugs are undergoing clinical trials but the progress
they signify in science is considerable and opens the door to a
proliferation of improved treatment techniques.

Multi-Therapy
The multi hit model of cancer, also known as the Knudson hypothesis, is the theory originally proposed in 1953 hypothesizing
a stepwise component to oncogenesis.The theory suggests that
cancer onset is not the result of a single mutation, rather the
outcome of many mutations, creating conditions for the perfect
storm that is cancer (Nordling, 1953). Knudson’s hypothesis
has greater validity after “Hallmarks of Cancer” was published
by Weinberg and Hanahan (Hanahan & Weinberg, 2000). The
hallmarks reiterate the idea that cancer is multi-faceted and
more complex than a single aberration in physiology and development. The theory gives rise to an alternate approach to
treatments; if the disease is multifaceted, then so must be the
treatment plan. Various treatment proposals utilize this theory for multi-hit therapy. Some antiangiogenic treatments are
being applied in conjunction with others for a comprehensive
approach. Several attempts have been made, or are now in trials,
that couple effective treatments like that of TMZ with newer
medications to enhance their effectiveness. In concurrence with
TMZ, patients have been tested with a wide variety of pharmaceutical cocktails, including gefitinib and erlotinib, a pair of
EGFR inhibitors (Bleeker, et al., 2011). Patients have also been
treated with radiotherapy and Gliadel wafers. These wafers
are intracranial implants containing carmustine, a nitrosourea
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alkylating agent, and give a steady treatment of chemotherapy
to their host after being inserted into the brain (van den Bent
et al., 2008). Direct insertion prevents the need to circumvent
the blood brain barrier and offers a continuous administration
of the drug for the duration of the treatment. As a nitrosourea,
carmustine alkylates DNA strands, preventing normal gene
expression in cancer cells and dampening tumor development.
Further, contrary to previous research, resistance to a single alkylating agent does not predict resistance to alternate alkylating
agents, allowing for a multi-agent approach to prevent cancer
gene expression (Schabel, 1976).
The development of chimeric antigen receptor T-cell therapy
(CAR-T) builds on the success of above-mentioned treatments
such as retroviral genetic manipulation and immune system
enhancement. This technique utilizes engineered T-cells to recognize specific markers in cancer cells and induce apoptosis.
One lab at the Memorial Sloan Kettering Cancer Center focused on B cell acute lymphoblastic leukemia and is examining options to extend this therapy to gliomas. In the leukemia
study, patients with relapsed B cell acute lymphoblastic leukemia had T-cells isolated from plasma and treated with a vector.
The vector programmed T-cells to produce chimeric antigen
receptor, a receptor that can be engineered to enable the T
cells to recognize specific proteins found in cancers (CD19 in
this case) (Brentjens et al., 2013). One particular advantage of
CAR-T therapy is the use of the patient’s own immune cells.
Using autologous material decreases the incidence of rejection
or other complications that frequently occur with the introduction of foreign cells (Almasbak, et al., 2016). CAR-T therapy
has demonstrated high rates of success with above an 88% long
term survival rate and is being evaluated for expansion to a
greater variety of cancers, including high- and low-grade glioma
(Wilkins, Keeler, & Flotte, 2017).
The range of ideas employed with multi-hit therapies and
techniques takes advantage of the advances made in genetic
and molecular research. Introducing therapies that make use
of immunotherapy and genetic recombination, or that address
multiple facets of angiogenesis are particularly useful in tackling
the multidimensional aspects of cancer. Combination treatments allow scientists to develop a more comprehensive blend
that can address the particular deficiencies associated with each
individual medication and enable an extensive treatment plan
for the greatest chances of survival.

Conclusion
Glioblastoma multiforme is a high-grade malignancy with a poor
prognosis. While additional preventative research is required to
improve diagnostic methods and screening, management methods are under rapid development to improve not only survival
but also quality of life. A greater focus on intermolecular functioning within GBM helps provide a better understanding of how
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to effectively diagnose and recognize the cancer. Additionally,
such information allows the introduction of periodic screening
in higher risk individuals as determined by these advances. By
analyzing intermolecular pathways such as kinase receptors and
genetic modifications, researchers can develop steps or procedures to counter the cancer. This basic research extends itself
heavily to the applied sector and allows for the creation of therapies and treatments that respond to the characteristics and actions unique to this disease and the complexities of its location.
Many treatments have already been proposed in an attempt
to contain the rapid tumor proliferation associated with glioblastomas. With the knowledge gained from the success and
failures of these treatments, adjusted multi-therapy approaches
and novel replacement techniques have been developed. From
genetics and immunological studies to bacterial and retroviral
infections, these alternatives offer increased variability and possibility for patients. Despite the grim prognosis that typically
accompanies the diagnosis of GBM, there is the potential for the
cancer to no longer be as debilitating as it currently is or once
was. Particularly through immunotherapy and gene therapy, as
well as the use of antiangiogenics and nitrosourea alkylating
agents, GBM can soon be combatted beyond the standard of
surgical resection and chemotherapy.
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Abstract
Neuraxial analgesia is one of the most popular and effective forms of pain relief for labor and childbirth used by more than 50%
of women in North America. Despite the standard use of the procedure, there is much that is still inconclusive about the side
effects on mother and baby. Current studies show it has an impact on some outcomes and seemingly no effect on others. While
the extent of the impact is still unclear, there are some adverse side effects of neuraxial analgesia, which include instrumental
deliveries, respiratory distress and lower Apgar scores. Further research is required to conclude how and to what extent neuraxial
analgesia impacts mother and baby.
Introduction

Oxytocin Augmentation

Labor and childbirth are known to be extremely painful experiences. Over the years there have been multiple methods developed which provide pain relief. Neuraxial analgesia, known
colloquially as ‘epidural’, is one of the most popular forms of pain
relief and is used by 50-70% of women in North America. It became a standard form of labor analgesia during the 1970s (Silva
and Halpern 2010).
When neuraxial analgesia is administered, a small amount of
anesthetic is inserted into the epidural space of the spine to
prevent pain signals from traveling from the spine to the brain
(Schrock and Harraway-Smith 2012). The drugs used most often
in North America are bupivacaine and ropivacaine (Silva and
Halpern 2010). There are few forms of epidurals used. For the
epidural procedure, a catheter is inserted directly into the epidural space of the spine and the patient receives a continuous
flow or multiple injections of local anesthetic. Spinal anesthesia
refers to local anesthesia inserted into the subarachnoid space
and one injection is usually sufficient. Combined spinal-epidural
analgesia includes an initial spinal intrathecal injection as well as
an epidural catheter for additional drugs. Neuraxial analgesia is an
umbrella term which includes all three methods: epidural, spinal
and combined spinal-epidural.
This text includes all three types of neuraxial analgesia used
in labor. When using the term ‘epidural’, it refers to any of the
three forms.
During labor and delivery, the primary concern is the safety
and health of the mother and neonate.
Despite the longevity and standardized use of the procedure,
there is much that is still unknown about the side effects of epidural analgesia and its impact on labor progress and maternal
and neonatal outcomes.This text aims to explore if there are any
adverse effects of epidural on the process of labor and delivery
and on the health of the mother and neonate.

There are several ways in which epidural may have an effect on
the mother during labor. Epidural has been linked to increased
need for oxytocin augmentation during labor and delivery.
Oxytocin is a hormone secreted by the pituitary gland. During
labor, it stimulates uterine contractions and dilates the cervix.
Oxytocin is continually secreted during labor through a positive
feedback loop. Contractions push the fetal head towards the cervix which stimulates additional oxytocin to be produced. If labor
does not progress at a proper rate, synthetic oxytocin can be
administered intravenously to strengthen the contractions. This
process helps progress the labor, however, it increases the risk
of multiple adverse outcomes for the neonate (Bell et al. 2014).
A retrospective case-control study was done using clinical records of all mothers admitted to Riga hospital between January
1, 2013, and December 31, 2013. Infants included in the study
were singleton pregnancies, at least 37 weeks of gestation, in
cephalic position and vaginally delivered.
Epidural analgesia was given on demand, and the birth had
to occur more than one hour after the epidural analgesia was
used. Eight hundred and thirty-two women were included in
the study, 304 who received epidural and 528 in the control
group. Women who had epidural analgesia had higher rates of
augmentation of their first stage of labor with oxytocin than
women who did not receive epidural analgesia (Krievina et al.
2015). These findings are consistent with a study which also
found increased oxytocin use in women receiving epidural analgesia (Decca et al. 2004).
Another study of 160 women, 80 receiving epidural analgesia
and 80 in the control group found no difference in the percentage of patients who received oxytocin, but the maximum rate of
oxytocin infusion was significantly higher in the epidural group,
compared to the control group [P=.001] (Mousa et al. 2012).
These studies have exhibited an increase in the relationship
between epidural and the need for synthetic oxytocin administration, which increases the risks for complications during labor
and delivery.

Methods
Original studies and scientific papers found through TouroLib
access to databases such as PubMed, Proquest, and EBSCO
were used fir this review. Google scholar was also used. Many of
the studies are retrospective since readily available data greatly
increases the population sample size. To ensure the research included pertains to current techniques, most studies used were
published within the last ten years.

Length of Second Stage Labor
Epidural has also been studied in association with its effect on the
second stage of labor. The second stage of labor is also known
as the pushing stage. Prolonged second stage labor has been
associated with adverse effects on neonatal outcome, including
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an increased relative risk of birth-asphyxia related complications
and increased chances of NICU admission (Sandstrom et al.
2017). The longer the second stage of labor, the lower the infants
one-minute Apgar score was and the higher the incidences of asphyxia. Prolonged second stage labor also has adverse effects on
the mother. Li et al., discovered that the longer the second stage
of labor progressed, the higher the incidences of cesarean section
and postpartum hemorrhaging (Li et al. 2011). A study conducted
across Washington state found that in nulliparous women, there
was a two-fold increase in the median duration of second stage
labor in women who received epidural analgesia when compared
to those who did not. It also recorded a two-hour increase in
second stage labor in the 95th percentile for women who received epidural analgesia (Souter et al. 2018).
A similar retrospective analysis was performed on all live,
singleton, full term, vaginal deliveries in a university hospital
between the years 2012-2014. Exclusion criteria included operative deliveries due to fetal distress, major fetal anomalies and
chromosomal abnormalities The inclusion criteria were met by
15,499 deliveries. In this sample, women delivering with epidural analgesia were associated with an additional 82 minutes of
second stage labor in the 95th percentile for both nulliparous
and multiparous women. The study examined the effects of epidural analgesia on both nulliparous and multiparous women, and
within each of those groups, there were women who received
oxytocin augmentation were compared to those who did not.
There was a significant effect found in all four groups. This study
found epidural analgesia to be overall associated with over a
one-hour increase in second stage labor (Shmueli et al. 2016).
A retrospective cohort study done on all live, singleton births
in the University of California, San Francisco between 1976 and
2008 studied the effects of epidural on labor length. The study
excluded pregnancy complications and cesarean sections that
took place during the first stage of labor. The study included
42,268 women, where 49.9% had received epidural analgesia
and 50.1% did not. Statistical analysis showed that women in
the 95th percentile of the second stage of labor who received
epidural analgesia had an average difference of more than two
hours in duration of second stage labor when compared to
women who did not receive an epidural. This number was statistically significant in both nulliparous and multiparous women
(Cheng et al. 2014).

Instrumental or Operative Vaginal Delivery
Epidural has also been studied in its association with the need
for instrumental or operative vaginal delivery. Instrumental or
operative vaginal delivery is when forceps or vacuum extraction
is used to extract the fetus from the vagina. This has been associated with adverse neonatal outcomes.
One study conducted on 2052 women in San Diego studied
the risk of instrumental vaginal deliveries and cesarean sections
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in nulliparous and multiparous women when epidural analgesia is administered during the first stage of labor. The study
excluded multiple births, inducements and preterm births. In
nulliparous women, the relative risk of operative vaginal delivery
was 2.5 when compared to women without an epidural. For
multiparous women, the crude relative risk was 11.5 for operative deliveries (Nguyen et al. 2010).
A retrospective study on 350 female patients who received
epidural analgesia and 1400 controls showed that vacuum extraction and cesarean sections were more frequently performed
in the epidural group than the control group [p<0.001].The epidural analgesia slowed down the progress of labor, which led to
an increased rate of instrumental deliveries. The instrumental
delivery appeared to affect the neonatal outcome more than
the epidural analgesia itself (Hasegawa et al 2013).
A study conducted on 100 neonates born with epidural analgesia and 100 without had results consistent with other studies
regarding epidurals and instrumental deliveries. Instrumental
delivery, which included both forceps and vacuum extraction,
had taken place during 13 births, 11 of which were from the epidural group [p<.010], making this a statistically significant study
(Shrestha et al. 2014).
Krievina et al. 2015, whose population size was 832, discovered no difference between epidural analgesia groups and the
non-epidural groups in regards to the use of vacuum extraction.
The study recorded vacuum extraction only used in first-time
mothers (Krievina et al. 2015).
While not indisputably conclusive, there is evidence in the
research of a correlation between epidural analgesia and an increased need for instrumental deliveries.

Cesarean Section
A few studies noted the association between epidural analgesia and increased rate or risk of cesarean sections. Nguyen et
al., (2010) conducted a study showing that administration of
epidural analgesia during the first stage of labor increased cesarean section rates (Nguyen et al. 2010). Hasegawa et al., (2013)
also recorded that cesarean sections were more frequently
performed on the group of women receiving epidural analgesia
than the control group [p<.001] (Hasegawa et al., 2013). Mousa
et al. and Decca et al. both recorded no increased cesarean
section rates (Mousa et al. 2012) (Decca et al. 2004).The results
of the studies disagreed but both Nguyen et al. and Hasegawa
et al. studies consisted of significantly larger populations than
either Mousa et al. or Decca et al.

Maternal Fever
Epidural is known to increase maternal temperature. Maternal
temperature during labor and delivery is associated with effects
on the neonate. Intrapartum fever is related to infectious and
noninfectious etiology. It is a well-known risk factor for adverse
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neonatal outcomes including neonatal sepsis, seizures, asphyxia
and mortality (Petrova et al. 2001). It is also known to effect
obstetric outcomes; intrapartum fever significantly increases
the rates of cesarean sections and operative vaginal deliveries
(Lieberman et al. 1999).Whether increased fever related to epidural has the same adverse effects as other intrapartum fever is
a question that has been studied.
One study was performed to investigate the relationship
between combined-spinal epidural and increased maternal intrapartum temperature. Seventy women were included in the
study, 35 receiving combined spinal-epidural anesthesia and 35
who did not receive any pharmacological form of pain relief. At
the start of the study, the median temperature of the women
was the same in both groups; after the first hour, there was an
increase of intrapartum maternal temperature in the women
receiving epidural analgesia. The difference in temperature between the two groups remained until the sixth hour and onward, where no statistically significant difference was found.
Five of the 35 women receiving combined-spinal epidural
developed intrapartum fever while no fever was found in the
group receiving non-pharmacological pain relief (P=0.027).
However, there were no statistically significant differences in
neonatal outcome. None of the infants born to mothers who
had intrapartum fever developed neonatal sepsis, required antibiotic treatment, nor were they evaluated for neonatal infection.
This study showed that combined-spinal epidural had an impact
on intrapartum maternal temperature and can cause fever. It
does not, however, have any adverse effects on neonatal or maternal outcome (de Orange et al. 2011).
A statewide study was conducted in Colorado on the association
between epidural analgesia, maternal fever and neonatal antibiotics.
Antibiotic administration to neonates who are at risk of infection
is essential in preventing neonatal sepsis. However, unnecessary exposure to antibiotics is associated with significant risks.
There was no difference found between epidural and non-epidural groups in the administration of antibiotics to newborns
born to mothers with fever. Women who received epidural analgesia were 5.4 times more likely to develop intrapartum fever.
However, the infants had antibiotics administered equally in all
cases of fever, regardless of what the cause was. This indicates
that infants born to mothers who received epidural analgesia
are more at risk of receiving unnecessary antibiotic treatment
(White et al. 2017). While epidural-related fever did not seem
to have a physiological effect on the neonate, the fever did lead
to unnecessary antibiotic exposure.

Apgar Scores
One of the first assessments performed on a neonate is the
Apgar score. The Apgar scoring system is a rapid method of assessing the clinical status of a newborn at one and five minutes
of age. The Apgar score comprises of five components: 1. Color

2. Heart rate 3. Reflexes 4. Muscle tone and 5. Respiration. Each
component is given a score of 0,1, or 2. This is an accepted and
standard method for reporting the status of an infant immediately after birth. While the Apgar score cannot be used to predict outcomes or diagnose alone, it is a useful tool in assessing
the newborn. Because this is the standard test performed on
all infants born in Western countries, it is simple data to collect
and study and is one of the foremost things to examine when
determining a baby’s status (acog.org). Since most studies are
conducted retroactively and all infants are scored on the Apgar
system, it is an easy and commonly studied component.
A study was conducted in Spain on all full-term infants excluding inductions, elective cesarean sections and major pregnancy complications. The mean Apgar scores at one and five
minutes were slightly but statistically significantly lower in
the group of infants exposed to epidural analgesia [p=0.001]
(Herrera-Gomez, 2015).
A different study conducted by Krievina et al. had a similar
infant population, however with only singleton infants included. There was no statistically significant difference in the Apgar
scores of infants whose mothers received epidural analgesia and
those whose mothers did not. In this case, the birth had to be
at least one hour after the epidural analgesia was administered.
Although the outcome was different than in the previous study,
the population size was much smaller in this study than in the
study conducted by Herrera-Gomez (Krievina et al. 2015).
Another study recorded the Apgar scores were significantly
lower in neonates who were delivered via vacuum extraction
when compared to those delivered via spontaneous vaginal
delivery and cesarean sections, regardless of whether the mother had an epidural or not. However, this study also found that
epidural analgesia significantly increased the incidences of operative delivery. This leads to an indirect association between epidural analgesia and lower Apgar scores (Hasegawa et al. 2013).

Respiratory Distress
One of the variables that is observed when a child is born is the
respiratory state of the newborn. A case-control study discusses
the effects that epidural analgesia can have on the respiratory
state of newborns in the immediate neonatal period. The case
consisted of newborns who had gone into respiratory distress.
The control group was comprised of site matched neonates of
similar gestational age who did not go into respiratory distress.
Infants included were late preterm or term. Exclusion criteria for
this case group were major congenital malformations associated
with newborn respiratory distress, culture-proven sepsis within 72 hours of birth or elective cesarean sections. Two hundred
and six infants and 206 matched controls were included in the
study. Seventy percent of infants who experienced respiratory
distress had mothers who were exposed to epidural analgesia. In
the control group 63% of infants had mothers who were exposed
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to epidural analgesia. After statistical adjustments, the difference
between the two groups was statistically significant [P=.04]. This
study shows an association between epidural use and subsequent
respiratory distress in the infant (Kumar et al. 2014).
A study conducted in Spain with 2399 infants studied the association between epidural analgesia and need for resuscitation.
From the infants born to mothers who used epidural analgesiac,
resuscitation was required in 28.7% versus 17.6% in the infants
whose mothers did not have epidural analgesia [p=.001]. This
study shows a correlation between epidural analgesia and the
risk of resuscitation in newborns (Hererra-Gomez 2015).

Breastfeeding
The benefits of breastfeeding both on infant and mother have
been well documented. In infants, breastfeeding is associated
with reduced incidences of respiratory and gastrointestinal
tract infections. Breastfeeding is also shown to reduce the longterm risk of diseases, obesity and diabetes. Maternal benefits
include reduced bleeding after delivery, more rapid involution of
the uterus and lower risks of future diseases (Eidelman 2012).
A study was conducted on the relationship between epidural
analgesia during labor and onset of lactation in healthy women.
Those included in the study were all singleton, full-term, vaginal
deliveries and pregnancies that had no other pathological conditions.Women who experienced complications during labor were
excluded. Only healthy babies with Apgar scores of greater than
eight and those that did not require intensive care were included.
All the women who participated in the study intended to breastfeed. There were 209 women who received epidural analgesia
and 157 who did not. There was a five and twenty day follow up
with the mother. There was no difference found in the onset of
lactation between the two groups. Onset of lactation was determined as the time between birth and the peak intensity of the
three major symptoms of lactation: breast tension, heat, and pain.
At 20 days postpartum, more mothers who received epidural analgesia were formula feeding their babies than the mothers who
did not receive epidural analgesia (Mauri et al. 2015).
Conflicting results were obtained in a retrospective study
conducted by Herrera-Gomez et al. 2015 on all full-term infants
born in San Juan de la Cruz Hospital between March 2010 and
March 2013. Exclusion criteria included induced labors, elective
cesarean sections and high-risk pregnancy factors. The study included 2399 infants. One of the variables studied was the onset
of early breastfeeding, which was defined as within the first two
hours of birth. Early breastfeeding onset was observed in 82.4%
of infants in the epidural group and in 91.1% of infants in the
non-epidural group, a significant difference with the odds ratio
(OR) factor of 1.96 (Herrera-Gomez et al. 2015).
A study by Dozier et al. (2013) which observed the relationship between epidural analgesia and breastfeeding cessation,
found similar results to Mauri et al. 2015. This study included

30

722 full term, singleton vaginal deliveries in which the mother-initiated breastfeeding. A significant crude relationship was
found between epidural analgesia and breastfeeding cessation
within 30 days [p<.01]. It was also found that the overall interaction between epidural analgesia and intravenous oxytocin
negatively affected breastfeeding (Dozier et al. 2013).
Another study conducted on 100 women who received epidural analgesia and 100 women who did not. Exclusion criteria
were cesarean sections, preterms, low birth weight and other
complications.The timing of the initiation of breastfeeding was divided into three groups: within six hours of birth, six to 24 hours
postpartum and after 24 hours. In the epidural and non-epidural
group, 96 and 98 infants in each group respectively had started
breastfeeding within six hours. Only one in each group established breastfeeding between six to twenty-four hours.Two newborns in the epidural group and one in the non-epidural group
started breastfeeding after 24 hours. The P value was .06 not a
statistically significant value (Shrestha et al. 2014).
Most studies show no significant difference in the onset of lactation between mothers who had epidurals and those who did
not. Women who did not have epidurals were more likely to be
breastfeeding for a longer period. However epidural analgesia was
not the primary factor in predicting the duration of breastfeeding.

Conclusion
The research discussed in this paper covered a variety of topics
such as oxytocin, length of labor, increased need for instrumental-assisted deliveries, Apgar scores and breastfeeding. There are,
however, many other areas of impact that have not been covered,
such as hypertension, NICU admission and urine passage. The
exact impact that epidural analgesia has on maternal and neonatal
outcomes is not conclusive. However, studies show that neuraxial
analgesia is associated with increased risk of some maternal and
neonatal outcomes such as instrumental deliveries, respiratory
distress and lower Apgar scores, while having less of an effect on
variables such as breastfeeding. Due to the considerable number
of variables that determine maternal and neonatal health, it is
difficult to identify which outcomes are due solely to epidural
analgesia. Most of the research focuses on whether neuraxial
analgesia causes side effects, but there is less research on the reasons why it does. Perhaps if the mechanism could be better understood, then more may be understood as to who is at greater
risk for experiencing side effects and clinicians can then have the
possibility and tools to better treat and educate mothers to be.
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Abstract
Parkinson’s disease is the second most common neurodegenerative disease that negatively affects many American lives. It is
characterized by the degeneration of dopamine-secreting neurons in the Substantia Nigra Pars Compacta (SNpc). Individuals
with Parkinson’s Disease lack motor coordination and experience severe motor impairments. Unfortunately, there is currently
no treatment method available that can successfully cure the disease. In fact, all of the mainstream available treatments only
eliminate some PD symptoms, and they cause many negative side effects. Although nontraditional, exercise is a side effect free
treatment method that can potentially slow the progression of the disease and alleviate some symptoms. This paper first gives a
comprehensive overview of the pathology and current treatments of Parkinson’s disease. Then this paper reviews the benefits of
exercise therapy for PD patients and the potential biological mechanisms that drive the success of exercise therapy.
Introduction
Although not as prevalent as Alzheimers, Parkinsons disease(PD)
is the second most common age-related neurodegenerative disorder (Paillard, et. al. 2015, Maiti, et. al. 2017). It occurs in about
1-2% of the population over 65 and has been found to occur
even less in younger populations (Maiti, et. al. 2017). Thus, age
is considered to be one of the most prevalent risk factors for
the development of the disease. Although Parkinson’s disease
does affect multiple parts of the brain, it is mainly characterized as a neurodegenerative disease that causes the degradation
of dopaminergic neurons located in the Substantia Nigra Pars
Compacta (SNpc) (Maiti, et. al. 2017, et. al. 2013). In a healthy
person, the axons of these neurons extend to the Striatum
where they help relay inhibitory signals by secreting dopamine
which in return causes the basal ganglia to send inhibitory signals to Globus Pallidus and thalamus. These inhibitory signals
help regulate movement by preventing the thalamus from over
stimulating the motor cortex and causing impairment of motor
coordination (Maiti, et. al. 2017). Due to the degradation of
SNpc neurons, patients with Parkinson’s disease have a significant decrease of dopamine secretion in the Striatum and as a
result they experience significant motor impairments (Petzinger,
et. al. 2013, Maiti, et. al. 2017).

Symptoms
PD is a neurodegenerative disorder that slowly worsens over
time, thus, individuals with Parkinson disease experience a wider
array of symptoms as the disease progresses. It takes around 15 to
20 years for PD symptoms to progress and it is estimated that the
first visible symptom is seen only once 80% of the SNcp neurons
have died out. Due to the progressive nature of the disease, early
symptoms are subtle and often unidentifiable (Sveinbjornsdottir,
2016, Maiti, et. al. 2017). At first, most individuals will experience
twitching in their arm, leg, jaw, lips or chin (Maiti, et. al. 2017).
This symptom is called a resting tremor and is observed in the
early stages of the disease in about 70% of PD patients (Maiti, et.
al. 2017) (Moustafa, et al., 2016). It is most commonly found in
the arms and the legs, and it usually starts off only on one side
of the body. Gradually, this tremor develops bilaterally affecting
both sides of the body (Maiti, Manna, & Dunbar, 2017).The second
most common symptom is rigidity or stiffness of the muscles and
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joints (Maiti, et. al. 2017) (Moustafa, et al., 2016). This side effect
causes individuals with PD to feel week and have severe cramping
pain (Maiti, et. al. 2017). Individuals with PD also lose their ability
to move quickly and experience a symptom called bradykinesia
(Moustafa, et al., 2016, Maiti, et. al. 2017). Bradykinesia is characterized by loss of automatic movements, slow handwriting,
decreased eye blinking, lower speech volume, difficulty initiating
movement and difficulty in stopping continuous movements. In
addition, PD patients also experience balance and coordination
problems and will often fall. All of the above symptoms are considered to be primary symptoms of Parkinson’s Disease and are
essential for the diagnoses of the disease (Sveinbjornsdottir, 2016,
Maiti, et. al. 2017).
In addition to the above symptoms ,some secondary symptoms
may develop.These include continued changes in speech including
the slurring of words, the repetition of words and excessively
slow or abnormally fast speech. Urination and defecation become
exceedingly hard due to the slow movement of smooth muscle in the digestive tract. Swallowing and chewing food becomes
very difficult because of the bodies inability to perform peristalsis
properly. In addition, PD patients often have a hard time staying
asleep at night due to “insomnia, Rem sleep behavior disorder,
sleep apnea, sleep attacks and restless leg syndrome (Maiti, et. al.
2017).” Some people with PD also experience depression, mood
problems, anxiety, cognitive dysfunction, apathy and Dementia
(Chauduri & Schapira, 2009) (Maiti, et. al. 2017).

Mechanisms of Parkinson’s Disease
Parkinson’s Disease can manifest due to external factors or as a
result of inherited genetic mutations. Most cases of PD are considered to be non-genetic forms of PD, that result from environmental stimuli (Maiti, Manna, & Dunbar, 2017). Both genetic
forms and sporadic forms of PD follow similar mechanisms of
neuronal degeneration. Three of the most probable pathways
of neuronal degeneration are death through mitochondrial
dysfunction, A-synuclein aggregation, malfunctioning chaperone
proteins and Autophagy lysosomal pathway damage.
Mitochondrial dysfunction can be caused by both genetic and
environmental factors. Some environmental factors that cause
PD include pesticides, herbicides, fungicides, and insecticides.
Consequently, farmers and individuals who live in rural areas
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are considered to be more susceptible to PD due to direct exposure to these substances through the air and drinking water.
Other environmental factors that cause PD included bacterial
toxins, viruses and illegal street drugs such as synthetic forms
of heroin and rotenone. These environmental factors “inhibit complex one activity and cause dysfunction in the electron
transport chain which causes oxidative stress (Maiti, et.al. 2017,
p. 12).” Gene mutations of the DJ-1 and Pink 1 genes also cause
mitochondrial dysfunction that can result in oxidative stress by
inhibiting the formation of mitochondrial protective proteins.
Once initiated by either environmental or genetic factors, oxidative stress causes the phosphorylation of tau proteins which
eventually aggregate to form Lewy Bodies. These Lewy bodies
accumulate in the cell making it exceedingly hard for the cell to
complete basic tasks needed for neuronal function . Lewy bodies also make pores in the cell membrane resulting in “neuronal death via oxidative stress, energy failure, excitotoxicity, and
neuronal inflammation. Eventually, the infected neurons begin to
die due to their inability to perform tasks essential for survival”.
In addition to oxidative stress, mitochondrial dysfunction can
also directly lead to energy failure. Energy failure refers to the
cells inability to produce the chemical energy needed for cell
survival. Energy failure causes the degeneration and death of
dopaminergic neurons (Maiti, Manna, & Dunbar, 2017).
Mutations in the a-synuclein gene cause an alternative mechanism of neuronal degeneration. This mutation leads to the
creation of misfolded α-synuclein proteins that eventually aggregate and develop into Lewy Bodies . Lewy bodies block up
the cell making it close to impossible for basic cell functions to
be completed. In addition, the Lewy bodies can make holes in
the cell membrane which cause cell death by initiating, oxidative stress, energy failure, excitotoxicity, and neuroinflammation
(Maiti, et. al. 2017). Thus, the α-synuclein gene mutation directly
affects neuronal cell death.
Mutations of the parkin and UCHL1 genes can lead to the
death of SNpc neurons by causing the destruction of ubiquitin-proteasome system(UPS) and molecular chaperones (Maiti,
Manna, & Dunbar, 2017). The UPS actively brakes down short
polypeptides into intracellular plasma membrane proteins, and
it also helps with degeneration of “misfolded or damaged proteins in the cytosol, nucleus or endoplasmic reticulum (Maitiet.
Al. 2017, p. 9).” Chaperone proteins play an important role in
ensuring that proteins are folded properly. Damage to these
two systems lead to the accumulation of misfolded proteins and
to the impairment of the Autophagy Lysosomal pathway(ALP).
The ALP helps degrade large protein debris that cannot be degraded by the UPS. When the UPS, chaperone proteins and ALP
fail to complete their respective jobs, misfolded proteins begin
to aggregate in the cell and form Lewy bodies (Maiti, Manna, &
Dunbar, 2017). The Lewy bodies go on to disrupt cell function
leading to the degeneration SNpc neurons.

The Spread of the Disease
Many researchers believe that once Parkinson’s disease is initiated, Lewy body infected neurons transmit the disease to adjacent
uninfected neurons (Maiti, Manna, & Dunbar, 2017).This method
of proliferation is known as the prion hypothesis. Interestingly,
many studies have found that α-synuclein begins to aggregate
in the enteroendocrine cells of the gastrointestinal tract and
then spreads to the brain via prion infection. Although this may
be the method of proliferation used in some cases of PD, it is
definitely not used in all PD cases since Lewy bodies are not
necessary for initiation of PD (Maiti, et. al. 2017).
Inflammation may also be responsible for the spread of
Parkinson’s disease (Zhang, et al., 2011) (Phania, et. al. 2012).
Neuronal inflammation occurs due to head trauma or the development of pathogenic disease such as PD. Inflammation in the
PD brain is characterized by activated microglia cells, astrocyte
cells and imported T-cells that crossed the blood-brain barrier
(Cebrián & Sulzer, 2017). In the case of Parkinson’s disease, the
immune response is unbalanced, and instead of eliminating the
disease it aids in the progression of the disease.
Microglia cells are activated as a result of α-synuclein accumulation (Cebrián & Sulzer, 2017). Once activated they act as
phagocytic cells and participate in the removal of toxins and
dead neurons (Vivekanantham, et al., 2015). They also produce
“a plethora of pro-inflammatory mediators including prostaglandins, cytokines, chemokines, complement, proteinases, ROSs
and RNSs (Vivekanantham, et al., 2015).” These substances initiate cell death by directly causing oxidative stress. In addition,
microglia phagocytose extracellular neuromelanin that was released by dying neurons (Cebrián & Sulzer, 2017). During this
process cytokines and hydrogen peroxide are released and cell
death via oxidative stress is initiated (Zhang, et al., 2011).
Astrocytes are supposed to help regulate the immune response by protecting neurons from oxidative stress. In theory
this would allow the microglia cells to participate in the immune
responses without initiating neuronal cell death. However, because Parkinson’s disease affects a part of the brain that has
almost no astrocytes, this regulatory system fails to occur. In
addition, many of the astrocytes present in the PD brain contain
α-synuclein aggregations and release harmful substances such
as cytokines, chemokines, and IFN-T (Cebrián & Sulzer, 2017).
Thus, although astrocytes have the potential to be neuroprotective in Parkinson’s disease, they are neurodestructive.
In addition to the damage that both astrocytes and microglia
cells cause independently, they also work together to proliferate
the disease by increasing the permeability of the blood-brain
barrier. They accomplish this task by releasing cytokines which
actively increase the permeability of the blood-brain barrier.This
allows CD4 T cells and CD8 T cells to enter the central nervous
system easily. Once the T cells reach the SNcp, they are activated by microglia cells that present antigens on their surfaces
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using MHC II molecules and MHC I molecules (Kannarkat, Boss,
& Tansey, 2013). This activation causes the release of more cytokines which leads to cytotoxicity and further activation of
microglia cells (Kannarkat, et. al. 2013, Federoff, 2014). Thus,
infiltrating T cells aid in the progression of Parkinson’s disease
(Phania, et. al. 2012).

Treatment
Traditional treatment for Parkinson’s disease is limited to medications, surgeries, stem cell implantation and gene therapies that
are only effective in eliminating side effects and cannot cure
the disease. Most of these treatment methods have a multitude
of side effects and only work for a limited amount of time or
on a small population of Parkinson’s patients. Various tratmentoptions and their success in treating PD are reviewed below
with a particular focus on their success in treating PD and their
adverse side effects.

Medications
Levodopa, a precursor form of dopamine, is perhaps the most
common PD medication (Connolly & Lang, 2014) because it
can cross the blood-brain barrier where it is converted to dopamine. By increasing dopamine levels in the brain, this medication successfully reduces resting tremors (Maiti, et. al. 2017).
Unfortunately, Levodopa has also been found to cause vomiting, nausea, restlessness, drowsiness, low blood pressure, sudden onset of sleep and impulsive control disorders (Connolly
& Lang, 2014) (Maiti, et. al. 2017). Additionally, chronic use of
levodopa results in dyskinesia and motor fluctuations (Smith, et.
al. 2012). Levodopa also has been found to quickly lose its effectiveness because it is converted immediately upon arrival into
the central nervous system and by the time it reaches the target
area enzymes have already started breaking it down (Maiti, et.
al. 2017). Thus, to increase the potency of levodopa, many dopamine agonists are administered in combination with levodopa.
Monoamine oxidase-B (MAO-B) inhibitors such as selegiline
and rasagiline are examples of dopamine agonists that are used
in combination with levodopa (Maiti, et. al. 2017). MAO-B is an
enzyme that participates in the breakdown of dopamine (Kay
et. al. 2013). MAO-B inhibitors help prevent the breakdown of
dopamine and increase the potency of levodopa (Smith, et. al.
2012) (Maiti, et. al. 2017).Although these medications have been
successful in prolonging the effects of levodopa, they also cause
a multitude of negative side effects. Which include, “Dizziness,
dry mouth, insomnia, muscle pain, rash, nausea, constipation,
severe headache, tachycardia, arrhythmia, hallucinations, chorea,
or difficulty in breathing (Maiti, Manna, & Dunbar, 2017, p. 19).”
Another commonly used dopamine agonist is Catechol-Omethyltransferase (COMT) inhibitors (Maiti, Manna, & Dunbar,
2017). These drugs prevent the breakdown of dopamine and
increase the efficiency of levodopa (Smith, Wichmann, Factor, &
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DeLong, 2012) (Maiti, Manna, & Dunbar, 2017). Entacapone and
tolcapone are two examples of commonly used COMT inhibitors
(Smith,Wichmann, Factor, & DeLong, 2012). Along with increasing
the lifespan of dopamine these drugs cause hepatotoxic, nausea,
orthostatic hypotension, urine discoloration, dizziness and mitochondrial dysfunction (Maiti, Manna, & Dunbar, 2017).
Dopamine agonists such as pramipexole and ropinirole are
examples of drugs that are used instead of levodopa to treat the
early stages of Parkinson’s disease.They help alleviate Parkinson’s
symptoms by increasing dopamine levels in the brain.These drugs
are not as effective as levodopa, and they cause similar side effects
as levodopa. Some of the side effects commonly observed while
administering these drugs are hallucinations, low blood pressure,
nausea, dizziness, drowsiness, dry mouth, swollen legs and feeling
faint upon standing (Maiti, et. al. 2017).
Anticholinergic drugs are also used to treat Parkinson’s disease. These drugs inhibit the release of acetylcholine, which
is overproduced in the brains of Parkinson’s patients due to
diminished dopamine inhibitory signaling (Maiti, et. al. 2017).
They are successful in alleviating tremor and rigidity in about
50% of patients (Smith, et. al. 2012) (Maiti, et. al. 2017). Their
adverse side effects include memory loss, confusion, hallucinations, constipation, urination problems, dry mouth, dry eyes and
blurred vision (Smith, et. al. 2012). Due to the limited population
that can be helped with anticholinergic drugs and the adverse
side effects of these drugs they are less commonly used for the
treatment of PD.

Surgical Treatments
Deep brain stimulation(DBS) surgery is a common surgery used
to treat the advanced stages of Parkinson’s disease.This surgery
is only performed once all the medications mentioned above
begin to lose their potency (Smith, et. al. 2012). Additionally, this
surgery can only be performed on individuals who had success
in using levodopa and show no signs of dementia or psychiatric
abnormalities (Smith, et. al. 2012) (Okun, 2012). During DBS
surgery electrodes are implanted into GPi and STN of the brain
(Okun, 2012) (Maiti, et. al. 2017). These electrodes are attached
to two batteries that are implanted in the chest directly under
the color bone (Maiti, et. al. 2017). Electrical signals are then
generated by the implanted batteries and sent to the electrodes
in the brain where they stimulate inactive neurons (Okun, 2012)
(Maiti, et. al. 2017). Once implanted this device is controlled by
an external handheld device (Maiti, et. al. 2017). DBS has been
shown to successfully eliminate many motor abnormalities including motor fluctuations. Additionally, because DBS eliminates
the need for levodopa it successfully reduces dyskinesia and
dystonia (Smith, et. al. 2012) (Maiti, et. al. 2017). Unfortunately,
DBS entails a surgery that can cause stroke, hemorrhage, infection, speech issues and balance problems (Okun, 2012) (Maiti,
et. al. 2017) (Smith, et. al. 2012). DBS has also been found to
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increase depression, mania and suicide risk (Okun, 2012). Thus,
although DBS can be helpful in treating PD, it may also cause
adverse symptoms that can lead to death.
Another two surgeries which are used to treat Parkinson’s
disease are pallidotomy and thalamotomy. Pallidotomy is a surgery in which a part of the globus pallidus is destroyed . As a
result of this destruction, “the synaptic connections with thalamus or striatum are altered in a way which decreases tremor,
rigidity, bradykinesia and posture abnormalities in PD patients
(Maiti, et. al. 2017, p. 21).” Thalamotomy is the destruction of the
thalamus, which disrupts the connection between the basal ganglia and the motor cortex. This procedure restores neurotransmitter balance and reduces tremor . However, thalamotomy is
unsuccessful in alleviating other symptoms such as bradykinesia,
rigidity, and dyskinesias (Maiti, et. al. 2017).

Stem Cell Implantation
Stem cell implantation therapy involves the implantation of
human fetal-derived dopaminergic tissues into the striatum.
Implantation of these tissues into the brain results in higher
levels of dopamine, which indicates that these stem cells mature
properly and are able to create synapses.When porcine-derived
dopamine-producing cells are used moderate improvements in
symptom control are observed. However, when allogenic human
fetal ventral mesencephalic cells are used much greater symptom relief is observed (Maiti, et. al. 2017). “These cells survive
and make appropriate synaptic connections, while increasing DA
levels within the host cells (Maiti, et. al. 2017, p. 22).” Although
stem cell implantation seems promising, it causes many safety issues including unchecked proliferation and tumor development
(Smith, et. al. 2012). Thus, more research is needed to develop
this treatment technique and increase its safety.

Gene Therapy
Although most cases of Parkinson’s disease are sporadic, there
are some genetic forms of the disease. Scientists are now starting to develop gene therapy techniques that can cure the genetic forms of PD. Some of the techniques that are being tested are
viral vector-mediated gene delivery, AADC-TH -GCH therapy,
RNA interference-based therapy and CRISR-Cas-9 gene editing
system. Most of these therapies have been successful in animal
models, and some have also been used to treat humans successfully. However, most of these therapies must be tested further
in order to ensure their safety (Maiti, Manna, & Dunbar, 2017).

Exercise as a Treatment Method for PD
There is no treatment method for Parkinson’s disease that is
symptom-free. In fact, all of the treatments available for PD are
not successful at curing the disease, and when used they generate adverse side effects.Thus, Patients diagnosed with Parkinson’s
disease often feel helpless and experience depression because

until recently, their diagnosis meant awaiting and experiencing the
impending uncontrollable loss of movement until death.
However, in the past two decades, athletic programs such as
Boxing, Tai Chi, dancing, treadmill training and forced bicycling
have begun to bring hope to Parkinson’s patients.These programs
are designed in a way that teaches Parkinson’s patients physical
skills that helps stop the progression of the disease and even allows some individuals to regain full range of movement. Studies
have proven the success of these programs, but there is no significant scientific work that can explain how exercise alleviates
Parkinson’s symptoms on a biological level. In the past couple of
years, scientists have turned their attention to discovering the underlying biological mechanism that allows the above exercise programs to be so successful in treating Parkinson’s disease. Based
on the current scientific research the most probable mechanisms
are that exercise promotes neuroplasticity and neuroprotection.

The Two Main Components that make an
Exercise Program Successful
Most of the Successful exercise programs incorporate goal
based learning and aerobic exercise. The inclusion of these two
components helps promote neuroplasticity, which is defined as,
A process by which the brain encodes experiences and learns
new behaviors… the modification of existing neural networks
by addition or modification of synapses in response to changes in behavior or environment, which can encompass exercise.
Neuroplasticity includes a wide range of structural and physiological mechanisms including synaptogenesis, neurogenesis,
neuronal sprouting, and potentiation of synaptic strength, all of
which can lead to the strengthening, repair, or formation of neuronal circuitry (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013).
Goal-based learning refers to the incorporation of tasks that
are aimed at improving specific skills that are impaired in PD.
Intensity, specificity, complexity, repetition, and difficulty are all
important aspects of goal-based exercise that help drive. Goalbased exercise also stimulates cognitive engagement of the
prefrontal cognitive circuits. These circuits are involved in early
motor movement and the development of automaticity. Thus,
activation of prefrontal circuits helps patients with Parkinson’s
disease relearn skills that were previously automatic. Aerobic
exercises are similar to goal-based exercise in the fact that
it too promotes cognitive engagement and neuroplasticity.
“Aerobic exercise is defined as vigorous and sustained physical
activity that leads to increased cardiopulmonary function resulting in improved oxygen consumption (maximum oxygen uptake)
and blood flow to the brain (Petzinger, et. al. 2013, p. 719).” By
increasing blood flow to the brain, aerobic exercise stimulates
neuroplasticity and improves cognitive prefrontal cortex function. When goal based and aerobic exercise are combined their
effects are compounded, and significant changes in neuroplasticity are observed (Petzinger, et. al. 2013).
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The Successful Programs and how they Incorporate
Goal Based Learning and Aerobic Exercise
“Tai Chi, as a mind-body exercise, consists of a series of dancelike movements linked in a continuous sequence, flowing slowly
and smoothly from one movement to another that emphasizes
weight transfer and movement of the body.” (Yan Yang, 2015,
p. 2) It has been shown to improve dynamic postural control,
balance, gait, and quality of life (Petzinger, et. al. 2013, Yan Yang,
2015). In one study, scientists observed improved stride length,
stability and maximum excursion in patients who had participated in tai chi classes twice a week for 24 weeks (Petzinger,
Fisher, McEwen, Beeler, & Walsh, 2013).Tai chi incorporates cognitive engagement by practicing combinations of movements
and control of an individual’s center of gravity (Yan Yang, 2015).
However, it does not include intense aerobic exercise, and it
is not clear if this lowers its success rate compared to other
exercise debilitation programs.
Dance is an aerobic form of exercise that has also shown
promise as a potential treatment for Parkinson’s Disease.
Dance enhances motor learning by making people pay attention to music and rhythm (Blandy, Beevers, Kerry, & Morris,
2015) (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013). In
addition, partner dancing further stimulates cognitive engagement by teaching people partner coordination (Petzinger, Fisher,
McEwen, Beeler, & Walsh, 2013). By incorporating both cognitive and aerobic exercise, dance has been found to improve
gait, motor impairment and balance (Blandy, Beevers, Kerry, &
Morris, 2015).
Boxing therapy has become a very popular form of exercise therapy for PD in the past couple of years. In 2006 The
Rocksteady boxing foundation located in Indiana opened the
first noncontact boxing program for PD Patients. Since then,
Rocksteady boxing programs have been established across the
United States. Boxing therapy takes a whole-body approach by
including dynamic balance activities and multi-directional reaching and stepping. These programs also include jump rope and
framework activities that help improve people’s ability to initiate movement (Combs, et al., 2011). Boxing helps improve balance, gait, parkinsonian symptoms and quality of life (Combs, et
al., 2011) (Petzinger, et. al. 2013). Scientists have reported that
the benefits of boxing last for a long time even if patients stop
participating in as many classes as they originally did.The boxing
programs included aerobic exercise and goal-based exercise
by incorporating fast-paced multi-directional body movement
(Combs, et al., 2011). Thus, boxing is one of the most promising
forms of exercise therapy available for PD patients.
Cycling training is another popular form of exercise rehabilitation. Both forced cycling and voluntary cycling programs have
been found to help improve PD symptoms (Nadeau, et al., 2017).
In forced cycling PD patients are placed on an electric bike and
forced to pedal at a speed that is above their comfort level

36

(Ridgel, et. al. 2009). This system helps recruit cognitive involvement and has been shown to improve neuroplasticity in the
human brain. In addition, forced cycling helps improve tremor
and bradykinesia. Voluntary cycling has been shown to improve
cardiovascular capacity, executive function, motor learning and
walking speed (Nadeau, et al., 2017). Both voluntary and forced
cycling are promising treatment options for Parkinson’s Disease,
and scientist still have not determined which form of cycling is
more successful.
Treadmill training, when used to treat mild to moderate PD,
helps improve, “velocity, postural stability, gait rhythmicity and
joint excursion (Petzinger, Fisher, McEwen, Beeler, & Walsh,
2013, p. 717).” Some studies have reported treadmill training to
be completely infective at treating Parkinson’s disease. This inconsistency may be a result of improper feedback during workouts, which is supposed to promote cognitive engagement and
enhance motor learning (Petzinger, et. al. 2013). Thus, treadmill
training is a prime example of an exercise program that must
include both goal based and aerobic exercise in order to be
effective.

Neuroprotection
Neuroprotection is the driving force behind the neuroplastic
effects that both goal based and aerobic exercise exert on the
PD brain. Exercise provides neuroprotection by increasing dopamine release and dopamine receptor expression, decreasing
dopamine clearance from the synaptic terminals, stimulating the
release of neuroprotective factors and initiating an anti-inflammatory response.
Exercise therapy promotes the release of dopamine, decreases dopamine clearance from the synaptic cleft and facilitates the
binding of dopamine to D2 receptors in the dorsal striatum.
Exercise has been found to increase dopamine synthesis and release in both human and mice models (Horak & King, 2009). One
theory for how this is accomplished is that exercise increases
tyrosine hydroxylase (TH) levels in the PD brain. TH is an enzyme that increases dopamine levels by converting L-tyrosine
to L-dopa (a precursor form of dopamine) (Morgan, Corrigan,
& Baune, 2015). TH has also been found to decrease aggregated a-synuclein proteins, which play a primary role in neuronal
death in PD (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013).
In addition, exercise decreases DAT levels, which participates in
the degradation of dopamine in the synaptic clefts. This increases the dopamine available to bind to dopamine receptors. D2
receptors in the Putman are activated with intensive exercise
and are available to bind to dopamine (Jakowec, Wang, et. al.
2016). D2 receptors play an important role in cortical-striatal
glutamatergic modulation and are essential for motor learning
(Jakowec, et. al. 2016) (Petzinger, et al., 2015).
Exercise plays a role in modulating the inflammatory response
in the Parkinson’s diseased brain. It is well known that exercise
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reduces inflammation and oxidative stress (Shu, et al., 2014).
One of the ways that physical activity reduces inflammation is
by increasing anti-inflammatory cytokine interleukin 10. Exercise
also increases interleukin 6 which usually acts as an inflammatory substance, but in the case of exercise, its effects are anti-inflammatory. Interleukin 6 accomplishes its job by eliciting, “an
anti-inflammatory response that includes increased expression of
several factors including interleukin 10 and interleukin 1 receptor
antagonists, and inhibition of factors such as tumor necrosis factor alpha (Petzingeret, et. al. 2013, p. 722).” In addition, exercise
reduces the proliferation of astrocytes and microglia cells which
secrete harmful inflammatory cytokines. Physical activity also may
drive the conversion of activated microglia cells from M1 myeloid
cells which secret harmful cytokines to M2 myeloid cells which
helpful secret cytokines (Jakowec, et. al. 2016).This may mean that
exercise not only reduces inflammation but also stimulates the
development of a positive immune response.
Exercise also increases the secretion of neuronal protective factors, which include brain-derived neurotrophic factor
(BDNF), Galia cell-derived neurotrophic factor (GDNF) and hypoxia-inducible factor 1 alpha (HIF-1α). Both BDNF and GDNF
promote neuronal growth, prevent neuronal death and help
the neurons function properly (Paillard, Ronlland, & Barreto,
2015) (Morgan, Corrigan, & Baune, 2015). BDNF, in particular,
is activated by aerobic exercise and has been found to reduce
rigidity and muscle stiffness (Morgan, Corrigan, & Baune, 2015)
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016). Skilled
based exercise increases cortical-striatal function, which results
in an increased demand for oxygen.The lack of oxygen activates
transcription factor HIF-1α. This transcription factor increases
neuronal health by regulating genes that control, “Metabolism,
mitochondrial integrity … and signaling cascade pathways involved in nitric oxide synthase and glutamine synaptogenesis
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016, p. 41).”
Thus, both aerobic and skill-based exercise help increase the
release of neuroprotective factors.

Conclusion
Parkinson’s Disease is the second most common neurodegenerative disease, and its prevalence is expected to double by 2040
(Ridgel, et. al. 2015).There is no cure for Parkinson’s Disease. All
the available mainstream treatments cause adverse side effects
and are only successful at eliminating a small number of symptoms. However, alternative therapies such as exercise have been
found to reduce targeted symptoms, without causing negative
side effects. Unfortunately, exercise therapy although growing in
popularity is not being used by most primary doctors to treat
Parkinson’s Disease. Educating affected individuals and medical
practitioners on the benefits of exercise programs can potentially help improve the lives of many individuals. Why should
medications that cause a plethora of side effects be prescribed

when we can use exercise programs instead? Why tell patients
that there is no hope in sight for them, when in fact exercise
can potentially stop the progression of Parkinson’s disease and
in some cases eliminate all Parkinson’s disease symptoms. It
is time for medical professionals to change their outlook on
Parkinson’s Disease, instead of relaying a message of helplessness they should relay a message of hope.
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Abstract
Objective:To determine the significance of various types of dietary fat in the progression of atherosclerosis leading to heart disease.
Methods: Study inclusion criteria constituted relevance to the discussion topic and peer reviewed literature. Age of the published
material was taken into account as well, with greater preference being given to more recent research as the topic of nutrition and
its relation to chronic disease remains an emerging science.
Results: This research review found an overall significant relationship between the type (monounsaturated, polyunsaturated, saturated and trans-fat) of dietary fat intake and the incidence of cardiovascular disease. While earlier research identified an
increased risk of cardiovascular disease to be associated with an overall increased intake of dietary fat, newer studies recognized
the increased risk to be associated more specifically with saturated and trans fatty acids. Substitution of other dietary fats in
place of saturated fat in the diet also plays a role in cardiovascular disease. The studies reviewed here found a protective effect
of polyunsaturated fatty acids when replacing saturated fat in the diet. On the other hand, replacing saturated fats with carbohydrates has no evidence of improved cardiovascular health. Studies looking at the implications of substituting saturated fat with
monounsaturated fats remain inconclusive at this time. Aside from dietary fat intake, the progression of atherosclerosis leading to
cardiovascular disease can be caused by oxidative stress such as in the case of hyperglycemia and diabetes.
Conclusions: As health care costs continue to rise in this country, preventive medicine plays an increasingly important role in the
prevention and treatment of chronic disease. Research shows that decreasing the percentage of saturated fats in the diet and substituting these with healthier polyunsaturated fats, as well as minimizing oxidative stress in the body can decrease the incidence
of cardiovascular disease, a leading cause of death in the United States.
Introduction

Methods

In February of 1980 the United States Department of Agriculture
and Department of Health and Human Services jointly published the first set of Dietary Guidelines for Americans. During
this time, health scientists were beginning to focus on the link
between macronutrient intake and a correlated risk for chronic
diseases. In these original guidelines, Americans were encouraged to keep their total fat intake levels below thirty percent of
their diet, have less than ten percent of dietary fat come from
saturated fat, and maintain a cholesterol intake that was under
300 mg per day (Canty, 2018).
The guidelines have been updated every five years since and
have evolved based on accumulating scientific evidence, population patterns in health status, food consumption, and physical
activity. The 2015 Dietary Guidelines have a stronger emphasis
on healthy eating patterns and regular physical activity. However,
there has been minimal change in the recommendations for fat
intake for almost 40 years since the first set of guidelines. In
2015, the Dietary Guidelines for Americans recommended that
fat be 20-35% of the diet with less than 10% coming from saturated fat and minimizing trans fats as much as possible. While
the 2015 guidelines did not address cholesterol, the recommendations from 2010 remain the same as well (<300 mg/day) (U.S.
Dept. of Health and Human Services, 2015).
Controlling fat intake has consistently been recommended to
improve health for Americans with a specific focus on limiting
saturated fat in the diet. However, heart disease, a form of cardiovascular disease, remains to be the leading cause of death
for both men and women worldwide. Stroke, a complication of
cardiovascular disease is the fifth leading cause of death in the
Unites States. Dietary fat intake is a major modifiable risk factor
in the development and progression of cardiovascular disease.
(Center for Disease Control, 2017).

Studies reviewed in this paper were selected from journal databases, library catalogs, and Health and Nutrition Science professional websites. Papers were gathered from PubMed, CINAHL,
Medline, and similar scientific search engines using advanced
search phrases “PUFA,” “MUFA,” “dietary fat intake,” “trans-fat,”
“oxidative stress” and “CVD”.
The writer considered over 36 papers and over 20 papers
were included in the final research review. Study inclusion criteria consisted of relevance to the discussion topic and peer-reviewed literature. Age of the published material was taken into
account as well, with greater preference being given to more
recent research as the topic of nutrition and its relation to
chronic disease remains an emerging science.
To improve the writer and reader’s understanding of the relation between dietary fat intake and disease, noted textbooks in
advanced biochemistry topics were referenced and included in
the discussion section of this paper.

Discussion
Fat is an essential macronutrient required by the body. In 1927,
the effects of fat deficiency on growth and development inspired researchers Evans and Burrs to dub fat “vitamin F”. Two
years later, in 1929, Evans and Burrs found that a fat-free diet in
weanling rats produced impaired growth, scaly skin, tail necrosis, increased mortality, and impaired fertility (Ross, et. al, 2014).
These symptoms were reversed when provided with linoleic or
linolenic acid and the term “essential fatty acids” was coined.
Almost thirty years later, in 1958, Essential Fatty Acid Deficiency
(EFAD) was first demonstrated in humans, when infants fed a
milk-based diet lacking essential fatty acids (EFA) showed severe
skin symptoms alleviated by the addition of linoleic acid. Total
Parenteral Nutrition Support, lacking fat-soluble vitamins, was
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also shown to produce EFAD in a 6-year-old girl maintained on
total parenteral nutrition for five months (Burr, 1981).
We require fat and fat-soluble vitamins for energy reserves,
cell signaling, synthesis of hormones, and their structural role in
cell membranes (Canty, 2018). The average intake of fat in this
country has remained relatively consistent since the 1990s.
The average American consumes 33% of his calories from fat
and 10% from saturated fat.There were significant changes over
the years in the consumption of monounsaturated fat (MUFA)
(14.6% to 13%, p = 0.03) and polyunsaturated fat (PUFA) (6.9%8.0%, p = <0.001) as well as the ratio of PUFAs to saturated fat
(7.1%-8.1%, p = < 0.001) (fig. 1) (Vadiveloo, at. al. 2013).
Atherosclerosis is the narrowing of the arterial wall caused
by a buildup of plaque. As the endothelial layer on the artery
wall weakens, it becomes susceptible to plaque accumulation by
a high concentration of Low-Density Lipoprotein (LDL) -cholesterol in the blood. As the plaque begins to build, monocytes
and macrophages are attracted to the site of the plaque contributing to stenosis (Narrowing of the artery lumen). The layer
of smooth muscle in the artery begins to grow a fibrous cap
over the plaque. As the plaque continues to develop, this cap can
rupture and form a blood clot that may cause a heart attack or a
stroke (Escott-Stump, 2015, Mahan and Raymond, 2017).

Figure 1:Trends in dietary fat consumption (NHANES)
Source: Canty, D. Advanced Nutrition: Protein, Fats and Carbohydrates.
Spring 2018.

Types of Fats
As part of the Strong Heart Study, researchers examined the
association between dietary fat intake and coronary heart disease in 2,938 Indian American adults ages 45-79 for an average
of 7 years. Over 400 participants experienced Coronary Heart
Disease (CHD) during this time, including 138 fatalities. The researchers divided participants into two age group categories,
47-59 years and 60-79 years. Across both age groups, individuals
who developed CHD were more likely male, hypertensive and
with lower High-Density LipoProteins (HDL) levels and higher
serum triglycerides. Amongst the older group, those that developed CHD had higher LDL levels as well. Amongst the younger
group, an increasing rate of mortality due to CHD was seen
with greater quartiles of total fat intake, specifically saturated
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and monounsaturated fat (Lee, et. Al. 1990). This study suggests
that abnormal lipoprotein levels (low HDL, high LDL) are associated with an increased morbidity in adults. Additionally, total
fat, rather than a specific type of fat, is associated with increased
mortality from CHD.
The Seven Countries Study (Keys, et. al. 1984) investigated the
intake of various fatty acids as well as dietary cholesterol in relation to serum cholesterol and 25-year mortality from coronary
heart disease. The study was carried out from 1956-1964 and
constituted 16 cohorts across seven countries to include over
12,000 men between the ages of 40-59 years. Dietary intake data
was collected and standardized by one dietitian. In 1960 total
lipids were measured (at that time there was no instrument available to measure trans-fat, omega-3 or omega-6 fatty acids). Data
was collected and reported for saturated, monounsaturated and
polyunsaturated fats. Later, in 1987, total lipids were isolated and
cis and trans fats, as well as omega-3 fatty acids, were identified.
The individual saturated fatty acids, namely lauric acid and myristic acid, were significantly related to cholesterol levels (p < 0.001).
Moreover, the researchers identified a strong positive relationship between the intake of saturated fats and death rates from
CHD (p <0.001) (fig. 2). It is worthwhile to note that a 25-year
lapse in time from the collection of data to the analysis may have
impacted the researchers’ findings.

Figure 2: Correlations Between Fat Intakes (E%) and Serum
Cholesterol and 25y CHD Death Rate
Source: Canty, D. Advanced Nutrition: Protein, Fats and
Carbohydrates. Spring 2018.
More recent studies support these findings as well, indicating
that the source of dietary fat influences heart disease. A 20 year
follow up of the Nurses’ Health Study looked at the association specific types of dietary fat intake as they relate to the
risk of coronary heart disease. The study consisted of 78,778
US women who were without CVD or diabetes at the initiation of the study in 1980. At the follow up, 1,766 incidences
of CHD were reported, 525 of which were fatal. Researchers
found that intake of polyunsaturated fats was inversely associated with CHD (P = 0.004) (fig. 3). The results were substantial
amongst women with an overweight BMI (>35 kg/m2). Trans-fat
intake was associated with an increased risk of developing CHD
(P=0.01), particularly in women under 65 years of age (Colditz,
Hankinson, 2005).
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Figure 3: Fat intake and CHD risk in women; Nurse’s Health Study
20y Follow-up
Source: Canty, D. Advanced Nutrition: Protein, Fats and Carbohydrates.
Spring 2018.
These findings are consistent with a 2006 cross-sectional
study of 1,123 adults between the ages of 20 and 98 explaining
the possible connection between the inverse relationships. The
researchers looked at the relationship between fasting plasma
polyunsaturated fatty acid (PUFA) levels and markers of inflammation. They found a statistically significant, negative correlation
between the intake of PUFAs, specifically omega-3 and omega-6
fatty acids and plasma levels of pro-inflammatory markers (IL-6,
TNF, IL-10, CRP). This study suggests that the anti-inflammatory
properties of polyunsaturated fatty acids are associated with
lowering plasma levels of pro-inflammatory markers that play a
role in the progression of atherosclerosis (Ferruci, et. Al. 2006)

Replacing Saturated Fat in the Diet
Current guidelines from the HHS and USDA recommend <10%
of calories come from saturated fat and the American Heart
Association recommends no more than 5-6% of intake should
come from saturated fat to decrease LDL cholesterol. However,
there are fewer studies and recommendations discussing what the
recommended replacement for saturated fat in the diet should be.
A meta-analysis of eight randomized control trials that included over 1,000 incidences of CHD amongst 13,614 participants,
found that increased PUFA intake in place of saturated fat in
the diet reduced CHD events by 19% (Mozaffarian, et. Al. 2010).
More specifically, each 5% increase in PUFA consumption reduced the risk of CHD by 10%. The analysis suggests that these
improvements in the incidence of CHD were likely the effect
that PUFAs had on lowering LDL in the blood. The short-term
studies part of this identified a 5% energy intake from PUFAs
that replaced a 5% energy intake from saturated fat lowered
LDL cholesterol by 10 mg/dl while having no significant impact
on HDL cholesterol. This intake of PUFAs in place of saturated fats lowered the total cholesterol to HDL ratio by 0.16.
Conversely, no change in the total cholesterol to HDL ratio
was found when saturated fat in the diet was replaced with
carbohydrates. The observational studies identified a 44% decrease in CHD risk associated with each unit decrease of total

cholesterol to HDL ratio.
It is important to note that these studies measured the effects
of replacing saturated fatty acids with PUFAs in the diet and
therefore cannot ascertain whether the benefits were related to the decrease in saturated fatty acids or the increase in
dietary PUFAs. It can be concluded that replacing saturated
fats with PUFAs in the diet likely decreases the incidence of
CHD while replacing saturated fat with carbohydrates does not.
Consequently, it may be concluded that the effects of replacing
saturated fat in the diet with monounsaturated fat are mixed.
Future studies looking at the implication of replacing saturated
fat with proteins and/or MUFAs would be beneficial.

Animal vs. Plant Fats
Emerging research looked at monounsaturated fatty acids to
identify if the source of MUFAs had a relationship to its impact on heart disease. Researchers used data from the Nurses’
Health Study that included 63,000 women and data from the
Health Professionals Follow-Up study that included 30,000 men.
Both of these studies utilized food frequency questionnaires administered every four years to evaluate participants’ diets.
When analyzed, participants with a higher intake of MUFAs
from plant sources showed a 16% lower risk of death (from any
cause) compared with those that had a lower intake. In contrast,
participants with a higher intake of MUFAs coming from animal
protein exhibited a 21% increase in risk of death related to any
cause. Replacing dietary MUFAs from animal sources for the
equivalent per gram in plant sources may lower the risk for
death by heart disease or any cause of death between 24% and
26% (Roeder, 2018).
Similar findings have been reported for with saturated fat. It is
thought that plant sources of saturated fat may, in fact, play less
of a role in the morbidity and mortality from coronary heart
disease than animal sources. These findings can be explained
by a recent study looking at the structural implications of fatty
acids. An animal source of saturated fatty acids is located mainly
at the sn-2 position of the glycerol backbone as shown in figure
5 and affects the metabolism, functionality, and physiological effects of the saturated fatty acids (fig. 4) (Nettelton, et. al. 2017).
The Multi-Ethnic Study of Atherosclerosis aimed to determine
the association between SFA intake from varying food service
and in the incidence of CVD. The study included 5,209 participants between the ages of 45–84 that were followed for a
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Figure 4: Implications of Structure and Position of Saturated
Fatty Acids Source: Nettleton, 2017.
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decade from 2000. Diet was assessed using a food frequency
questionnaire and over 300 cases of CVD were assessed during
follow up valuations.
After adjusting for confounding factors, researchers concluded that a higher intake of saturated fat from dairy sources was
associated with a lower risk of CVD (95% CI for + 5 grams per
day and 5% of energy intake from dairy sources of saturated fat).
In contrast, meat saturated fat was associated with an increased
risk of developing CVD with the same increase in grams per day
and % energy intake (fig. 5).
Substituting 2% of energy intake from meat sources of saturated fat with dairy sources of saturated fat was associated with

Figure 5: Dietary Source of Saturated Fat May Affect CVD Risk
Source: Canty, D. Advanced Nutrition: Protein, Fats and
Carbohydrates. Spring 2018.
a 25% decreased risk of CVD (Otto, et. al. 2012). This particular
study found no association between CVD and intake of plant
or butter saturated fats, however, intakes recorded in the Food
Frequency Questionnaires were narrow.

Processed Fat:Trans Fat
Since in 2006, food manufacturers have been required to list
trans-fat on all food labels. Trans fats (trans unsaturated fatty
acids) are artificially produced solid fats. Liquid vegetable oils are
heated with catalysts in a process called hydrogenation, which
breaks double bonds in unsaturated fats and adds hydrogens,
thereby solidifying the fat, making it a solid at room temperature.
The current dietary guidelines for healthy Americans recommend keeping trans-fat intake “as low as possible” (< 10% of
total calories). These recommendations are based on studies
that have found that trans fats increase LDL-cholesterol levels
in the blood while decreasing healthy levels of HDL-cholesterol.
One early study demonstrated this by providing 34 adult women
and 25 adult men with three diets that each study subject followed for three consecutive weeks. All three diets were mixed,
natural diets and identical in nutrient consumption except for
10% of energy intake coming from oleic acid (a monounsaturated fat with one cis bond), trans isomers of oleic acid, or
saturated fatty acids. LDL cholesterol was significantly higher
on the trans fatty acid diet compared to the other two diets (P
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<0.0001) with no significant differences found between men and
women (Mensink, Katan, 1990).
A significant relationship has been reported between dietary
trans-fat and coronary heart disease. Dietary data was studied from participants in the Nurses’ Health Study and intake of
trans fat was calculated using the questionnaires completed by
more than 80,000 female participants, all of whom were without diagnosed cardiovascular disease at the time. Over the 8
year follow up period, 431 cases of new CHD were diagnosed.
Adjusting for age and total caloric intake, the intake of trans
fat was directly related to increased risk of CHD (P = 0.001).
Margarines, cookies, cakes and refined white bread were each
significantly associated with an increased risk of developing
CHD, with a stronger association found for the participants
who stated consistent margarine intake for the last 10 years
(Willett, 1993).
More recently, the DASH diet (Dietary Approach to Stop
Hypertension) has been found to reduce the risk of cardiovascular disease in women. The DASH diet focuses on consuming
adequate servings of fruits and vegetables, lean proteins and
limiting intake of saturated and trans fatty acids (2 a day where
a serving is 1 teaspoon of margarine). A study followed more
than 88,000 women between the ages of 34 and 59 years. Food
frequency questionnaires were collected 7 times between 1980
and 2004. Over 2,000 cases of nonfatal myocardial infarction,
over 3,000 strokes and 976 women died of CHD over the 24year follow-up period. After adjusting for confounding factors,
increased DASH scores were associated with decreased risk of
acquiring some form of CVD (P <0.01) (Fung, et. al. 2018).

Do PUFAs Have any Faults in Relation to Disease?
Lipid peroxidation is the oxidative deterioration of lipids possessing double bonds by interaction with a reactive oxygen species (ROS). Given their higher content of double bonds, PUFAs
are more susceptible to oxidation than SFAs and even MUFAs.
Antioxidants, such as vitamin E and vitamin C, in our diets and
in our bodies, serve to detoxify the oxidative damage caused by
ROS. In a healthy individual, the generation of reactive oxygen
species is in normal balance with antioxidant activity. However,
increasing amounts of oxidative damage and/or decreasing
amounts of antioxidants leads to oxidative stress in which elevated levels of ROSs can lead to oxidative damaging of proteins,
carbohydrates and DNA molecules.
Oxidative stress has been linked to disease states such as atherosclerosis and certain cancers.The question remains whether
the disease state causes the increased lipid peroxidation and
oxidative stress or if the oxidative damage leads to the disease
state (Ross, et. al, 2014).

Coconut Oil: Celebrity Status Threatened
The American Heart Association published a 2018 Presidential
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Advisory that had much of the health community involved in a
conversation regarding saturated fats and their role in oxidative
damage and chronic disease. The AHA’s advisory mentioned a
New York Times piece highlighting a recent health survey in the
United States which found that 73% of Americans classified coconut oil as a “health food” compared to 37% of nutritionists. The
AHA contributes the positive perception of coconut oil in its
relation to health promotion and disease prevention to a result
of good marketing by the coconut oil industry (Sacks, et. al. 2017).
Statistics from the USDA reveal that coconut oil consumption
increased from 2013 to 2014 by 9.55% and then dropped in
2014 and 2015 to 6.23% and 13.47% respectively. This information sheds some light on the increased promotion of coconut
oil as a health food by the coconut oil industry and the belief
of Americans, that it is a health food. However, coconut oil’s
nutrition profile did not change during this time. It remains to
be 82% saturated fat, and like all densely saturated fats, plays a
role in cardiovascular disease.
A recent review looked at seven interventional studies comparing coconut oil with unsaturated fats in the diet and their
individual influences on lipid profiles of study participants. All
seven trials resulted in higher total cholesterol for those receiving coconut oil intervention, all of which were statistically significant. Six out of the seven studies found a statistically significant
increase of LDL cholesterol for the intervention group. HDL
levels were statistically significantly raised in five studies for
those receiving the coconut oil intervention (Eyres, et. al. 2016).
The AHA warns consumers that the HDL improvements seen
with diet or drug treatment cannot be directly linked to changes
in CVD occurrences and therefore encourages Americans to
look at the LDL changes as effected by various fats alone in
regard to their role in CVD (Sacks, et. al. 2017).

Atherosclerosis: Other Players
As the walls of the arteries get thicker, narrowing the lumen
due to plaque buildup, patients with atherosclerosis experience
worsening symptoms of CVD, including hypertension (Nelms
et. al 2016) . During the initial stages of plaque buildup, the endothelial cells of the luminal lining, which provide the barrier
between the lumen and the vascular wall, may experience dysfunction and contribute to increased plaque and blood pressure.
Certain stimuli can trigger the dysfunction of the endothelial
cells, deeming these stimuli proatherogenic. Diabetes and oxidative stress are amongst the major players that contribute to the
eventual loss of functionality of the endothelial cells, along with
dyslipidemia, abnormally elevated cholesterol or fats (lipids) in
the blood (Chistiakov, et. al. 2015).
Glucosamine, often used in the management of osteoarthritis,
has anti-inflammatory effects by contributing to a redox state in
an oxidative environment. In an attempt to take advantage of its
properties, glucosamine supplements consisting of 300 mg were

given to 20 individuals daily for 30 days and arteriosclerosis and
CVD were compared to 19 controls. Flow-mediated vasodilation was monitored in all participants at the start and for the
duration of the four-week trial. At the end of four weeks, parameters such as blood pressure, blood glucose, and lipid levels
were measured. No significant changes were found in these clinical markers prior to or following the study between the two
groups. However, glucosamine supplementation significantly
improved flow-mediated vasodilation (P = 0.02) highlighting the
role that oxidative stress independently plays in atherosclerosis
and cardiovascular disease (Katoh, et. al. 2017).
This is similar to what is seen in the strong correlation between diabetes, specifically type 2, and incidence of CVD. The
American Heart Association considers diabetes to be one of
the seven top causes of cardiovascular disease. More than 68%
of people over the age of 65 with diabetes will die from a form
of heart disease. Adults with diabetes are twice to four times as
likely to die of heart disease than adults of the same age without
diabetes (American Heart Association, 2018).
Oxidative stress has been shown to contribute to atherosclerotic buildup in animal models. Elevated blood glucose in
type 2 diabetic patients allows for glucose persisting in the
bloodstream to become damaged, increases the amount and
rate at which reactive oxygen species (ROS) accumulate. ROS
are potent oxidants that, without adequate antioxidant activity,
can proliferate and cause oxidative damage in individuals leading
to the dysfunction and apoptosis of endothelial cells, worsening
atherosclerosis and hypertension leading to worsening cardiovascular complications (Jay, et. al. 2006).
A double-blinded crossover study looked at the role that
antioxidants could play in lowering levels of ROS and oxidative
stress and mortality risk due to CVD in diabetes over the age
of 55. Exclusion criteria included uncontrolled hypertension
and history of a myocardial infarction and/or stroke within the
last month. Participants were randomized to receive either
a vitamin E (a potent Anti-oxidant) supplement or a placebo
pill. At the end of eight weeks, researchers measured forearm
blood flow and found that vitamin E supplementation significantly improved blood flow (P <0.01), demonstrating improved
cardiovascular profiles in diabetic patients receiving antioxidant
supplementation (Alshiek, et. al. 2017).

Implications
The Lifestyle Heart Trial suggests a correlation between a lifestyle change in patients with atherosclerosis and regression in
their artery lesions. Forty-one participants with atherosclerosis
were randomized to an experimental group (n=22) and control
group (n=19). Angiographies were conducted at baseline and
again at a one-year follow-up. During the year the experimental
group was given a low-fat, vegetarian diet with less than 10%
of calories coming from fat and a ratio of PUFAs to saturated

43

Dovid Leib Glassner

fat of less than 1. The experimental group was also required
to participate in aerobic exercise and attend weekly support
group meetings. Following one year, blood serum was collected
and analyzed from all 22 participants. The results showed an
average percentage diameter stenosis decrease from 16.9% to
16.5% amongst the experimental group.The control group who
continued with their usual diet and lifestyle showed stenosis
progression from 15.5% to 18.5%. The average percentage regression in the diameter stenosis of the control group was 82%
(18 out of 22). In the experimental group, total cholesterol was
lowered by 24.3% and LDL concentration by 37.4%. This study
shows that a lifestyle change in patients with coronary heart
disease can lead to significant regression in arterial stenosis
(Ornish, et. al. 1990). Changes in lipid profiles and angina pectoris are displayed in the tables (ref., tables 1 and 2).

Conclusions and Recommendations
The Dietary Guidelines for Americans published every five years
is a set of evidence-based guidelines to promote healthy nutrition habits and prevent nutrition-related disease in the American
population. These guidelines are constantly evolving based on the
latest research findings and available science. Despite its regular
updates, the DGA has remained relatively consistent in its recommendation for the dietary consumption of fats.
Recent National Health and Nutrition Examination Survey
data shows Americans are consuming 33% of their calories in the
form of fat.This paper reviewed the literature on types of fats and
their individual relationship to the progression of cardiovascular
disease, the cause for one-third of all deaths in this country.
Indeed, the type of fat a person is consuming impacts his or
her risk of cardiovascular disease. Higher amounts of saturated
fat in the diet have been found to be associated with increased

Mean (SD) at Baseline
Experimental Group
(n=20-22)

Control Group
(n=17-19)

Mean (SD) at 12 Months
Experimental Group
(n=20-22)

Control Group
(n=17-19)

Serum Lipids (mmol/l)
- Total chol
- LDL
- HDL
- Triglycerides

5.88 (1.29)
3.92 (1.25)
1.00 (0.26)
2.38 (1.26)

6.34 (1.02)
4.32 (0.77)
1.35 (0.52)
2.45 (2.47)

4.45 (1.15)
2.46 (1.55)
0.97 (0.40)
2.91 (1.47)

6.00 (1.55)
4.07 (1.17)
1.31 (0.38)
2.24 (1.79)

Lipid Ratios
- Total/HDL
- LDL/HDL

6.33 (2.14)
4.18 (1.53)

5.32 (1.89)
3.59 (1.37)

5.15 (2.23)
2.89 (1.92)

4.93 (1.59)
3.33 (1.42)

134 (13)
83 (8)

140 (26)
82 (13)

127 (13)
79 (7)

131 (20)
77 (11)

91.1 (15.5)

80.4 (22.8)

81.0 (11.4)

81.8 (25.0)

Blood Pressure (mm Hg)
- Systolic
- Diastolic
Weight (kg)

Table 1: Changes in Risk Factors Source: Ornish, D. 1990
Chest pain

Mean (SD) at baseline
Experimental Group
(n=20)

Control Group
(n=17)

Experimental Group
(n=20)

Control Group
(n=17)

Frequency

5-10 (14-1)

2-35 (3-77)

0.45 (0.76)

6-24 (12-9)

Duration (min)

2-73 (4-69)

3-47 (7-95)

1-58 (4-48)

6-97 (14-5)

2-3 (1-6)

1-8 (1-1)

1-7 (1-2)

2-5 (1-2)

Severity

Table 2: Changes in Angina Pectoris Source: Ornish, D. 1990
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Mean (SD) at 12 months
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risk of CVD. Replacing saturated fat with carbohydrates has
not been found to improve lipid profiles or CVD risk factor
biomarkers. On the other hand, replacing saturated fat with
unsaturated fats, specifically PUFAs, have been associated with
lowering an individual’s risk of developing CVD. The data on
MUFAs remains inconclusive at this time.
The research suggests that health care professionals should
encourage their patients and clients, especially those at risk for
cardiovascular disease, to consume a diet lower in saturated
fat and to mindfully replace those items with wholesome, real
foods, and fats higher in PUFA content while remaining wary
of processed carbohydrates. As part of a healthy diet, consumers should also consume adequate foods high in antioxidants
to provide a buffer for the potentially oxidizing effect of a diet
higher in PUFAs.
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Abstract
Osteoporosis and Degenerative Disc Disease can cause a loss of height in the spine.This paper focuses on the mechanisms that
cause age-related loss of height and its effects. Possible relationships between receptor activator nuclear factor kappa-B ligand
(RANKL) and estrogen with osteoporosis are discussed, as well as possible genetic causes. Exercise may prevent osteoporosis.
Osteoporosis may cause a loss of height, vertebral fracture, a decrease in maximum lung capacity, and hip fracture. Degenerative
disc disease may cause shortening of the spine. Disc height loss can result in a reduction in the range of motion and stiffness
at the affected spinal segments. Degenerative disc disease may cause a small increase in vertebral height which can lead to
complications in treatments.
Introduction
As early as the age of 30, people may begin to become shorter.
Studies show that from the age of 40, people begin to lose about
half an inch per decade. Some health risks associated with loss of
height are spinal fracture, back pain, hip fracture (Hannan et al.,
2012), and a decrease in lung capacity (Krege et al., 2015). Total
health care costs in the United States of osteoporotic hip fractures
is estimated at 18 billion dollars annually (Hannan et al., 2012).
There are three main reasons why people become shorter
as they age, and they are all related to the spine. One reason is
osteoporosis, a decrease in bone density. As the skeleton loses
density, it compresses, making the body shorter. Osteoporosis
is the most common bone disease, affecting 200 million people
worldwide, and leading to over 9 million fractures annually (Yu
& Wang, 2016). Giving the aging population, the predicted annual
healthcare costs of an osteoporotic compression fracture in the
USA alone is 25.3 billion dollars. Loss of water in the intervertebral discs due to aging also accounts for shortening of the spine.
The discs become compressed, because of the weight placed on
them by the upper body, resulting in a loss of height (Jarman et
al., 2015). Another possible cause for shrinking is the abnormal
bending of the spine. However, the body isn’t really shortening,
rather bending, and just giving the appearance of loss of height.
Flattening of the arch of the foot may also give a person the
appearance of a shorter stature; however, most of a person’s
height loss can be attributed to changes in the lumbar spine
(Videman et al., 2014). This paper discusses the possible causes
and effects of osteoporosis and degenerative disc disease, and
how they result in a loss of height.

Methods
Data was found by using ProQuest and PubMed databases
through Touro college’s online library. Keywords used were loss
of height, osteoporosis, and degenerative disc disease.

Physiology of Osteoporosis
Bone is 30% collagen fibers and 70% non-organic minerals such
as calcium. Osteoblasts are cells that make bone. Osteoclasts
break down the bone and resorb the minerals into the blood,
but osteoblasts keep making new bone to counter the loss;
this is known as bone remodeling. Osteoporosis is a condition where osteolysis overshadows osteogenesis (Yu & Wang,
2016). Osteoporosis can begin at the age of 30, but it is most

pronounced in older people, especially in postmenopausal
women because estrogen suppresses the receptor activator
of nuclear factor kappa-B ligand (RANKL), a molecule that
promotes osteoclast differentiation and formation (EghbaliFatourechi et al., 2003). Estrogen also increases the expression
of osteoprotegerin (OPG), which functions as a decoy receptor
for RANKL (Hofbauer et al., 1999). During menopause, when
there is a decrease in estrogen, there is an increase in RANKL
and decrease in OPG, resulting in increased osteoclast activity,
and a net loss of bone.
Studies show that men also experience bone loss due to a
decrease in estradiol concentrations (Falahati-Nini et al., 2000).
However, in both men and women, a decrease in growth hormone secretion due to aging is also responsible for a decrease
in bone formation (Drake et al., 2015).
Trabecular bone loss begins in the third decade of life while
cortical loss typically begins in the sixth decade of life (Drake
et al., 2015). Trabecular loss, which occurs before gonadal sex
steroid deficiency, may be caused by secondary osteoporosis.
Secondary osteoporosis is bone loss caused by factors other
than aging or postmenopausal status. Glucocorticoid excess
can cause decreased production of osteoblast precursors and
increased apoptosis of mature osteoblasts. Primary hyperthyroidism causes cortical bone loss. Vitamin D deficiency causes
demineralization of bone and is associated with lower bone
density.Type 1 diabetes mellitus causes osteoporosis because of
an inability to reach peak bone mass (Emkey & Epstein, 2014).
There are many other causes of secondary osteoporosis, but
this paper focuses on age-related causes.
Since both genders experience trabecular bone loss with
aging, age-related factors other than sex steroid deficiency may
be involved. Cytokines accumulate due to aging factors, including
menopause, and make the bone marrow prone to inflammation
(Yu & Wang, 2016). Inflammation activates transcription factor
nuclear factor kB, which causes osteoclast differentiation and
inhibits osteoblasts (Chang et al., 2009). Also, oxidative stress,
characterized by the presence of too many reactive free radicals in the body, increases with age. Oxidative stress activates
nuclear factor-kB which in turn causes bone loss (Khosla et al.,
2011). It is unclear if osteoporosis causes further inflammation
in the bone marrow which would then activate more nuclear
factor-kB, exacerbating the osteoporosis (Yu & Wang, 2016).
Osteoporosis may indirectly cause further bone loss.
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Osteoblasts and adipocytes both come from a mesenchymal
stem cell. In osteoporosis, since osteoblasts production is inhibited, there are more adipocytes forming instead. Adipocytes
secrete the hormone leptin which has been found in mice to
promote adipogenesis and inhibit osteogenesis (Yue et al., 2016).
Osteoporosis is also caused by gene expression. Histone
Demethylases KDM4B and KDM6B remove gene silencing histones from the osteogenic master regulator gene (Ye et al., 2012).
Mice that had KDM6B knocked out had impaired osteogenesis
(Zhang et al., 2015). Aged mice and female mice that had their
ovaries removed had elevated levels of the osteogenic gene silencing histones, suggesting an epigenetic link between aging and
low estrogen levels with impaired osteogenesis (Ye, et al., 2012).
Studies of astronauts have shown that they lose bone from
bones that are normally weight bearing, such as the femur and
tibia. Astronauts returning to Earth have extensive bone resorption, which shows that osteoclasts were breaking down the
bone (Shigematsu et al., 1997). Normal bone density was not
restored after reambulation (Vico et al., 2000). Prolonged bed
rest is also associated with decreased bone density in weight
bearing. Interestingly, a study of 24 bedridden women showed
that high load resistive exercise had no significant impact on
bone loss, although it did prevent muscle atrophy (Beller et al.,
2011). These studies show that the force of gravity is necessary
for maintaining normal rates in bone remodeling, and a lack of
this force may result in osteoporosis.
Predisposing risks for osteoporosis occur during childhood
and adolescence because maximizing peak bone mass is important for its prevention. However, exercise during maturation can
mitigate the effects of osteoporosis. Weight-bearing exercises
are found to be effective in generating bone anabolism (Santos
et al., 2017). Exercise may be a form of prevention, but once osteoporosis develops, exercise may lead to osteoporotic fracture
due to the stress put on the weak bones.

Osteoporotic Vertebral Fracture and Height Loss
The decrease in bone density caused by osteoporosis can cause
vertebral fractures. Vertebral fractures can be measured using
the spinal deformity index (SDI). Using the SDI, a mild compression fracture (20-25% compression) in a vertebra is given
a value of one, moderate fractures (25-40% compression) are
two units, a severe fracture (more than 40% compression) is
given a value of 3 (fig. 1). The SDI is the sum of the units of each
vertebra from T4 to L4. Height loss was calculated by subtracting the current height from the arm span. The arm span length
was considered the person’s peak height. In a study of women
aged 70 years and older with osteoporosis and a history of at
least one moderate or severe vertebral fracture, for each unit
increase in SDI, height decreased by about 0.5 cm (Krege et
al., 2015). Osteoporosis causes a loss of bone in the vertebrae,
resulting originally in a decrease in density of the vertebrae.
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The weight placed on the spine may then cause the vertebrae
to compress, increasing the bone density of the vertebrae (the
density may be elevated due to compression; however, there is
a decrease in bone mass and height). Therefore, height loss is a
marker for vertebral fractures.

FRACTURE
STATUS

FRACTURE
GRADE

T4

none

0

T5

none

0

T6

mild

1

T7

moderate

2

T8

none

0

T9

none

0

T10

none

0

T11

mild

1

T12

none

0

L1

mild

1

L2

none

0

L3

none

0

L4

none

0

SDI = 1 + 2 + 1 + 1 = 5
Fig. 1. Spinal deformity index is the sum of fracture grades for T4
to L4 vertebrae. In the example shown, the patient has three mild
and one moderate vertebral fracture, for an SDI of 5. SDI, spinal
deformity index. Modified from Krege et al., 2015

Osteoporosis and Lung Capacity
SDI is also negatively correlated with pulmonary function. For
each unit increase in SDI, forced inspiratory vital capacity, which
is the maximum volume of air inhaled, decreased by 1.62% and
inspiratory time, the time it takes for the maximum volume of
air to be inhaled, decreased by 2.39% (Krege, et al., 2015). There
was no significant correlation between the flow rate, which is a
measurement of the volume of air inhaled per an amount of time,
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and the SDI. This result indicates that vertebral fracture is linked
with restrictive, not obstructive, lung disease. Restrictive lung disease occurs when the lungs aren’t compliant, and they become
stiff, limiting the lungs’ expansion, and causing a volume decrease.
An obstructive disease does not affect the lung volume; rather it
causes a decrease in flow due to the resistance of the obstruction. Therefore, since people with vertebral fractures experience
a decrease in lung capacity but not in flow rate, osteoporosis
can be classified as a restrictive lung disease. The reduction in
inspiratory time is caused by a decreased lung volume, so there
isn’t as much air going into the lungs, and therefore it requires
less time for inhalation. Perhaps the decrease in inspiratory vital
capacity is due to a loss of volume in the thoracic cavity because
of compression of the spine. This decrease in volume may limit
the compliance of the lungs. No evidence was found that would
suggest an effect of height loss on the heart.
Other studies were performed using expiratory measurements. One study found that for each thoracic vertebral
fracture forced vital capacity declined 9% (Leech et al., 1990).
Others suggested that there is no relationship between vertebral fractures and pulmonary function. However, the analysis
performed by Krege et. al. is unique in its use of SDI to quantify
the vertebral fracture. Another possible reason for different results found in the studies is because the other studies used expiratory measurements while Krege et al. used inspiratory measurements.Also, the measurement done by Leech et. al. was only
considering thoracic fractures while the study done by Krege et
al. considered both thoracic and lumbar segments. A limitation
to the Krege et al. study is that it combined both thoracic and
lumbar segments rather than assessing them separately.

Osteoporotic Hip Fracture
Height loss is also associated with osteoporotic hip fracture,
defined as incident fractures of the proximal femur occurring
either after age 50 or in postmenopausal women. A study that
followed 3081 adults over 50 years revealed a positive correlation between height loss and risk of hip fracture. For this study,
hip fracture was defined as a first-time fracture occurring in the
absence of overwhelming trauma. The study recorded height
loss of male and female participants over 24 years. Most participants were middle-aged during these 24 years. The study also
considered recent height loss, height loss occurring during the
two years prior to the hip fracture, as a possible correlation to
the risk of hip fracture. Most participants were elderly during
the two years of their recent height loss.
The study used Cox proportional hazards regression (HR) to
calculate hazard ratios and 95% confidence intervals for height
loss and risk of hip fracture. For each inch of height loss occurring during the 24 years, the HR was 1.4 in men and 1.04
in women. These results show that height loss was significantly
associated with hip fracture in men but not in women. Men with

long-term height loss of two inches or more had about twice
the risk of fracture than men with less height loss. Recent height
loss occurring two years prior to hip fracture increased the risk
of hip fracture by 54% for men and 21% for women. Recent
height loss was more of an indicator of fracture risk compared
to long-term height loss most probably because recent height
loss occurred during elderly ages while long-term height loss
occurred during the participants’ middle-aged years.
That study proved a relationship between height loss and hip
fracture; however, height loss can be caused by many factors,
postural changes, osteoporosis, disc degeneration, and kyphosis
which may contribute to fracture risk. No information was given
about posture for the participants, which is a limitation of the
study. The exact cause is unknown, but height loss is an indicator of an increased risk of hip fracture. Another limitation of
the study is that participants were all from one town and were
primarily Caucasian (Hannan, et al., 2012).

Physiology of Degenerative Disc Disease
The intervertebral disc has a hard-outer portion called the annulus fibrosus and a gelatinous inner portion called the nucleus
pulposus. The annulus fibrosis can further be divided into 2 portions. The outer zone is made of type 1 collagen fibers and the
inner zone is comprised of type 2 collagen fibers. The nucleus
pulposus is 85% water. The intervertebral discs act as a water
cushion and distribute pressure uniformly over the endplates
of the vertebrae. While a person is in an upright position, the
weight placed on the intervertebral discs causes the discs to
lose water.The water escapes to blood vessels in the bone marrow space in the endplate of the vertebrae. These blood vessels
are also responsible for giving the intervertebral discs nutrition. When the pressure on the intervertebral discs decreases,
like when a person lays down or in a zero-gravity environment,
fluid reenters the intervertebral disc. The difference in height
between a person in a vertical and horizontal position can be
1% of his height (Schuenke et al., 2011).
As people age, they may get what is known as degenerative
disc disease. However, there are those who view degenerative
disc disease different than normal disc ageing, maintaining that
degenerative disc disease is “an accelerated ageing process including structural failure”, while there are those who use the
two terms synonymously (Galbusera et al., 2014). In this paper,
degenerative disc disease refers to disc degeneration associated
with normal ageing.
Over time, the annulus fibrosus weakens and loses elasticity.
Also, proteoglycans, water retaining molecules, diminish within
the degenerating discs. With the decrease in water, the discs
lose their ability to resist compression and torque. The discs
shrink because of the weight placed on them, and less water is
present to counter this force (Jarman et al., 2015). This compression of the intervertebral discs results in a decrease in a
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person’s overall height. Studies show that a decrease in estrogen
can cause disc degeneration (Lou & Chen, 2014).

Disc Height Loss
A study of 37 men and 33 women, with an average age of 48
showed that degenerative disc disease is positively correlated
with disc height loss. The 70 participants were asymptomatic
for back pain to exclude pathologic degeneration. Additionally,
participants were not diagnosed with osteoporosis and didn’t
have any spinal fractures. T2-weighted MR images were used
to determine if the patient had degenerative disc disease. T2weighted MRI signals water content; therefore, an MR image
showing a white disc indicated a healthy disc that contained
water, while images of a dark disc indicated degenerative disc
disease since the dark color in the image indicated that the disc
lacked water. Another indicator of degenerative disc disease is
an absence of the differentiation of the nucleus pulposus and the
annulus fibrosis. The study used MR imaging of the lumbar spine
to assess the height and shape of the intervertebral discs. The
height of the disc was measured as the mean of the anterior
and posterior disc height. Disc convexity was calculated as the
ratio of the central disc height and the mean of the anterior and
posterior height.
The study showed that disc degeneration resulted in a decrease in disc height. Also, the lower intervertebral discs were
shorter than discs higher in the spine (for example, the disc
between L2 and L3 was shorter than the disc between L1 and
L2), most probably because the greater weight placed on the
lower discs cause them to be more compressed. Degenerative
effects on disc height were found to be more pronounced with
increasing age. Weight, overall height, and gender did not correlate with disc height. Discs were found to be less convex in
the presence of disc degeneration. Also, the lower level discs
were less convex. One drawback of this study is that participants didn’t have osteoporosis, so the effects of degenerative
disc disease together with osteoporosis can’t be determined
(Pfirrmann et al., 2006).

Height Changes in Intervertebral Discs
and Vertebrae
Another study was done using 232 monozygotic twin men. The
fact that they are twins is not relevant to the findings of this study.
Intervertebral disc and lumbar vertebrae heights were measured
from MRIs and compared with the measurements of one group
after five years and the remainder after 16 years. After five years,
the vertebrae did not significantly increase in height. However,
after 15 years, the vertebrae significantly increased by an average
of 3.1% which was an average of 0.8 mm. The lower vertebrae
increased in height more than the upper vertebrae did. The disc
heights had a mean decrease of 3.45% or 0.4 mm after five years
and an average decrease of 10% or 1.2 mm after 15 years. Disc
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height loss was greater than the height increase of the vertebrae,
resulting in a net loss of height. The axial disc areas significantly
increased by 4.7% over 5 years and 14.2% over 15 years. Disc
volume was calculated by multiplying the mean disc height by the
axial disc area. Over 5 years, the disc volume did not significantly
change, but after 15 years, the volume significantly increased by
2.3% in the discs between L2 and L4, and significantly increased
by 3.7% in the discs between L4 and S1.
This study shows that disc shortening is associated with an
increase in vertebral height. A 1 mm decrease in the height of
either the superior or inferior discs was associated with an
increase of .09 mm in vertebral height. The effects of the superior and inferior discs are additive. Age was not a confounder
on the relationship between the discs and the vertebrae. Since
the vertebrae increase as the discs decrease, the lumbar spine
only minimally decreases. The reason for this vertebra-disc relationship may be because the increased tension between the
vertebra and annulus fibrosus causes ossification to strengthen
the connection between the disc and the vertebra. This reason
would help explain why vertebral height increases occur more
at the anterior and posterior sections of the endplates, because
it attaches to the annulus. Another possible explanation for the
relationship between disc height and vertebral height is that
endplate lesions can expose the vertebrae to disc substances,
which may lead to inflammation and bone growth on the endplate. Support to this hypothesis is that studies have found an
association between disc degeneration and lesions of the bony
endplate.
Over the 15-year study, the lumbar spine decreased by an
average of 1.4% or 2.0 mm.The mean decrease in total height of
participants was 3 mm. Most of the overall height loss experienced by participants of this study occurred in the lumbar spine
(Videman et al., 2014).

Degenerative Disc Disease and Spinal Flexibility
Intervertebral disc height loss may result in a decrease in the
range of motion and stiffness of the affected spinal segment. It is
unclear however if disc height loss is the cause, or possibly due
to damages of annular tissue or ligaments. One possible way to
restore spinal flexibility is to inject a hydrogel to compensate
for the loss of height of the discs (Balkovec et al., 2016).
A possible concern with simply using a hydrogel to add height
to the discs is that sometimes the surrounding vertebra increases in size as was found in the Videman et al. study, so there may
no longer be sufficient space for a larger disc in the spine.

Conclusion
Osteoporosis may cause a loss of height, vertebral fracture, a decrease in lung capacity, and hip fracture. Osteoporosis is caused
by activation of RANKL and a reduction in osteoprotegerin.
Histone demethylase KDM4B is also linked to osteoporosis. A

What Are the Mechanisms and Effects of Age-Related Shortening of the Spine?

decrease in Estrogen can cause osteoporosis. Weight-bearing
exercise may reduce the progression of osteoporosis.
Degenerative disc disease may cause shortening of the spine.
Discs lower in the spine experience a greater loss of height, presumably because the greater weight placed on them causes them
to condense more. Disc height loss may result in a decrease in
the range of motion and stiffness of the affected spinal segments.
Further studies should be done to determine the effects of
the enlargement of the vertebral bodies in response to degenerative disc disease. Using a hydrogel to restore height in the intervertebral discs may not be a sufficient method of treatment
since the intervertebral space may be partially occupied by
newly formed vertebral bone. Also, further studies are needed
to examine if degenerative disc disease can cause an increase in
bone density of the lumbar spine. Bone density scans are taken
of the lumbar spine to diagnose a patient with osteoporosis, but
if degenerative disc disease is increasing the bone density, then
the diagnosis may be incorrect.The bone density measurements
would appear to be within normal limits even though the patent
may have osteoporosis.
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Abstract
Xenotransplantation is a breakthrough medicinal technology that is an attempt to change the lives of millions of people. The
problems in the current organ transplant system risk the lives of patients each and every day. Intense waiting periods and
extremely costly procedures exemplify the stress and pressure that these patients face as an attempt to save their own lives.
Xenotransplantation is the idea of growing human organs in a different species, using incredible stem-cell and CRISPR technology.
This can introduce an answer to some of the issues in the current transplant system. Many technical and ethical issues are
becoming relevant with the introduction of this new medical phenomenon. If these barriers can be overcome, xenotransplantation
can offer a quicker, cheaper, and more effective option for patients in need of an organ transplant.
Introduction
Thousands of sick patients are in desperate need of an organ
transplant, often having their entire lives depending on this one
vital procedure. Before they can undergo treatment, a proper
organ donor must be found, and the process is harder than
ever imagined. Numerous factors affect the long waiting time, a
period that can frequently become over a year. The main slowdown is the simple shortage of organs ready for transplant. In
response to the overwhelming need for organ donations, new
medical research is being explored as an attempt to alleviate the
high demand. Xenotransplantation poses as a possible solution
to this problem and has the capabilities to be very helpful in the
medical world; releasing the great amount of stress and anxiety
involved in the classic organ transplant system that is now in
place. However, this new medical process introduces new biomedical and ethical issues. Scientists and doctors are currently
exploring the possibilities of this new technology, weighing the
costs against the benefits; an important attempt to improve the
medical world of organ transplantation.

History of Organ Transplants
The concept of organ transfer in a procedural sense has been
around for centuries, in-fact cases of organ transplantation dates
back to ancient times. There is even written proof and documentation from archeological records that suggest that organ
and tissue transplantation is thousands of years old. However,
modern-day organ transplantation is a relatively new medical
phenomenon that has saved the lives of millions of people from
end-stage organ failure.
In the early 1900’s, Dr. Alexis Carrel experimented with kidney transplantations in cats, becoming the first surgeon to explore vascular surgery (Howard et.al., 2012). Carrel’journey to
organ transplantations started with success in vascular surgery
and suturing of vessels. These experiments also advanced the
knowledge of organ preservation, showing that human tissue
could be stored in either saline solution, the patient’s serum,
or defibrinated blood, until it is needed. Carrel then went on
to organ transplantations, experimenting with kidney transplantations between dogs, and from dogs to cats. He realized that
the animals only lived with the transplant for a short period
of time and he knew that there was some sort of rejection
going on in the host’s body. Alexis Carrel made extraordinary

advancements in the medical exploration of organ transplants
and created the possibility for more research in this area
(Rothwell, 2011). In 1923, Dr. Harold Neuhof wrote a book
called The Transplantation of Tissues, which revealed the work
of many different tissue transplants including skin, cornea, muscle, pancreas and nerve tissue (Howard et.al., 2012).
Soon after, the first human kidney transplant was recorded
using a kidney from a donor that had died six hours prior. The
blood type of the donor was type B and the recipient was type
O, which prevented the kidney from functioning, leading to the
patient’s death. However, this may not have been the only cause
for the disfunction of the kidney as other trials have also been
proven unsuccessful. In 1953, a kidney transplant was done from
mother to son which only lasted three weeks before the recipient rejected the donor organ. In the beginning years of the
1950’s, Dr. David Hume performed almost ten kidney transplantations which are now considered the first of their kind in the
modern era of transplantation. However, none of the recipients
had a long-term survival after their kidney transplant.
These and other trials revealed that such organ transplants
would not be possible without immunosuppressant drugs. With
this development, organ transplant became a real option for
patients with organ failure. Dr. Joseph Murray performed the
first successful kidney transplant in 1962, leading into many
other victorious cases around the world. The ‘60’s were very
progressive years for this specific research and medication, as
the first lung and heart transplants were also done during this
time (Howard et. al., 2012).

Problems With the Current Organ Transplant
System
As immunosuppressant drugs allowed organ transplantation to
start becoming a viable option for victims of organ failure, the
need for transplantable organs became overwhelming. In the past,
kidneys from living donors were being used, but this supply is limited and not nearly enough to provide for all in need. Even with
deceased donors for transplants, the available donor organs, unfortunately, do not cover the demand (United Network for Organ
Sharing, Data, 2018).
Although most technical problems involved in the process have
been solved, organ transplantation is not seen as a long-term cure
for patients as there are still biological issues and financial problems.
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The biggest and most complicated problem is the patient’s
rejection of the new organ. When a patient undergoes an organ
transplant surgery, the body’s immune system becomes stimulated against the “foreign” organ and tries to kill it. Patients
are usually given strong medication to suppress their entire
immune system, but that can become counterproductive as the
patient is now vulnerable to other diseases. Different drugs,
such as Cyclosporin, have been approved to control much of
the rejection, but transplantations can still have those dangerous
effects (MTF Biologics, 2017). Although they have been shown
to improve symptoms, these drugs can have many negative side
effects including tremors and seizures.
Another problem is the long waiting period that patients wait
in order to receive a proper match for donation. There are simply not enough donors to fill the demands, causing many victims
to die in the ‘waiting room’. Although the shortage of organs is
the main cause for the waiting time, the length that the patient
waits can vary, depending on a number of factors. The blood or
tissue type, the size of the organ, and the medical urgency of the
situation are some factors that will fluctuate the waiting time. In
any case, the patient almost always needs to wait for a proper
donor before proceeding with the transplant.This is not practical
in many cases when the organ transplant is extremely urgent. On
average, twenty people die every day while waiting for an organ
donor (United Network for Organ Sharing, Data, 2018).
Also, organ transplants are extremely costly and many people
simply cannot afford such medical procedures. Kidney transplants cost over four hundred thousand dollars, and a heart
transplant goes up to over one million (Rapp & Vandermey,
2017). This cost does not even include the health maintenance
of such a procedure, nor the cost of immunosuppressant drugs
that cost as much as ten thousand dollars per year, for life
(Gordon, et. al. 2008).

Methodology of Xenotransplantation
Looking for a solution to this unmet medical need, researchers have come up with a new method known as
Xenotransplantation, which is the process of “grafting or transplanting organs or tissues between members of different species.” Xenotransplantation is using stem-cell and CRISPR technology to grow human organs in a host of a different species.
This idea comes from chimerism, the ability to create a “living
thing that is composed of cells from two or more organisms”
(Dunlap, 2017). The basic procedure is to use the pig as a host
by cutting out the HOX genes that code for growing certain
organs and the genes that code for porcine microorganisms
from their genome. HOX genes are the sequence of genes in
the genome that directs the body organization in an embryo
(KhanAcademy, Khanacademy.org, 2018). Using CRISPR-Cas9
technology, described below, genetic engineers can knock out
the genes in the pig that code for the development of specific
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organs, and replace them with specialized human stem cells that
will grow human organs instead. The hypothesis is that infusing
differentiated human stem-cells into this embryo will result in
the pig growing a human organ instead of its own.

CRISPR-Cas9 Technology
CRISPR-Cas9 stands for Clustered Regularly Interspaced Short
Palindromic Repeats, and is breakthrough technology in genome
editing. CRISPR is a special region in DNA that is characterized
by having repeated nucleotides and spacers. This unique DNA
region was first recognized in bacterial genomes and has since
been adapted in the laboratory as the CRISPR Cas9 complex
(Vidyasagar, 2018). Cas9 is a protein that acts as the molecular scissors that can cut the DNA in a double-strand break.
When combined with a guide RNA (sgRNA), it forms the Cas9
Complex. The Cas9 first binds to a sequence in the genome
and the guide RNA unwinds the double helix. The guide RNA
is precisely designed to match up with the specific strand of
DNA that needs to be edited. Then, the Cas9, with the help of
its nuclease domains, cuts the DNA, creating a double-strand
break in the double-helix. The DNA tries to repair itself but the
reparations are usually flawed which inevitably shuts off that
particular gene. This is why CRISPR is “a great tool for knocking
out specific genes” (NatureVideoChannel, 2017).

Stem-Cell Research
Another biomedical technique is somatic cell nuclear transfer,
known as SCNT, or cloning. Conceptually, the nucleus from a
somatic (body) cell replaces the nucleus in a fertilized oocyte of
another individual.This hybrid blastocyst is capable of generating
a stem cell line” (Columbia.edu, 2018). The created stem cells
will be identical to the donor and have many uses in the medical
field. One such example would be to use these cloned cells to
create human organs in pigs a step in the xenotransplantation
process. The idea is to fuse the stem cells from the patient into
a porcine embryo, hoping that the pig will grow human organs
that can then be used as the transplant for the intended patient.
In a few short months, the patient could potentially be on his/
her way to a complete recovery. This will only be a possibility,
however, if the barriers of Xenotransplantation are overcome.

Brief History of Xenotransplantation
Aside from cross-species blood transfusions, which were
around since the 17th century, skin grafts are considered the
first attempted trial in xenotransplantation. Skin grafts from animals to human patients were performed as early as the 19th
century. Frog skin was the most popular species to was the
most frequent source of the donor material to the skin grafts.
Different attempts at xenotransplantation were tested, mostly
using primates as the donor animal. Out of thirteen trials, only
one kidney transplant from a chimpanzee to a human patient
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was successful with the patient living for an entire nine months
before dying as a result of rejection of the kidney. In 1964,
the first heart xenograft from a chimpanzee to a human was
performed. The patient died within two hours of the operation.
Later, in 1992, a doctor named Starzl performed a baboon to
human liver transplant, with the patient surviving for seventy
days. Along with the numerous failures, some of the early xenotransplants resulted in temporary patient survival. But, in general, the organs were rejected in an even more serious case than
with a same-species transplant. The rejections of this kind are
so severe that immunosuppressive drugs are not strong enough
to stop the rejective response to the xenografts (Cooper, 2015)

The Advantages of Porcine Xenotransplantation
Recently, the focus has been on the use of organs from the pig
and hog family, porcine, as they are comparable to human organs in size, anatomy and physiology, compared to other species
(Niu, Wei, & Lin, 2017). Pigs, compared to other species such as
baboons, would be a valuable candidate for organ xenotransplantation. Pigs can be bred in large herds and with a relatively
short maternity period, making them a more available option. In
addition, they are not a costly animal to breed (Cooper, 2015).
The advantages of xenotransplantation from pigs would be
enormous, starting with the obvious increase in availability of
organs for transplantation. Right now, there is a shortage of
human organs for transplants, but using organs from another
species will solve this problem, it will also make immediate
transplant surgery possible for patients with an urgent situation.
In addition, organs that are retrieved from human cadavers have
already experienced the trauma of brain death which may lead
to other issues later on. With animal donor organs, the organs
will be removed from a healthy pig that is under anesthesia,
avoiding the problem altogether. Another important solution
that xenotransplantation brings is the decrease of the risk of
a pathogen being transferred from the donor to the patient.
Diseases such as the West Nile Virus and rabies have been
passed through organ transplant surgery resulting in a number
of deaths. The pigs intended to be used for xenotransplantation
are being raised in the best conditions and are being supervised
closely which reduces the likelihood of any illness to be transferred from donor to patient (Cooper, 2015).

Zoonoses and Porcine Endogenous Retrovirus
(PERV)
CRISPR-Cas9 can be used in xenotransplantation research by
knocking out specific genes in the pig that cause rejection when
transplanted into human patients. Zoonoses are diseases that
are transferred between humans and animals, caused by bacteria, parasites, and viruses. These diseases pose the major barrier preventing xenotransplantation from becoming proto-call
in the medical world. The potential transfer of porcine related

infections into the human genome is a major risk of xenotransplantation. The pig herds intended to be used for medical
reasons have been raised under the most sanitary conditions
and have been screened for most pathogens and viruses that
can possibly harm the recipient. However, porcine endogenous
retroviruses that lie in the porcine genome have the capability
to hurt human health. PERV are viral elements in the porcine
genome, and being that they are innately a part of the DNA, the
retroviruses cannot be eliminated by means of selective breeding or drugs. PERVs have the ability to recombine with other
genetic elements of the recipient’s genome. Similar to pigs, humans have their own set of endogenous retroviruses, known as
human endogenous retroviruses, or HERVs. If the PERV were to
come in contact with the human endogenous retroviruses, the
former genes can recombine and disturb the human genome.
Naturally, the HERVs are attempted to be halted by some sort
of stop codons or deletions, but some bypass the stop codons
and actually “play an important role in human physiology as well
as in pathogenesis” (Machnik, et al., 2014).
Studies of HERVs have concluded that class I of HERVS group
together with γ- and ε-retroviruses, and during a xenotransplantation it is these genes that can recombine with PERVs that
also belong to the γ-retroviral group (Machnik, et al., 2014).
Studies have recently confirmed that two out of three PERV
types, namely PERV-A and B, have been seen to replicate in
human cells during in-vitro research, meaning in a clinical setting.
To date, no PERV infection of human cells have been documented in-vivo, but the possibility of this occurring needs to be taken
into real account as new pathogens can be created at the point
of interaction, and these new pathogens can cause unpredictable damage (Prabha & Verghese, 2012).
Recent discoveries, however, have shown major advancements
in this area. Scientists have used CRISPR technology to successfully cut out sixty-two PERV sequences from a porcine genome.
The nuclei of these cells were then transferred into enucleated
pig oocytes by somatic cell nuclear transfer, and then implanted
into surrogate female pigs. The results were astonishing with
thirty-seven piglets being born, all with inactivated PERVs in the
genome. This research greatly expands the possibilities in the
realm of xenotransplantation, although other issues are yet to
be resolved (Denner, 2017).

The Issue of Rejection
With all the prementioned advantages, there are still barriers
preventing pig organ xenotransplantation from becoming the
standard medical procedure. Scientifically speaking, the biggest
barrier to overcome is the problem of rejection; the patient’s
natural response to an alien in the body. Firstly, within seconds
or minutes of the transplant, the possibility of hyperacute
rejection can happen. This type of rejection occurred when
pig organs were transplanted into nonhuman primates. The
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preformed antibodies of the receiver attached themselves to
the pig’s vascular endothelium and as protocol reaction to a
pathogen, the cascade system was initiated. This caused the endothelial cells to convert into procoagulant phenotypical cells,
resulting in hyperacute rejection. Attempts have been made to
prevent this by depleting the antipig antigens, or the complement system from the recipient’s serum, however, there are
still other forms of rejection that may occur. Acute humoral
xenograft rejection may occur during the first few days after the
transplant, and cellular rejection can become a problem even
weeks after the operation. This rejection is acute-cell mediated, meaning that different cells in the patient’s body recognize
the foreign organ as unfamiliar and begins to attack it. The cells
involved are usually the natural killer cells, macrophages, and
cytotoxic T cells. It is believed that even immunosuppressant
drugs cannot prevent this rejection from being triggered. If the
recipient is able to survive with the graft for a longer period of
time, chronic rejection may occur. The exact cause of this type
of rejection is not completely understood. However, the main
point regarding all types of rejections is that the antibodies or
killer-cells in the recipient attack the donated graft, resulting in
a slow, but ultimately fatal destruction of that organ (Esker &
Cooper, 2010). The information regarding the rejection or acceptance of a pig organ in a human patient is extremely limited,
as only a few procedures have been tested so far. The scientists
and doctors cannot study this further until a patient survives
the procedure for a longer time (McLean & Williamson, 2004).
Rejection of the organ can occur in any transplant, regardless
of whether the graft is from the same species or not. The difference is that in a xenotransplant rejection, the immunosuppressant drugs are not strong enough nor sophisticated enough to
significantly extend the patients survival time.

Potential Solution for Xenograft Reject
Genetic Engineering of the pigs is the newest and most successful method to date to prevent or mitigate the rejection of the
organ graft. One major advancement is the creation of a genetically engineered pig that expresses a human complement-regulatory protein. This protein is found in the pig’s vascular endothelial cells and protects the tissue of this donated organ from
being attacked by the pre-formed antibodies during hyperacute
rejection (Bloom, Moulton, McCoy, Chapman, & Patterson,
1999). Genetic engineers have also produced pigs which have
had the gene for α1,3-galactosyltransferase removed. The gene
for α1,3-galactosyltransferase codes for the production of the
enzyme that adds Galα1,3Gal oligosaccharides to different basic
glycoproteins and glycolipids in pigs. In general, Gal is a major
target for the human antibodies, as it is seen as a major invader.
The removal of this gene, and therefore the halt of the Gal production in the pigs, has significantly reduced the hyperacute rejections that usually occur during the pig to nonhuman primate
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xenograft trials (Esker & Cooper, 2010).
The results of this research have been positive; the length of
survival time increasing by the use of the genetically engineered
pig organs.A pig heart of this type lasted for 3-6 months, kidneys
for close to three months, and livers for days. The extension
of the survival period is proof of the success of the genetic
research (Esker & Cooper, 2010).
There are also genetic solutions being studied that will disable
the natural killer cells and the macrophages from attacking the
xenograft, although they have yet to be tested in pig to nonhuman-primate transplant. Genetic engineers are working on
producing pigs that are HLA-E or HLA-G transgenic as these
immunoregulatory molecules are expected to stop natural killer cell cytotoxicity (Esker & Cooper, 2010).

The Issue of Coagulation Dysregulation
Another barrier that has arisen during the xenotransplantation trials is the development of thrombotic coagulopathy and
consumptive coagulopathy, different types of coagulation dysregulation. Coagulation dysregulation is irregular blood clotting
in areas of the circulatory system. The xenograft recipient will
usually develop one of these, or possibly both, which poses a big
limitation to the survival time of the graft. In heart transplants
from genetically modified pigs to baboons, thrombotic coagulopathy is the predominant symptom, while in the kidney graft,
the baboon developed consumptive coagulopathy. It is thought
that physiological differences between pigs and primates are the
causes for these problems, although the exact reason for the
coagulation dysregulation development remains unclear. It is
known, however, that activated endothelial cells of the donated
organ are the cause for inflammation and coagulation in the
recipient. Ischemia, or inflammation, is inevitable in most types
of organ transplants, but various types of intertwined factors
can be the cause of graft endothelial cell activation (Cowan,
Robson, & d’Apice, 2011). One proposition suggests that the
endothelial cells activated by either the antibodies or the start
of the complement, increase the activity of TF, tissue factor.
The introduction of the TF into the portal vein activates the
instant blood-mediated inflammatory reaction, known as IBMIR.
Characteristics of IBMIR are platelet binding, complement activation, and thrombosis (Esker & Cooper, 2010).

Ethical Problems With Xenotransplantation
In addition to the biological barriers of Xenotransplantation,
problems regarding ethical and moral topics come into question
when researching the possibilities for the future.Transplantation
in general has a public risk associated with the administration of
immunosuppressant drugs.These drugs are known to lower the
patient’s ability to fight off infections, and therefore increase the
risk of contamination. For the patient, the risks involved need
to be weighed by their own physician; however there are public
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concerns involved as well.The new genetic engineering, plus the
previously used immunosuppressant drugs, have the potential to
“open the way for the emergence of new viral mosaics into the
general population” (Anderson, 2006).
The opposing side of the ethical debate brings up valid points
as well. With thousands of people in desperate need of organ
donations, is it ethically fair to deprive them of the possible solution that can potentially save so many lives? The introduction of
xenotransplantation can greatly reduce the waiting period for an
organ donation, and additionally provide the patient with a longterm graft. The immunosuppressant drugs have saved so many
people from death; is it morally okay to ban them on the slight
chance that they can cause an infection outbreak? These questions are some of the many that have come up in discussion over
the last couple of years, as the medical world is coming closer to
introducing this new phenomenon to regular medical protocol.
Another ethical problem involved in xenotransplantation is
the issue of personal privacy and confidentiality. This question
arises due to the necessity of monitoring of the patient after
an organ transplant, going as far as to institute a lifetime surveillance of the patient. This surveillance has become a part of
the system as an attempt to prevent pathogenic diseases from
spreading through organ transplant surgery. As previously discussed, the pathogenic risks involved in xenotransplantation are
very great and have caused medical outbreaks in the past. In
fact, in the year 2000, a hepatitis C breakout was reported due
to an infected donor that was mistaken to be healthy. Since
then, tremendous precautions have been taken while looking
for organ donors, as the transfer of pathogens through transplants can lead to numerous fatalities. Opponents of the monitoring system believe that this provision is an invasion of the
patients’ privacy, as well as the privacy of their family and friends.
Here lies the question whether or not the invasion of privacy
is considered to be ethical for the safety of the patien and the
“problem of maintaining ethical standards in situations such as
this is vexing” (Anderson, 2006).
The only possible way to effectively protect society from infectious diseases via xenotransplantation is if the national and international powers decide on a logical system, keeping the ethical
debates in mind. The World Health Organization has previously
come together to discuss this exact topic, although no agreement
was yet to be decided. To date, the only guidelines put in place
are those of the Food and Drug Administration’s Recombinant
DNA Advisory Council. The RAC approved gene recombination
studies to be done at Harvard and MIT, advancing the medical
research of this field. The RAC’s permission was granted with
the consent of the citizens of Massachusetts, justifying the ethical
questions involved in such research (Anderson, 2006).
The American Society of Transplant Physicians voice their
concern of infectious diseases being spread internationally. They
feel that United States regulations are not strong enough in

comparison to the severity of the risk involved. It is presently
legal for patients in need of an organ donation to receive organs from live donors living in impoverished countries, where
infections are known to be rampant. For example, there is a
website named Liver4you.org which arranges liver donations
from people in the Philippine Islands. Bringing these diseases
across to the United States through the organ transplant poses
as a major threat to the wellbeing of society (Anderson, 2006).
Often, doctors and surgeons are also researchers of new
xenotransplantation medication, which poses additional ethical
questions regarding the split between their medical responsibilities and their personal studies. The physicians can frequently
be confronted with “the well-being of the patient in direct opposition to the advancement of academic medicine” (Anderson,
2006). An example of what might result from such a situation
is a doctor convincing a patient to participate in a clinical trial
that he/she would otherwise not join. An infamous case of this
sort, known as the Baby Fae case, took place in 1984 when a
young child was used in a medical trial of a xenotransplantation
using a baboon heart. The parents were encouraged by optimistic doctors who hoped to provide the baby with “immediate
and long-term survival” but she only survived for four weeks
following the graft. Medical researchers have become cautious
getting involved in xenotransplantation studies in fear of this
sort of issue cropping up, in addition to the history of medical
science misconduct (Anderson, 2006).
Additionally, with the introduction of stem cells into the pig
embryo, the possibility of creating a pig with human elements
presents an ethical issue. The ethical debate discusses the possibility of human gametes to be created and an embryo to be
formed as an interspecies chimera. Although it is agreed upon
that the embryo would not be able to develop, the mere creation of it poses as an ethical question. Also, the differentiation
of human stem cells needs to be studied in depth as the question arises of what is stopping the stem cells from entering the
pig’s brain, or other areas, which will blur the margin of what is
considered human and what is considered animal? Is it morally
permissible to perform a procedure that can potentially give a
pig, human, high-level brain functions? These ideas are unlikely
in the scheme of things, but pose concerns in the biomedical
world nonetheless (Masaski & Nakauchi, 2017).

Conclusion
Scientific researchers are constantly trying to better the medical world; looking for solutions and applying their incredible
knowledge to helping humanity. The biomedical field is exploring the possibilities of genetic engineering combined with
stem-cell research, hoping for xenotransplantation to one day
become a standard medical procedure for patients with organ
failure. When it comes to genetic engineering, the possibilities
are endless; however, xenotransplantation has many barriers to
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overcome before it can become the standard medical procedure. However, the latest research may explore the best course
of action regarding this dynamic research. Researchers have
proposed for xenografts to be used for patients in the waiting
period that are waiting for an organ donor. This way, although
xenotransplantation is not yet a final solution, it will at least
minimize the number of deaths of patients, and the health risks
for waiting for a proper transplant. This change in proto-call
has the tremendous potential to save millions of lives, giving the
patient the ability to live the few months until they can receive
a proper transplant. Researchers are only beginning to uncover
the technology’s tremendous potential and long-term survival
of xenografts may be a few years away. Even so, it is possible that
for now, temporary xenotransplantation can be the life-saving
procedure that patients are hoping for (Servick, 2017).
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Abstract
In the last half a century, researchers and scientists discovered the application of somatic cell nuclear transfer (SCNT) to clone
mammalian embryos to produce a line of pluripotent stem cells for medical and laboratory use. This is a breakthrough technology
that is applied to stem cell research, regenerative medicine, and cloning. Somatic cells are non-germ cells that are differentiated
but provide the nuclei that are transferred to enucleated oocytes. The replacement of the nuclei results in a developing embryo
that contains the genetic information of the donated nucleus, which can either be transplanted into a surrogate mother to
produce a genetically similar offspring or grow in-vitro to extract embryonic stem cells (ESC). This process has made it possible
for the cloning of numerous mammalian species, such as pigs, cattle, mice, and, recently, primates. Although success has been
evident in mammals, human derivation of pluripotent embryonic stem cells has been difficult to obtain.The difficulty stems from
the premature activation of the oocyte and the improper reprogramming of the donated nucleus. This paper focuses on the
development of human nuclear transfer embryonic stem cells (ntESC) and its application in regenerative medicine. Studies done
on primates provide information on the barriers of this procedure on humans and the proper modifications on regular SCNT
protocol.The use of deacetylase inhibitor TSA, phosphate inhibitor caffeine, and HVJ-E for proper membrane fusion are only some
of the recent methods found for proper nuclear reprogramming and embryonic development. Breakthroughs in the methylation of
DNA and histones in mice provided insight to a barrier in human embryo development. As a result, derivation of embryonic stem
cells was successful and tested for pluripotency. Insulin beta cells and cardiomyocytes have been produced using this modified
SCNT protocol and hold great potential for the future of science. The use of nuclear transfer embryonic stem cells is important
in the development of stem cells that can differentiate into specialized cells, such as neurons, that can potentially be used to cure
disease, like Parkinson’s. Even more so, these cells will retain the genome of the patient and reduce immune incompatibility. The
paper goes on to discuss the ethical issues that impede researchers from advancing in this area.
Introduction
Somatic cell nuclear transfer (SCNT) is a laboratory technique in
which the somatic cell nucleus is transferred into an enucleated
oocyte. The egg is developed into a blastocyst, an early embryonic stage where the opening of a cavity in the morula between
the inner cell mass and the enveloping layer is filled with fluid.
This procedure was first theorized in 1938 by Hans Spemann, a
German embryologist, in his book Embryonic Development and
Induction. He proposed an experiment to replace the nucleus
of an unfertilized egg with a differentiated embryo nucleus. He
pondered on whether such a transplant of a differentiated nucleus can give rise to an organism (Wellner, 2010). This was a
start to the idea of cloning that was initially attempted in 1952.
Scientists Robert Briggs and Thomas King transplanted nuclei
from an advanced blastula cell into enucleated eggs of Rana pipiens, also known as leopard frogs.They saw a normal development
of embryo resulting in the first cloned organism.Their study provided a basis for the SCNT protocol. As well, they determined
that success is attributed to the transfer of a nucleus from the
same species of frog. Transplanting the nucleus of a bullfrog led
to an arrest at the blastula stage and inevitably died (Briggs et.
al, 1952). Alluding to the core principle in SCNT mechanics of
donor nucleus and oocyte recipient compatibility.
In 1996, the first cloned mammal using a fully differentiated
adult cell was executed by Campbell et al. (1996) in Scotland.
Dolly, the cloned sheep born in 1997, was a breakthrough in
determining the nuances of SCNT. They figured out that the
development of embryos reconstructed by nuclear transfer is
highly dependent on the interaction of the donor nucleus and
recipient cytoplasm (Campbell et al., 1996). Their findings aided

in further successes of cloned organisms and nuclear transfer
embryonic stem cells (ntESC) derivation. Such findings include
the effects of cytoplasmic kinase activity and maturation promoting factor (MPF) on chromosomal damage. The expression
of cytokeratin and lamin A/C, markers associated with differentiation, was also reported indicating the development of ESC.
Research in this area after this incident paved the road to develop human ntESC and the extensive studies done on primates
contributed to a modified SCNT approach.
The important application of this process is to produce
a culture of embryonic stem cells that are created from the
inner cell mass of the blastocyst. Stem cells are undifferentiated
cells that can either produce cells that continue as stem cells
or are differentiated into specialized cells. The implications of
this procedure of generating personalized embryonic stem cells
is useful for disease mechanism, and development of therapies
(Tachibana et al, 2013), i.e. regenerative medicine or replacing
damaged cells in patients, like cardiomyocytes to replace damaged heart tissue or insulin-producing beta cells for diabetic
patients, by eliminating the prospect of immune incompatibility
(Lanza et al, 1999). However, therapeutic cloning refers to the
derivation of nuclear transfer embryonic stem cells without
uterine transplantation that has been successful in mice and
cattle, derived from ntESC lines in cloned blastocysts (Yang et.
al, 2007). However, human ntESC has been notoriously difficult
due to its failure to progress past the eight-cell stage because of
inactivation of critical embryonic genes. Due to ethical and legal
restrictions, further research in this area is moving at a slower
pace. Therefore the question arises, can SCNT be used to produce human pluripotent stem cells for regenerative medicine?
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Methods
The information gathered in this paper was collected from several sources such as Touro College Online Library and NCBI.
The searches for “Somatic cell nuclear transfer”, “Cloning”,
and “Therapeutic Cloning” led to the majority of articles used
obtained from PubMed and Nature. The articles discuss the
experimental studies done at various times and an analysis of
these studies provided material for this discussion. Some review
articles were necessary in the development of this analysis.

Discussion: Nuclear Reprogramming
For successful embryonic development the proper nuclear and
cytoplast-mediated reprogramming is necessary. Campbell and
colleagues (1993) specified morphological events that occur in
nuclear transfer at the merging of a nucleated blastomere or
karyoplast into the cytoplast of an enucleated metaphase II arrested oocyte (MII). Oocytes in MII state have a higher success
rate in nuclear reprogramming in the cytoplasm due to certain
factors. In mammals, the fusion of the two specimens is induced
by an electric pulse to promote fusion and activation of the
enucleated egg. Studies in mice, pigs, and cattle display that certain morphological events occur at the point of fusion, including
nuclear envelop breakdown (NEBD) followed by premature
chromosome condensation (PCC), dispersal of nucleoli, reformation of the nuclear envelope, and nuclear swelling (Campbell
et. al, 1993). The induction of NEBD and PCC are important for
the reprogramming of gene expression and increased embryo
development. These events vary depending on both the species
and nuclei at different cycle stages. In rabbits, blastocyst development was found to be greater when the blastomeres were
in G1 or early S phase than in late S phase or G2 (Collas et. al,
1992). A possible explanation for such observations was found
in the cell cycle regulation with an emphasis on cellular DNA
replication by maturation promoting factor (MPF).
A study showed the necessary implication of MPF activity at
G1/S and G2 stages. MPF is a complex of two proteins, cyclins
and p34cdc2. P34cdc2 is a protein kinase that is regulated by
phosphorylation changes and interaction with cyclins. P34cdc2
does not change during the cell division cycle while cyclin does.
P34cdc2 kinase triggers the entry of the cell into the M phase
that produces NEBD, chromatin condensation, and other morphological changes in the cell. Therefore, MPF primary function is to promote nuclear breakdown, spindle formation, and
chromatin condensation. Mammalian oocytes at the MII phase
contain high levels of MPF. Upon fertilization or activation, MPF
levels decline resulting in the decondensation of chromatin and
formation of pronuclei. Therefore, NEBD and PCC occurrence
in the donor nucleus suggests a correlation between MPF with
NEBD and PCC activity. NEBD and PCC probably remove
the nuclear membrane to allow ooplasmic remodeling factors
access to the donor cell chromatin for the re-replication of
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previously replicated DNA and the synthesis of DNA in the
donor nucleus at any cell stage. As well as, contributes to the
reformation of the nuclear membrane. A problem arises when
MPF activity is low at the time of fusion (Campbell et al., 1993).
When MPF is low at the time of fusion, from premature activation of the enucleated egg, the nuclear membrane is maintained. G1 donor nuclei will replicate their DNA, however, G2
nuclei will not rereplicate and a low frequency of development
arises. However, interestingly enough, this suggests that, at slow
MPF decline at the time of fusion, in any other phase other than
G1, the DNA will rereplicate resulting in aneuploidy. This correlates with the results of the study done by Collas et. al (1992)
regarding the development of rabbit blastocyst. In rabbits, at G1,
early S, and late S phases, metaphase plates, and spindles were
detected but abnormalities, like incomplete spindle formation
and incomplete chromosome condensation, was present in late
S phases (Campbell et. al, 1993).
A study was done by Mitalipov et. al (2007) built on the aspect
of MPF regulation in primates and nuclear remodeling through
lamin A/C staining. Lamins, an intermediate filament superfamily of proteins, are part of the nuclear lamina found on the
inner layer of the nuclear envelope. Lamin types A and C are
expressed in many differentiated somatic cells. Lamins A/C are
essential in size, shape, and strength determination of the nuclear envelop as well as maintaining lamina structure. (Hutchison
and Worman, 2004). These proteins tend to depolymerize
during late prophase and become undetectable in the MI or MII
oocytes. At fertilization, cytoplasmic lamins are gathered into
the forming pronucleus (Prather et al., 1989). Lamin A/C has
been used to assess the extent of nuclear remodeling following
SCNT because of the changes in the nuclear lamina, as shown in
this 1study, in monkeys.
MPF levels, as mentioned before, result from premature oocyte activation and a failure to induce nuclear remodeling. In
studies with mice and cattle, the fusion of a donor cell with an
oocyte was done through electroporation. Electroporation in
a calcium ion fusion medium increases the calcium levels that
trigger a rapid decline of histone H1 kinase and even MPF activity. Using electrofusion with calcium ion or magnesium ion free
buffers or performing all manipulations free of these ions can
minimize premature activation of the oocyte (Mitalipov, 2007).
An improvement in the in-vitro development of pig (Boquest et
al., 2002) and primate blastocysts (Mitalipov et al., 2007), which
was shown from lamin A/C profile under these modifications was
similar to those detected in sperm-fertilized controls. To supplement electroporation as a fusing agent in human SCNT, HVJ-E
virus, hemagglutinating virus of Japan-envelope, a non-infectious
vesicle used as an agent for cell fusion, showed a high rate of
fusion. However, embryonic development past the compact morula failed, even though ionomycin and 6-Dimethylaminopyridine
(DMAP) were used to activate the cell at the appropriate time.
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Therefore, implementing electroporation, which is not necessary
for cell fusion but rather for timely cell activation, increased blastocyst development. It is necessary as an activation stimulus in
conjunction with ionomycin and DMAP (Tachibana et. al, 2013).
Extended exposure of the chromatin to the non-activated MII
cytoplast enhances embryonic development. An MII oocyte has
high levels of MPF but enucleation, which also removes cytoplasm from the oocyte, reduces MPF levels (Lee & Campbell,
2006). The disassembly of the nuclear lamina with the chromosome condensation is attributed to the phosphorylation of
MPF. To prolong the presence of MPF, use of caffeine, a protein phosphatase inhibitor, or MG-132, a proteasome inhibitor,
increased nuclear remodeling in the donor nucleus. MG-132
prevents spontaneous oocyte activation, as seen by the weak/
partial lamin A/C signal in C/C1 (figure 1). More exposure to
MG-132 reduces the lamin A/C signal and increases the chromatin condensation, as seen by DAPI blue stain (Mitalipov et.
al, 2007). However, proteasome activity impacts development
events, in contrast to caffeine that has high cleavage rates and
regular blastocyst formation. However, caffeine does not affect
the frequency of blastocyst formation (Lee & Campbell, 2006;
Mitalipov et. al, 2007). Embryos usually do not develop past day12.These conclusions suggest there is more than merely nuclear
remodeling that affects the success of SCNT.

DAPI

Lamin A/C

Premature activation of the MII oocyte is a likely occurrence,
especially in aged or overstimulated oocytes. Therapeutic cloning or ESC derivation from discarded, aged, or failure-to-fertilize
oocytes are unlikely to succeed (Mitalipov et al., 2007). Ovarian
stimulation can also affect the quality of the oocyte, thus, tampering with the success of the procedure. A study was conducted to
compare three groups of oocyte donation cycles, <10 oocytes
per cycle, 11-15 oocytes per cycle, and >16 oocytes per cycle.
Survival of the egg after spindle removal until embryonic cleavage
was similar amongst the three groups. However, more >16 oocyte/cycle groups arrested after the eighth cell stage. Additionally,
the quality of the blastocysts correlated inversely with the number of oocytes collected per cycle. ntESC derived from these
oocytes were mainly from the <10 oocyte/cycle group and none
from the >16 oocyte/cycle group (Tachibana et al., 2013). This
shows that both the donated nucleus and recipient oocyte contribute to the success of ntESC derivation and development.
Another challenge to SCNT embryonic development is the
consequence of microtubule and centrosomal protein depletion.
This is a result of enucleation of the oocyte that extracts the
spindle with defective reformation of the spindle by the donor
nucleus. However, when the somatic cell nucleus is transferred
to an oocyte containing its own chromosomes it results in a
functional polyploid blastocyst that can develop into ESC. This
can mean that certain reprogramming factors, associated with
the spindle apparatus, are present in the MII oocyte (Tachibana
et al., 2013) and are removed upon enucleation. Modification in
the SCNT protocol of spindle removal is necessary to successfully execute nuclear reprogramming and blastocyst formation.
The standard procedure of enucleation and spindle extraction
is by adding bisbenzimide staining and UV exposure in mammals,
such was executed in pigs (Polejaeva et al., 2000). However, if
meiosis-specific factors are retained during spindle removal
then only spontaneous activation of the cell causes its decline.
By using the methods above to protect against premature activation, SCNT embryo development increases and spindle-like
structures are formed. This method increased ESC derivation
in primates that displayed similarities to human IVF-derived
blastocysts than the manipulated spindle transfer embryos
(Tachibana et al., 2013).

Epigenetic Regulation

Figure 1: Lamin A/C signaling and DAPI staining for exposure of
MG-132 (Mitalipov et al, 2007)

Nuclear reprogramming is a crucial step for the success of
embryonic development. However, it is not limited to the first
steps of activation. Reprogramming gene expression in the inner
cell mass (ICM) is a necessary component for the continuation of embryonic development and especially for derivation of
pluripotent ntESCs. Normal development requires epigenetic
modifications, which includes DNA methylation and histone
modification. The ICM and trophectoderm are distinguished in
the blastocyst with a predominant increase of DNA and histone
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methylation in the ICM, affecting genomic imprinting and X
chromosome activation in females (Yang et al., 2007).
In normal embryonic development, methylation occurs preferentially in the ICM, a process in which a methyl group is added
to the 5th carbon of the cytosine ring next to a guanine base,
through DNA methyltransferases (DNMT). In female mice, for
example, demethylation occurs due to DNMT during subsequent
cleavages. In male mice, it is demethylated in the pronucleus after
fertilization. Chromatin configuration establishes the ‘histone
code,’ a cellular memory responsible for maintaining the identity
of differentiated cells. Histones are proteins that contribute to
the make-up of chromatin. They have an exposed N-terminus
end, which is either modified through methylation, acetylation,
ubiquitinylation, or phosphorylation. For example, the acetylation
of histone 3 Lys9 (H3K9) induces an open chromatin configuration giving transcription factors access while the methylation or
demethylation of H3K9 inactivates it (Yang et al., 2007).
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor,
has shown a significant impact on embryonic development in
mammals and primates (Sawai et al., 2012; Mitalipov et al., 2007).
A study was conducted on bovine animals using 5nM and 50nM
of TSA. The group that was treated with 50nM of TSA showed
significant blastocyst development.TSA increased histone H4K8
and histone H3K9K14 acetylation, which activates gene tran-

Figure 3:TSA structure. Selleckchem.com
scripts. However, FGF4 in bovine, required for ICM formation
and trophectoderm differentiation, was still considerably low
and did not change through the treatment of TSA. It is mainly
affected by DNA methylation signifying that DNA methylation
is an important factor for nuclear reprogramming (Sawai et al.,
2012). Therefore, it is proper to conclude that TSA is necessary,
as Mitalipov’s study on primates and Tachibana’s study on human
ntESC both come to the same conclusion, yet DNA methylation
is another component to embryonic development.
DNA and histone methylation is pertinent to improve the
ntESC derivation. The first developmental defects of SCNT appears at the time of zygotic genome activation (ZGA) which
occurs at the 4 to 8 cell stage in humans and bovine and at the
2-cell stage in mice. Difficulties in ZGA are due to epigenetic
barriers existing in the genome. Certain genomic domains resistant to ZGA in SCNT embryos, known as reprogramming
resistant regions (RRRs), have been identified. Enrichment of
mouse RRRs with histone H3, lysine 9 methylation (H3K9me3)
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in the donor genome results in a barrier to transcriptional reprogramming. They must be removed by specific demethylase
or by ridding it of H3K9 methyltransferases. Kdm4d, H3K9me3specific histone demethylase, greatly reduces H3K9me3 levels.
The injection of Kdm4d mRNA increased the blastocyst rate up
to 88.6% (Matoba et al., 2014).
In the study done by Chung et al. (2015), it was found that
H3K9me3 also serves as a barrier in human SCNT. Using the
same oocytes that failed to develop into blastocysts, they demonstrated that Kdm4a overexpression significantly improved embryonic development. Compared to the IVF derived embryos,
of 707 genomic regions in SCNT embryos, 308 were termed as
RRRs with the same enrichment of H3K9me3 as seen in mice.
This study also showed that the injection of Kdm4a wild-type,
not Kdm4d catalytic mutant used in the original study on mice,
had a greater blastocyst rate, 90.3%, in SCNT embryos. To test
the efficiency in this demethylase on humans, Kdm4a mRNA
was injected at different stages of SCNT embryonic develop-

Figure 4 (Chung et al., 2015)
ment. Injecting it upon activation, after fusion by HVJ-E, showed
no effect prior to ZGA completion. However, the effect was
noticeable at the end when 8 blastocysts were developed, with
no development of the control group. In a conventional ESC
derivation medium, seven attached to the MEF feeder cell and
four stable ntESC lines were derived. As shown in Figure 5, immunostaining revealed that NANOG, OCT4, SOX2, SSEA-4, and
TRA1-60, transcription factors that maintain ESC differentiation,
were all expressed similar to human ESC line derived by IVF.
Likewise, these ntESC’s expressed pluripotency marker genes
that were indistinguishable from IVF derived ESC. Additionally,
these ntESCs underwent immunostaining of embryoid bodies
(EB), aggregates of ESC, for two weeks in vitro giving rise to the

Can Somatic Cell Nuclear Transfer Produce Human Pluripotent
Stem Cells for Regenerative Medicine?

differentiation into all three germ layers. Proving its differentiation ability. Karyotyping, the process of chromosome pairing,
demonstrated normal chromosomal number and the same sex
chromosome of the donor nucleus, and Short Tandem Repeat
(STR) analysis showed all 16 repeat markers on the genome is
perfectly matched to the donor somatic cell. A sequence analysis of mitochondrial DNA (mtDNA) demonstrated that the single-nucleotide polymorphism of ntESCs matched the mtDNA
of the donor oocyte and not the donor nucleus. A necessary
analysis that demonstrates the idea that mtDNA is transmitted
by the fertilized oocyte and not from the DNA in the cell’s
nucleus (Chung et al., 2015).
Although blastocyst development in SCNT embryos was improved, the success of humans, merely 27%, compared to the success of mice, 90%, suggests that all modifications to SCNT protocol
must be utilized, especially proper oocyte quality. That is a major
factor for ntESC derivation. Human oocyte varies tremendously
even from a single ovulation. Therefore, even some blastocysts
formed through IVF were not supported (Chung et al., 2015).

Fetal vs. Adult Somatic Cell
In order for SCNT to be regarded as having practical medical
significance there must be a way to generate ntESC from adult
somatic cells. Most experiments use various fetal fibroblasts as
somatic nuclei donors. However, patients that are in need of this
procedure are mainly aged. Therefore, a recent study done by
Chung et al. (2014) determined whether dermal fibroblasts from
35 and 75- year-old males can undergo successful SCNT procedure. The debate on adult vs. fetal cells is regarding the age-related changes, such as shortened telomeres and oxidative DNA
damage that can potentially obstruct nuclear reprogramming.
Even though fetal fibroblasts were used in numerous researches,
there were no clear claims of age impedance on SCNT. Using
the non-modified, standard SCNT protocol, no aneuploidy was
produced in the resultant human ESC. Therefore, the modified SCNT protocol established by Mitalipov et al. (2007) and
Tachibana et al. (2013) on fetal fibroblasts was used, with two
groups forming. One group was activated 2 hr after implantation
and the other group was activated after 30 min. However, only
two blastocysts hatched from the 2 hr group, one from each age
subtype, leading to the generation of ESC lines. The difference
in time duration can be explained by the possibility for the necessary extra time needed for reprogramming that is dependent
on the exposure of the donor nucleus to the recipient oocyte
cytoplast. Both ntESC lines displayed the same sixteen STR
markers located on the human autosomal and allosomal loci as
the donor somatic cell and differed from the oocyte donor. The
mtDNA was verified being inherited by the oocyte donor in
both ntESC lines and expression of transcription factors OCT-4,
SSEA-4, TRA-1-60, and TRA-1-81 was present. Pluripotency was
confirmed through spontaneous differentiation into the three

germ layers by immunostaining of embryoid bodies. Further
confirmation of pluripotency was through teratoma formation
assays that demonstrated outgrowth of tissue from the germ
layers. Despite the low success rate, this study portrayed the
efficiency of the modified SCNT protocol and greatly implies
the possibility of using SCNT to generate patient-specific ESC
for medical use (Chung et al., 2014).

Application of Therapeutic Cloning on
Regenerative Medicine
Therapeutic cloning holds great promise in regenerative medicine and gene therapy. It has numerous research and clinical applications, such as producing a vector for gene delivery, creating
animal models of human diseases, and cell replacement therapy
in regenerative medicine. It can permanently cure Parkinson’s
disease or diabetes mellitus. Barberi et al. (2003) conducted
a study on mice using SCNT with nuclei from cumulus and
tail-tip cells. Two ntESC lines were differentiated into motor,
GABAminergic, serotonergic, and dopaminergic neurons, that
displayed synapse formation and normal electrophysiological
properties in vitro. Mice with Parkinson-like lesion were injected with dopaminergic neurons into the cortical striatum
induced by 6-hydroxydopamine. An 80% survival rate 8 weeks
post-transplantation was observed from ntESC contrary to 40%
for stem-cell derived neurons (Kfoury, 2007).
Furthermore, SCNT can allow for organogenesis and patient-specific rescue of genetic mutations. In cell replacement
therapy, therapeutic cloning has the potential to create various
types of tissues such as osteoblasts to counteract osteoporosis. Deshpande et al. (2006) transferred motor neurons derived
from ESC to rats with a severed spinal cord showing SCNT
application for spinal cord regeneration. A potential cure for
paralysis in humans. Therapeutic cloning eliminates the issue of
immune rejection and organ shortage by engineering tissues and
organs. Patient-specific cardiomyocytes, blood vessels, and skin
can treat infarctus, atherosclerosis, and severe burns (Kfoury,
2007). With the use of the modified SCNT protocols, diploid
pluripotent stem cells that were derived from a patient with
type 1 diabetes were produced (Yamada et al, 2014). Such advancements in medicine hold hope for cures of various diseases.

iPSC vs. ntESC
IPSCs, induced pluripotent stem cells, is a laboratory technique that reprograms differentiated cells back to pluripotency
using specific transcriptional factors. The medical application of
human iPSCs has opened the door for rapid stem cell therapy. A
set of essential transcription factors, called reprogramming factors, trigger the destruction of the existing state of somatic cells
by changing their epigenetic status, leading to alterations in their
gene expression. The changes in the gene expression induce
secondary epigenetic changes, including DNA methylation and
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alterations of the nuclear structure. However, there are roadblocks to reprogramming that need to be removed because cellular identity is stabilized. However, transcription factors such
as Oct4, Sox2, Klf4, and c‐Myc are sufficient to destabilize the
existing order in the original cells and re-construct a new order.
Therefore, transcription factors associated with development
may undertake important actions during the reprogramming
process. This produces stem cells that are similar to embryonic
stem cells but has a few disadvantages when compared to ntESCs (Takahashi & Yamanaka, 2013).
ESC is considered the ground state which is believed to have
a greater chance of successful differentiation than iPSC. During
reprogramming, iPSCs-specific methylation and transcriptional
abnormalities in imprinted regions and X chromosomes were
observed with such abnormalities less frequent in ntESCs
(Nazor et al.,2012). In some instances, a number of highly proliferative colonies appear that are not pluripotent and can form
into tumors. Furthermore, iPSCs do not efficiently silence the
expression pattern from where they are derived from and fail
to induce some ESC specific genes (Bilic & Belmonte, 2011).
A major advantage of SCNT-based ntESCs is the fact that
it contains mtDNA originating from the oocyte. Irrespective
of the nuclear donor cell mtDNA, ntESCs have the potential
to produce functional cells and tissues for cell therapies. Thus,
SCNT offers a strategy for correcting mtDNA mutations and
retaining the metabolic function of pluripotent cells from patients with inherited mtDNA diseases.
MtDNA that is specific to the oocyte recipient of cloned
embryos was first determined in the study done by Evans et
al. (1999), with co-researcher Dr. John Loike. They showed nuclear transfer-derived sheep were homoplasmic. The random
partitioning of mtDNAs does not occur. This may be due to
the failure of the donor mitochondria to enter the ooplasm
following electrofusion. It can be hypothesized that an active
mechanism operates to destroy the donor mitochondria in the
recipient ooplasm, similarly to what is thought to happen to
sperm-derived mitochondria in fertilized ova in human reproduction. These results have implications for future attempts to
correct maternally inherited mitochondrial genetic disorders
by nuclear transfer involving a somatic or germline cell from a
woman containing a pathogenic mtDNA mutation but normal
nuclear DNA and a recipient enucleated oocyte.

Ethical and Legal Issues
Research in this field has been held back due to controversial
ethical issues. Legal constraints and lack of funding results in
the impediment of therapeutic cloning (Lo & Parham, 2009). A
major objection to SCNT is the belief that creating embryos
for research, with the intention of mutilating these embryos,
violates human respect and integrity. Sandel (2004) argued in his
article on embryo ethics, “Although every oak tree was once
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an acorn, it does not follow that acorns are oak trees, or that
I should treat the loss of an acorn . . . as the same kind of loss
as the death of an oak tree.” This is an opinion based question
whether an embryo varies in essence from a developed human
being. Evaluation whether the use of embryos for medical research justifies its destruction. Meanwhile, legislative actions, especially in Europe, hinders SCNT advancement that contributes
to its slow progression.

Conclusion
Therapeutic cloning is feasible through modified SCNT protocol. Research in mammals and primates aided in the success
of human ntESC derivation by establishing the correlation between oocyte and donor nucleus quality, nuclear reprogramming, and proper gene expression. All steps led to the derivation of pluripotent ESC that were differentiated into various
specialized cells, such as cardiomyocytes and insulin beta cells.
The developed embryo harboring mtDNA from the recipient
oocyte holds an advantage over iPSC cells by constituting metabolically functional cells from mitochondrial diseased cells.
More research is needed to expand and apply this technique in
medical practice; however, ethical and legislative actions repress
the advancement in this area.

References

Barberi, T., Klivenyi, P., Calingasan, N.Y., Lee, H., Kawamata, H.,
Loonam, K., Perrier, A.L., Bruses, J., Rubio, M.E., Topf, N., Tabar,V.,
Harrison, N.L., Beal, M.F., Moore, M.A., Studer, L. (2003) Neural
subtype specification of fertilization and nuclear transfer
embryonic stem cells and application in parkinsonian mice. Nat
Biotechnol. Oct;21(10):1200–7.
Bilic, J., Belmonte, J.C. (2011). Concise Review: Induced
Pluripotent Stem Cells Versus Embryonic Stem Cells: Close
Enough or Yet Too Far Apart? Cell Stem Cell.Vol 3 Issue 1. doi.
org/10.1002/stem.700
Boquest, A.C., Grupen, C.G., Harrison, S.J., McIlfatrick, S.M.,
Ashman, R.J., d’Apice, A.J., Nottle, M.B. (2002). Production of
cloned pigs from cultured fetal fibroblast cells, Biol Reprod. vol.
66 (pg. 1283-1287)
Briggs, R., & King, T. J. (1952). Transplantation of living nuclei
from blastula cells into enucleated frogs eggs. Proceedings of
the National Academy of Sciences,38(5), 455-463. doi:10.1073/
pnas.38.5.455
Campbell, K., Ritchie, W. A., & Wilmut, I. (1993). NuclearCytoplasmic Interactions during the First Cell Cycle of
Nuclear Transfer Reconstructed Bovine Embryos: Implications
for Deoxyribonucleic Acid Replication and Development1.
Biology of Reproduction,49(5), 933-942. doi:10.1095/
biolreprod49.5.933
Campbell, K. H., Mcwhir, J., Ritchie, W. A., & Wilmut, I. (1996).
Sheep cloned by nuclear transfer from a cultured cell line.
Nature,380(6569), 64-66. doi:10.1038/380064a0

Can Somatic Cell Nuclear Transfer Produce Human Pluripotent
Stem Cells for Regenerative Medicine?

Chung,Y. G., Matoba, S., Liu,Y., Eum, J. H., Lu, F., Jiang, W., . . .
Zhang,Y. (2015). Histone Demethylase Expression Enhances
Human Somatic Cell Nuclear Transfer Efficiency and Promotes
Derivation of Pluripotent Stem Cells. Cell Stem Cell,17(6),
758-766. doi:10.1016/j.stem.2015.10.001

stem.2012.02.013.

Chung,Y. G. et al. (2014). Human Somatic Cell Nuclear Transfer
Using Adult Cells. Cell Press,14(6), 777-780.

Prather, R.S., Sims, M.M., Maul, G.G., First, N.L., Schatten, G.
(1989). Nuclear lamin antigens are developmentally regulated
during porcine and bovine embryogenesis, Biol Reprod. vol. 41
(pg. 123-132)

Collas P, Pinto-Correia C, Ponce de Leon FA, Robl JM. Effect
of donor cell cycle stage on chromatin and spindle morphology in nuclear transplant rabbit embryos. Biol Reprod 1992;
46:501-511.
Deshpande DM1, Kim YS, Martinez T, Carmen J,…. Rothstein
JD, Kerr DA. (2006). Recovery from paralysis in adult rats
using embryonic stem cells. Ann Neurol. 2006 Jul; 60(1):32-44.
PubMed.
Evans, M. J., Gurer, C., Loike, J. D., Wilmut, I., Schnieke, A. E., &
Schon, E. A. (1999). Mitochondrial DNA genotypes in nuclear
transfer-derived cloned sheep. Nature Genetics,23(1), 90-93.
doi:10.1038/12696
Hutchison CJ, Worman HJ. A-type lamins: guardians of the
soma?, Nature Cell Biology ( 2004) vol. 6. pp. 1062-1067.
Kfoury, C. (2007). Therapeutic cloning: Promises and issues.
McGill Journal of Medicine. 2007 Jul; 10(2): 112–120. PMID: 1
8523539
Lanza, Robert P., Cibelli, Jose B.West, Michael D. (1999).
Prospects for the use of nuclear transfer in human transplantation. Nature Biotechnology. Dec99,Vol. 17 Issue 12, p1171. 4p.
PMID:10585712 doi:10.1038/70709
Lee, J., & Campbell, K. H. (2006). Effects of Enucleation
and Caffeine on Maturation-Promoting Factor (MPF) and
Mitogen-Activated Protein Kinase (MAPK) Activities in Ovine
Oocytes Used as Recipient Cytoplasts for Nuclear Transfer1.
Biology of Reproduction,74(4), 691-698. doi:10.1095/
biolreprod.105.043885
Li, E. Chromatin modification and epigenetic reprogramming in
mammalian development. Nat. Rev. Genet. 3, 662–673 (2002).
34.

Polejaeva, I.A., Chen, S.H., Vaught, T.D., Page, R.L., Mullins, J.,
Ball, S., Dai,Y., Boone, J., Walker, S., Ayares, D.L., et al. (2000).
Cloned pigs produced by nuclear transfer from adult somatic
cells, Nature (London). vol. 407 (pg. 86-90)

Sandel MJ. (2004). Embryo ethics -- the moral logic of stem-cell
research. New England Journal of Medicine. 2004;351:207-209
Sawai, K., Fujii, T., Hirayama, H., Hashizume, T., & Minamihashi,
A. (2012). Epigenetic Status and Full-term Development of
Bovine Cloned Embryos Treated with Trichostatin A. Journal of
Reproduction and Development,58(3), 302-309. doi:10.1262/
jrd.2011-020
Tachibana et. al, Human embryonic stem cells (hESCs) derived
from somatic cell nuclear transfer (SCNT). (2013). ScienceBusiness EXchange,6(21). doi:10.1038/scibx.2013.530
Takahashi, K.,Yamanaka, S. (2013) Induced pluripotent stem
cells in medicine and biology. Development. 140: 2457-2461;
doi: 10.1242/dev.092551
Wellner, K. (2010, June 15). The Embryo Project
Encyclopedia. Retrieved from https://embryo.asu.edu/pages/
hans-spemann-1869-1941
Yamada, Mitsutoshi; Johannesson, Bjarki; Sagi, Ido; Burnett, Lisa
Cole; Kort, Daniel H; et al. (2014). Human oocytes reprogram
adult somatic nuclei of a type 1 diabetic to diploid pluripotent
stem cells. Nature; London.Vol. 510, Iss. 7506, (Jun 26, 2014):
533-6.
Yang X, Smith SL, Tian XC, Lewin HA, Renard JP, Wakayama
T.(2007). Nuclear reprogramming of cloned embryos and its
implications for therapeutic cloning. Nature Genetics. 2007
Oct. 39(10):1285. PMID: 17325680 doi: 10.1038/ng1973

Lo, B., Parham, L. (2009). Ethical Issues in Stem Cell Research.
Endocr Rev. 2009 May; 30(3): 204–213. doi: 10.1210/er.20080031 PMCID: PMC2726839
Matoba, S., Liu,Y., Lu, F., Iwabuchi, K., Shen, L., Inoue, A., & Zhang,
Y. (2014). Embryonic Development following Somatic Cell
Nuclear Transfer Impeded by Persisting Histone Methylation.
Cell,159(4), 884-895. doi:10.1016/j.cell.2014.09.055
Mitalipov, S., Zhou, Q., Byrne, J., Ji, W., Norgren, R., & Wolf, D.
(2007). Reprogramming following somatic cell nuclear transfer
in primates is dependent upon nuclear remodeling. Human
Reproduction,22(8), 2232-2242. doi:10.1093/humrep/dem136
Nazor, K.L., Altun, G., Lynch, C., Tran, H., Harness, J.V., Slavin,
I., et al. (2012) Recurrent variations in DNA methylation in
human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell. 2012 May 4;10(5):620-34. doi: 10.1016/j.

65

Relaxin as a Cure for Fibrosis
Sarah Akilov
Sarah Akilov graduated in June of 2018 with a B.S. degree in Biology and is attending the SUNY College of Optometry.

Abstract
Until recently, relaxin has been known as a hormone that pertained to the female reproductive system. Its ability to remodel the
extracellular matrix is responsible for its known reproductive effects. Current research has indicated that it may be useful as a
drug to combat fibrosis. Relaxin has been proposed as an antifibrotic drug to target a variety of organs, including the skin, lung,
kidney, liver, and heart. Studies done using the relaxin null knockout mouse have given scientists insight into the workings of this
hormone. Human studies have also been done to test the efficacy of relaxin in its reversal of fibrosis.With more research, perhaps
relaxin can be used as a drug in the future.
Introduction
Fibrosis is a hardening or scarring of tissue that results from
the repair of injuries in the body. It is estimated that 45-50%
of deaths in the Western world are caused wholly or in part
by fibrosis in various organs in the body. Currently, there is no
available cure for damage caused by fibrosis (Summers, 2016).
Relaxin is a peptide hormone usually associated with the reproductive system. Relaxin has been found to be pleiotropic,
meaning that it is active in many varying roles in the body. It is
produced in both pregnant and non-pregnant females as well
as in males (Pallardy, 2016). It appears that relaxin can be manipulated to target injured organs in order to reverse fibrosis
and prevent its further progression. There have been studies
conducted that point to relaxin as a possible cure for fibrosis
in various organs, including the skin, lung, kidney and heart (Tan,
et. al. 2016). Fibrosis is a part of the pathology of many different
human diseases and thus is said to account for 45-50% of deaths
in the western world (Summers, 2016).

Methods
Information in this paper is based primarily on research accessed through the Touro Library Databases.The peer reviewed,
scholarly journal articles were retrieved through the Proquest
or Pubmed databases.

Fibrosis and its Causes
Fibrosis is an exaggeration of the scarring and hardening of tissue usually caused by the body’s normal response to injury. It is
characterized by a build-up of extracellular matrix (ECM) components, or scar tissue, in place of normal tissue. Particularly,
there is a buildup of fibrillar collagens, such as types I and III.
Fibrogenesis is the body’s mechanism of healing and repairing
wounds.What occurs in fibrogenesis is that myofibroblasts rush
to the site of the injury and release cytokines.This causes fibroblasts to proliferate and build up the ECM producing fibrillar
collagen creating a scar in place of the damaged tissue (Baum, et.
al. 2011). Excessive build-up of connective tissue can be harmful to underlying tissue and organs. This is because the ECM is
the framework for the cells and extracellular structures in the
body.Therefore, if the normal form of the ECM is disrupted, the
tissue in which it is present will not continue to function as it
should (Bathgate, et. al. 2003). Fibrosis is often caused by chronic
inflammatory reactions that can be a result of various stimuli
among which are persistent bacterial and viral infections, autoimmune and allergic reactions, and tissue injury (Wynn, 2008).

66

The body has a system that works to clear accumulated extracellular matrix materials. Matrix Metalloproteinases (MMP’s)
are a group of enzymes that break down extracellular matrix
proteins, such as collagen. Part of the body’s normal way of
repairing itself after tissue injury is to inhibit the production
of these enzymes and to increase the secretion of Matrix
Metalloproteinase Inhibitors (MMPIs), and more specifically,
Tissue Inhibitors of Metalloproteinases (TIMPs). Thus, scar tissue replaces the injured tissue, and the body can heal itself. This
too is favorable in a normal situation, but if this process continues unceasingly, it can result in disruption of normal organ function as the matrix builds up without anything present to break
it down. An imbalance between collagen degrading enzymes will
also cause fibrosis (Bennett, et. al. 2009).

What is Relaxin?
Relaxin was first discovered in 1926 by Frederick Hisaw as a
hormone present in pregnant guinea pigs. The function of relaxin observed at the time, was that it relaxed the pelvic ligaments and the cervix of the uterus to make it possible to carry
the fetus and to prepare the area for parturition. Later, it was
discovered that it was through collagen remodeling that relaxin was able to play this important role in pregnancy and birth
(Pallardy, 2016). Upon closer inspection of the relaxed ligaments
it was seen that the collagen was remodeled from dense bundles to looser, less structured fibers (Bennett, et. al. 2009).
Relaxin is produced by various structures in the female’s reproductive tract including the placenta, corpus luteum and uterus, though this varies by species. During the first trimester of
pregnancy, relaxin rises from practically undetectable levels to
1ng/mL and then slowly wanes as delivery draws near. Relaxin is
also present in non-pregnant human females and males (Pallardy,
2016). In males, relaxin is produced by the prostate gland and
can be found in the seminal fluid, though it is not usually detected in circulation (Bennet, 2009).
Relaxin is a peptide hormone whose two-chain structure is
similar to that of insulin. In humans and higher primates, three
genes for relaxin have been discovered, which include encoding proteins known as H1, H2 and H3 relaxin. In rodents, only
two relaxin genes have been discovered: relaxin-1 and relaxin-3,
which are equivalent to the H2 and H3 in humans, respectively.
The H3 relaxin gene was discovered in 2002 and is known to
act mainly in the brain. H2 relaxin in humans- the product of the
RLN2 gene, and relaxin-1 in rodents- the product of the RLN1
gene, are the major circulating forms of relaxin and are the ones
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that are thought to have an effect on fibrosis (reference to relaxin for the duration of the paper will refer to these forms of
relaxin) (Samuel, et. al. 2007).
There has been a lot of research in the past few years that has
tried to find more uses for relaxin in the body. There have been
identified relaxin-binding sites in various places in the body in
both males in females, including in the heart and brain. This suggests that relaxin may also influence nonreproductive areas of
the body and leads scientists to do further research into these
possible uses (Samuel, et. al. 2016).

Knockout Mouse Studies
To aid scientists in the understanding of relaxin, a relaxin-null
nockout mouse was created by The Howard Florey Institute
in Melbourne, Australia. A knockout mouse is a mouse that
was genetically modified in order to remove or “knockout” a
specific gene. Using such a mouse helps give scientists insight
into the biology of a particular gene (Austin, et. al. 2004). The
mouse established to research relaxin is the Rln1-KO mouse,
meaning that the Rln1 gene, that codes for the major circulating form of relaxin in animals, was removed. However, the Rln3
gene was not removed. Monitoring the development of these
mice showed that the reproductive organs, in both males and females, were underdeveloped. In pregnant females, the mammary
glands, nipples, and pubic symphysis were underdeveloped, and
lactation was prevented. In the male mice, the testis, epididymis
and prostate did not mature properly. Later, it was discovered
that abnormal development in knock-out mice was due to excess collagen. In addition to this, as the mice aged, there was a
buildup of interstitial collagen in the heart, lung, kidney, and skin.
This eventually caused malfunction in these organs, appearing
more prominently in the male mice.
Scientists then administered recombinant human (H2) relaxin
to the knockout mice and saw that it was helpful in reversing the
fibrosis and restoring organ function. The relaxin was helpful in
both early and late stages of the fibrosis, but worked to different
extents depending on the organ. These findings point to a use of
relaxin as a drug to reverse and prevent fibrosis in human pathological situations (Bathgate, et. al. 2003 and Samuel, et. al. 2005b).
In 2009 a study was done on relaxin null knockout mice to
test the efficacy of using recombinant relaxin as a treatment
for the fibrosis that developed in them. The study also aimed to
test if it was significant when in the progression of the fibrosis
the relaxin was administered.There were two groups of mice, in
one group, relaxin was given to 9 month-old mice, during early
stages of fibrosis. The other group was given relaxin when their
fibrosis was more progressed, at 12 months of age. There was
less fibrosis in the 9-month group, and no difference in the 12month group when compared to the untreated controls. This
points to the fact that administered relaxin will be more effective in earlier stages of fibrosis (Giannakis, et. al. 2009).

Relaxin null knockout mice were used to test the effects of
relaxin on scleroderma, a form of dermal fibrosis. It is a connective tissue disease that causes fibrosis or various internal
organs in addition to skin thickening. Untreated, scleroderma
can cause irreversible damage. The study indicated that relaxin
is more effective in treating dermal fibrosis in its early stages.
(Samuel, et. al. 2005a).

How does Relaxin Help Reverse Fibrosis?
Relaxin binds with its endogenous receptor, relaxin family
peptide receptor 1 (RXFP1), which is also known as LGR7.
This inhibits the actions of major profibrotic factors such as
transforming growth factor beta 1 (TGFb1), and angiotensin II
in several organs. As a result of this, there will be a decreased
expression of types I, III, and V collagens, interstitial collagens
and type IV basement membrane collagen. There will also be
an increase in the breakdown of collagen via the activation of
MMP’s and an inhibition of the TIMPs (Samuel, et. al. 2016, fig 1)

Mechanisms
The mechanisms involved in the antifibrotic effects of relaxin
are not currently well known by the scientific community. The
primary receptor for relaxin is LGR7, or RXFP1, and was only
recently discovered in 2002. Before this was known, the LGR7
and LGR8 relaxin receptors were known as orphan G-protein
receptors. (Bennet, 2009). It is interesting to note that these receptors exist in organs outside the reproductive tract, pointing
to the fact that relaxin has other functions than it was historically thought. Perhaps as the understanding of the pathway used
by relaxin is enhanced, we will better be able to use relaxin as a
drug for the treatment of fibrosis (Samuel, et. al. 2005a).

Discussion: Clinical Trial for Relaxin
In the 1950’s, there was the emergence of the idea that relaxin
could be used to treat fibrosis, and it was clinically tested then
and again in the 1990’s. These studies failed to reach the levels of effectiveness that were required for it to pass as a drug,
but shed a lot of light onto the antifibrotic actions of relaxin
(Samuel, et. al. 2005a).
A randomized, double-blind, placebo-controlled study was
conducted using recombinant human relaxin in the treatment
of systemic sclerosis. This was a phase III trial for testing relaxin
as a possible drug to reverse fibrosis. Systemic sclerosis, also
called systemic scleroderma, is a disease in which there is a
buildup of collagen in various organs in the body. This is an ideal
disease with which to test for the efficacy of relaxin, as the
hallmark of this disease is ongoing fibrosis. The patients were
divided into 2 random groups, one of which was given the actual
drug, and the other group was given a placebo. In addition to
this, neither those being treated, nor the researchers administering the medication knew who belonged to which group.
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were administered 200mcg/kg/day for 28 days. This is approximately 50 times the relaxin present in a normal pregnant
woman. The relaxin was unhelpful in reducing the fibrosis, but
it was concluded that in these doses relaxin was safe and well
tolerated. Some adverse side effects included; Development of
a rash and pain at the site of infusion, minor bleeding in some
cases, and decreased concentration of blood hemoglobin
(Seibold, et. al. 1998).
It appears that the body itself uses relaxin as a mechanism to
combat fibrosis. This was shown in a study of 50 patients with
systemic sclerosis, an autoimmune disorder that causes fibrosis
of the skin and internal organs, and 50 healthy patients in which
normal relaxin levels were measured and the results were statistically analyzed. In the diseased patients, the measured levels
of relaxin in the bloodstream was significantly higher than in the
healthy subjects. It was hypothesized that this was the body’s
response and effort to reverse the fibrosis (Giordano, et. al.
2005). Thus, using relaxin as a drug for fibrotic patients is in
accordance with the way nature would tackle the problem, and
therefore worth further research.

Pulmonary Fibrosis

Increased ECM/Collagen Degradation
Decreased ECM/Collagen Deposition

Fig.1 Mechanism for relaxin’s role in inhibiting fibrogenesis. (Modified
from Samuel, et. al.2016.)
There was not a significant difference in the levels of fibrosis
between the two groups. In addition, it seems that there were
negative side effects to those that were administered the relaxin
drug. The forced vital capacity in those patients given relaxin
was decreased, and there were adverse renal effects primarily
after they stopped giving them the relaxin. The study concluded
that if relaxin is ever to be used in the reversal of fibrosis, there
must be intensive monitoring of blood pressure and of renal
function (Khanna, et. al. 2009).
One proposed reason for why relaxin was not effective in this
study was because the degree of scleroderma in the patients in
this trial was quite advanced. In the relaxin-null mouse model it
was also seen that relaxin was less effective in more advanced
stages of fibrosis (Bennet, 2009). Although this study is less optimistic about the use of relaxin as a drug in the near future, it may
be possible that as research continues, and we learn more about
relaxin and how it works in the body, it will seem more plausible.

Other Human Relaxin Studies
There was a study done to test the safety of administering recombinant human relaxin to people. The scleroderma patients
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IPF or Idiopathic Pulmonary Fibrosis, is a lung disease in which
there is fibrosis of the lungs for an unknown reason. It was
found that the gene expression of the main relaxin receptor,
RXFP1, is 2.9-fold less in lung samples taken from patients with
IPF compared with lungs of normal control subjects. There
was also a study done in an in vitro model, in which IPF fibroblasts were grown in media that was treated with transforming growth factor TGFb1. It was found that the expression of
the RXFP1 protein was decreased in immunoblots. It was thus
hypothesized that relaxin treatments will not be too effective
in patients with IPF. The authors also speculate that the loss
of RXFP1 expression is a common factor in fibrotic diseases
and therefore may have been part of the reason that the clinical trials to treat scleroderma with relaxin failed (Tan, et. al.
2016). Royce et. al. point out that these findings are surprising
because relaxin has proved to be effective in reducing fibrosis in
many human fibroblast culture models in which TGFb1 is used
to stimulate collagen synthesis. They argue that the functional activity of the relaxin receptor cannot be determined using
gene expression studies alone and point out that there may
have been other factors involved that caused these results.
Therefore, they conclude, more research must be done before
relaxin-based therapies for fibrosis can be either ruled out or
implemented clinically (Royce, at al, 2016).

Hepatic fibrosis
Fibrosis of the liver, like forms of fibrosis in other organs, is categorized by increased collagen deposition and decreased ECM
degradation. To test the effects of relaxin on hepatic fibrosis in
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vivo, scientists established fibrosis in mice using carbon tetrachloride. The mice were administered the carbon tetrachloride
for 4 weeks, followed by 4 weeks of administration of relaxin in
addition to carbon tetrachloride. Relaxin decreased the hepatic
collagen expression, increased the expression of the MMPs, and
decreased the TIMPs. This suggests that relaxin might be a possible treatment for established hepatic fibrosis (Bennet, et. al. 2014).
The common endpoint of many liver diseases caused by
chronic liver injury is fibrosis. The major profibrogenic cell type
that is activated in cases of chronic liver injury is the hepatic
stellate cell-myofibroblast (HSC-MF).This cell produces scar tissue and contributes to portal hypertension (PHT) by increasing
the resistance within the hepatic vascular system. It was seen
in past studies that the expression on RXFP1 was increased in
human and rat HSC-MFs and in various studies on parts of the
liver that were affected by fibrosis. In the model of rat fibrosis
it was seen that the administering relaxin helped to reduce the
fibrogenesis and reduce the PHT (McBride, et. al. 2017).
Relaxin has a short in vivo half-life.This is an obstacle to using
it as a drug for treatment, especially in models of disease that require long-term administration of the drug, such as liver disease.
In an effort to find a new drug to combat liver fibrosis, there
was an attempt to find small molecules that are similar to relaxin and that will act as agonists for the RXFP1 receptor.There are
currently high throughput screening (HTS) technologies which
allow scientists to explore vast libraries of compounds in a quick
and efficient manner.This helps to identify molecules that can be
used as starting points for creating new drugs. One compound,
ML290, was found to be most promising. It binds with RXFP1
and was therefore tested extensively. Although ML290 did exhibit some relaxin-like activity, there were many differences in
the way it bound to RXFP1 and its actions. Its effectiveness in
combating liver fibrosis has not yet been tested and for now it
does not seem that it will be a feasible replacement compound
for the treatment of fibrosis. Also, being as the actions of RXFP1
differ in various organs of the body, and are not well understood
in general, more research must be done before such a drug can
be produced (McBride, et. al. 2017).

Cardiac Fibrosis
Fibrosis is a hallmark of hypertensive cardiac disease. The ECM
has a great impact on the function of the heart, including regulating ventricular diastolic and systolic function. It also provides
the framework for the cardiomyocytes and coronary vessels.
There are many cardiac pathologies that result in fibrosis.
Among these are ischaemic injury, myocardial infarction, hypertension, and many others. This results in a vicious cycle, as
the accumulation of extracellular matrix via fibrosis leads to an
increase in the amount of those negative cardiac events, which
can in turn lead to more fibrosis. It was shown in relaxin knockout mouse studies that relaxin deficient mice have an elevated

collagen content in their cardiovascular system which leads to
diastolic dysfunction of the left ventricle (LV).
Spontaneously hypertensive rats (SHR), in which fibrosis was
not induced by having a lack of relaxin, rather it was the natural result of hypertension, were studied. When the rats were
administered relaxin over a 14 day period the initially elevated
collagen levels in the LV were now reduced. Fibroblast proliferation was inhibited, and MMP-2 expression increased.This means
that there was a decrease in collagen synthesis as well as an
increase in its breakdown. The study concluded that relaxin is a
potent drug that can be used to combat hypertensive diseases.
In addition to this, relaxin was compared to other hypertensive
drugs such as angiotensin converting enzyme inhibitors and aldosterone inhibitors. These drugs have many side effects and
only begin to help after prolonged periods of treatment. Relaxin,
on the other hand, managed to work at a much faster rate to
reduce fibrosis and did not have any notable side effects in this
study (Lekgabe, et. al. 2005).

Renal Fibrosis
Renal fibrosis is the accumulation of collagen in the kidney.
Specifically, in the renal resistance vessels, glomeruli and interstitial space. There is a very strong relation between cardiovascular diseases and renal diseases, as both diseases include high
blood pressure. The SHR were also used to study renal involvement. The experimental rats exhibited renal as well as cardiac
fibrosis. Administration of relaxin over a 14-day period showed
to reduce the fibrosis in the kidney cortex, thus halting renal
failure. (Lekgabe, et. al. 2005).
Another study treated rats with bromoethylamine, or BEA,
which causes severe renal interstitial fibrosis, one week later, the
rats were administered relaxin via an osmotic pump for a period
of 28 days. The aim was to see whether the relaxin would inhibit
the fibrosis that was caused by the BEA.The structure of the renal
tubules had been affected by much collagen deposition in the rats
treated with BEA alone.The rats treated with BEA in conjunction
with relaxin exhibited a 75% decrease in collagen deposition and
tubular structure was almost completely maintained. In addition
to this, it was seen that renal function was largely restored in the
relaxin-treated animals. The levels of creatinine clearance were
75% of those of the control mice. It is thus hypothesized that
the reduction of the fibrosis by relaxin is the cause for the restoration of renal function (Garber, et. al. 2001).

Conclusion
Fibrosis accounts for nearly half the deaths in the western world
and yet there are no known cures. Relaxin’s natural antifibrotic
properties make it a viable candidate for the treatment of fibrosis.
Although much research has already been done, relaxin must be
proven to be both safe and effective before it can begin to be implemented clinically, and thus there is a need for further research.
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Abstract
Music is an important part of cultures worldwide. It has been used throughout the ages as a method of conveying emotions to
the listener. However, there is some confusion about exactly which areas of the brain are affected by music. This study shows
the general areas of the brain stimulated by music, explaining how these sections influence emotion and learning capability. In
addition, this paper demonstrates that music therapy may be helpful in relieving stress or some neurological disorders, based on
the areas activated by music. Training in music has cognitive and motor coordination benefits, as well, because this training causes
structural changes in brains of musicians.
Introduction
conversion of short-term memory into long term memory and
According to the Merriam-Webster dictionary, music is the
“vocal, instrumental, or mechanical sounds having rhythm, melody, or harmony (Merriam-Webster, 2018).” However, the word
“music” suggests a much deeper meaning than the formal dictionary definition implies. Music is known as the “language of the
soul.” It speaks to its listener, conveying a message of emotions,
such as a calming sensation of relaxation or intense feeling of elation or sadness. The language is universal; even people who have
lost their ability to verbally communicate can understand the
empathy inherent in music (Ridder, et al., 2009).When a musician
plays his instrument, he is forming an emotional connection with
his listeners. But music has effects beyond emotions. Learning to
play music facilitates cognitive reasoning, motor coordination, and
sensory perception. Because music has this unique combination
of emotional connection and cognitive benefits, music therapy
has been developed to alleviate emotional and physical hardship
in a number of neurological illnesses. This analysis will discuss
the varying effects of music on the brain, including the physical
changes that manifest and the mechanisms through which music
leads to enhanced learning and emotion.Additionally, through this
study, the possible benefits of music therapy are revealed.

Methods
Research for this paper was gathered from Touro’s online library
from databases including ProQuest and EBSCO. Articles found
discuss the different areas of the brain affected by music, the usefulness of music therapy, differences in anatomy and processing
of stimuli in the brains of musicians and non-musicians, whether
music induces emotion, and the potential learning benefits to be
gained through musical training. Review articles, case studies and
experimental studies were used in forming the analysis.

Parts of the Brain Affected by Listening to Music
It is unclear, as of the research to date, exactly which parts of
the brain are stimulated by music. The general mechanism for
music that was heard travelling to the brain is as follows; music
enters the ear and is received by the cochlea. It is then transferred to the thalamus, and then to the auditory cortex for
processing (Boso, et al., 2006). If the person listening to the
music is deciding whether to buy that music, there is a further
association between the auditory cortex and the ventral striatum, which processes enjoyment (Koelsch, 2014).
Although most reward stimuli do not activate the hippocampal region, music does. The hippocampus’s main roles are the

spatial relations. It is also responsible for encoding information
from the amygdala, which controls emotion, with the long-term
memories. In other words, emotional memory becomes combined and remembered with long-term memory through the
hippocampus. This supports a growing theory that the hippocampus plays a role in emotional recollection that occurs when
listening to music. Because music affects emotions in a way unlike money, food or other reward stimuli, it couples emotion
and the memory of a specific piece of music. This activates the
hippocampus, leading to feelings of peacefulness, tenderness, joy,
or even sadness when the piece is later recalled (Koelsch, 2014).
People can have varying parts of their brain stimulated, depending on how they think of the song. For example, remembering a song in one’s head can stimulate the visual cortex, while
hearing the song stimulates the auditory cortex. Also, different
parts of music affect different areas of the brain; pitch, melody,
harmony and beat are usually processed in the right hemisphere
of the temporal lobe, while lyrics, pacing, frequency, and intensity
are analyzed in the left temporal lobe. The connection between
music and thoughts, which will stimulate emotions or previous
memories, is formed by the frontal lobe. The stimulation of the
frontal lobe is activated by the limbic system which provides the
emotions felt (Bennet, Bennet, 2008).
Although both speech and music utilize pitch, pitch seems
to be used differently in the different circumstances. While
speech cannot be “off-tune,” music can. It is possible, therefore,
that coarse contour in speech and music are processed in one
area, while a more finely-tuned pitch perception is analyzed in
a different area. This argument is strengthened by the fact that
there were cases of people who lost the ability to understand
language prosody but retained musical pitch acuity. However,
people who lost basic musical contour perception also lost
their speech prosody awareness (Zatorre, Baum, 2012).
Music is also processed in different areas depending on
whether the music is perceived as pleasant. Music that has dissonance and disharmony is more likely to be processed in the
temporal lobe, while music that is pleasant and has harmony will
be processed in the frontal lobe (Boso, et al., 2006).
Pleasant music is processed in the same way that primary
and secondary pleasure stimuli are generally handled. Music
activates the nucleus accumbens, ventral tegmentum area, hypothalamus, orbitofrontal cortex, and the insula-frontal cortex.
The nucleus accumbens is the center which processes pleasant
stimuli, and then releases dopamine into the ventral tegmentum
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area. In the brains of both musicians and non-musicians, listening
to music activates the mesolimbic dopaminergic reward system
(Herholz, Zatorre, 2012, Schlaug, et al., 2010, Menon, Levitin,
2005). Pleasant music, such as music which gives the listener
chills, or goosebumps, causes the release of dopamine both in
the ventral tegmentum and in the ventral striatum. The anticipation of chills, itself, releases dopamine, as well. However, the
exact area where dopamine is released when expecting such
music differs from when the expectation is fulfilled. Expected
chills activate dopamine in the ventral striatum.When the music
causes the chills to actually happen, the dorsal striatum becomes
activated with dopamine (Koelsch, 2014, Boso, et al., 2006). The
hypothalamus, too, gets activated, which lowers the heart rate
and breathing rate, leading people to feel calmed and relaxed by
music (Menon, Levitin, 2005).

Music Therapy as a Useful Tool
Music therapy is unique in that listening to music sends signals to
the visual, auditory and motor cortices simultaneously (Schlaug,
et al., 2010,Walworth, et al., 2008).The fronto-temporo-parietal
connection formed by music is a component of mirror neurons.
Because mirror neurons are important for the coupling of perceptional events and their motor response, listening to music,
and thereby activating these areas, may help link cognition and
perception, heightening concentration, memory and executive
control (Schlaug, et al., 2010).
Connected to the general cognitive and perceptive benefits is
the effect of music on reducing cognitive stress. This idea was
proven through a study conducted on eighty-nine college students. These students were given a cognitive stressor; they were
told that they would have to present a complicated speech.Then,
the control group worked on preparing their speech without
background music, while the experimental group was exposed to
music. The groups were given surveys to fill out before and after
the stressor was given. Also, salivary IgA levels were measured
to check if biologically, music can help boost the immune system.
The IgA test and the stress surveys indicated that the group listening to music experienced less stress and had a more effective,
boosted, immune system than the control group (Knight, Rickard,
2001). A study of patients who were waiting to undergo surgery
showed that music can return heart-rate, cardiac output and
blood pressure values to normal, non-stress levels. Additionally,
blood glucose levels and skin temperature will be overcompensated in the return to normal status when listening to music. Not
only will the brain restore blood glucose levels and skin temperature to the normal levels in response to listening to music, it
will establish levels corresponding to a state of relaxation. Music,
therefore, can relieve its listener of feelings of stress and induce
calmness in its place (Miluk-Kolasa, et al., 2002).
The stress-relieving benefits of music are helpful clinically
as well. Music can destress a patient before a difficult surgery.

72

Research done by Walworth et al. demonstrated that music
therapy can have psychological effects on patients undergoing
brain surgery. In their experiment, twenty-seven subjects who
were scheduled for a surgery were divided into two groups.
The control group did not receive any music therapy prior to
surgery, while the experimental group received twenty to fifty
minutes of therapy. Surveys taken by the subjects before and
after the surgery analyzed mood level, perception of hospitalization, and to what extent each subject felt anxious, stressed,
or pain. The results indicated that subjects who had received
the music therapy felt less anxiety and stress and were more
relaxed before and during the surgery. They generally had a better perception of their hospitalization. This is important since
studies have shown that pessimism and anxiety correlate with
worse outcomes in brain surgeries (Walworth, et al., 2008).
Another study which focused on spinal epidurals, as opposed to
brain surgery, concurs with Walworth et al. that music therapy
can decrease stress in patients undergoing surgery. The patients
having spinal anesthesia who listened to music throughout the
surgery had a shorter induction time and required less medication than the control group. Interestingly, the patients listening
to music did not recall hearing the music, suggesting that the
effects of music occur subconsciously. A possible explanation
for the reduction of necessary anesthesia is that the auditory
and pain pathways inhibit each other. This can be an important method for decreasing the amount of anesthesia necessary
non-pharmaceutically (Zhang, et al., 2005).
Music therapy can increase the quality of life for a patient with
fronto-temporal dementia. Listening to familiar music can allow
these patients to express themselves nonverbally, and thus allows
for the building of social interactions and communication. After
four weeks of music therapy, patients had less agitated behavior
and were less distressed. Whether the patient actively participated in the therapy sessions did not diminish the benefit of the
therapy, as both active and inactive participants clearly showed
less agitation than before the sessions (Ridder, et al., 2015).
In addition to helping patients psychologically by reducing
stress, music, and specifically musical training can help patients
physically. In one study, stroke patients learned to play an electronic drum and MIDI keyboard. The results showed that the
drum training improved gross motor skills, and the piano lessons honed fine motor skills. These patients began to recover some of their motor coordination. Additionally, brain tests
demonstrated that these patients had more success with motor
planning and neuronal coherence with music therapy than other
therapies. Interestingly, these skills were not limited to the musical instruments played.The coordination had improved overall,
in every activity attempted (Schneider, et al., 2007 ).

Different Music Affecting the Brain Differently
Music is a very broad term. It includes many genres, styles and
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pieces. Just as the varying aspects of music are processed in different areas of the brain, the various genres within music affect
the brain in unique ways.
A network analysis was conducted, based on imaging from 21
subjects, on different genres of music. Network imaging shows
the connections of the brain, along with the important functioning parts at a given point. The analysis illustrated that different
genres of music created “hubs” of activity in varying areas of the
brain, depending on the music. Specifically, classical music made
the largest hub in the auditory cortex. It is possible that the
size of the hub is related to the complexity of the music being
heard, and because classical music is often complex, its hub is
the largest (Wilkins, et al., 2012).
In addition to the different genres affecting the brain, preferred
music, as opposed to disliked music, shows different patterns in
the brain. When comparing a subject’s favorite song with songs
that the subject liked and disliked, all songs stimulated the default mode network, and particularly the precuneus. The precuneus is in the parietal lobe, anterior to the occipital lobe. This
area is important in the processes of self-reflection and episodic
memory, along with cognitive thinking and creativity. Although
the precuneus was activated by every music heard, there was a
strong correlation between the favorite song and liked song in
activation of the lateral parietal and medial prefrontal cortices.
The disliked song, however, had excitement that remained isolated in the precuneus. Another difference between the favorite
song and the liked and disliked songs is the involvement of the
hippocampi.While all the songs showed some stimulation of the
hippocampus, both the liked and disliked songs had auditory
cortex “hubs” that included the hippocampi, while the favorite
song had two separate hubs: one for the auditory cortex, and
a second for the hippocampi. The activation of the hippocampi
stimulates the encoding or retrieval of emotional memory. It
is possible that the separation of hubs when listening to the
favorite song leads to emotional memory retrieval, rather than
inscription.The interconnection of the precuneus and the other
areas contributes to the default mode network and causes the
feelings of self-reflection and creativity, along with memory encoding, specifically of emotional memories (Wilkins, et al., 2014).
Although liked-music stimulates the default mode network
and hippocampi leading to feelings of self-reflection and introspection, if the liked music is unfamiliar, it may not necessarily lead to the mesolimbic reward. Fourteen participants in a
study listened to music to determine familiarity and preferences
of songs. These participants listened to twelve songs in each
category previously determined: familiar liked, familiar disliked,
unfamiliar liked and unfamiliar disliked. Familiar music activated
the anterior cingulate cortex, amygdala, thalamus, putamen, right
nucleus accumbens, left hippocampus, temporal pole and orbitofrontal cortex. Unfamiliar music either did not activate these
regions altogether or activated them only slightly. There was an

increased blood oxygen level dependence, indicative of a lot of
activation, in the emotion-related areas, including the putamen,
amygdala and nucleus accumbens. The high amount of stimulation in the limbic and reward systems for familiar songs suggests
that familiarity with a song will increase the liking of the song.
The only difference in activation between the liked and disliked
songs was in the right anterior cingulate cortex and the inferior
frontal gyrus.This stimulation during liked songs correlates with
the known functions of these areas, namely, judging beautiful
stimuli (Pereira, et al., 2011).

Musicians vs. Non-Musicians
There are numerous differences between the way that musicians and non-musicians process music, and therefore, differences in their brain structures. Firstly, as mentioned previously,
music affects both hemispheres concurrently. However, while
the right hemisphere usually processes the long-term patterns,
such as pitch and melody, the left, usually dominant hemisphere,
evaluates the short-term patterns, including changes in rhythm
and frequency. Generally, while a musician is listening to music,
he is examining the form. Therefore, his left hemisphere would
be stimulated predominantly. On the other hand, a non-musician, who listens to music to enjoy the melody would be mainly
stimulating his right hemisphere (Bennet, Bennet, 2008).
Although in each case there is largely one hemisphere that
is excited, both hemispheres are stimulated each time music is
heard. Besides for hearing the music, the musician often performs complex hand sequences with his instrument, also exciting both hemispheres with his actions. The information is transmitted across both hemispheres through the corpus callosum.
Neurons stimulated most often get the most strengthened by
myelin sheath to allow for more efficient processing and faster
reactions (Iusca, 2011). Because musicians listen to and practice
playing music on a consistent basis, their neurons routinely fire
across the anterior corpus callosum, leading to a larger anterior corpus callosum with more myelinated axons and a greater
number of neuronal fibers than that the non-musician (Iusca,
2011, Herholz, Zatorre, 2012).
Another outcome of the need for musicians to use both hands
is that musicians lose dominance in a single hand and become
more ambidextrous.This is a necessary adaptation for the musical
profession, which has underlying neuronal reasoning. Because the
musicians use both hands to play complex musical sequences, the
part of the motor cortex which stimulates both hands, rather
than just the dominant hand, becomes strengthened with more
myelin sheath and a greater number of synapses. This phenomenon is especially true for a keyboard player (Iusca, 2011).
Musicians have an enhanced short-term plasticity in the
motor cortex, resulting in higher motor performance and synchronization in intricate manual tasks. For example, pianists
were able to learn a nonmusical finger tapping sequence quicker
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than non-musicians, which correlated to an increased activity
in their motor cortex. This, too, correlates with the noticeably larger finger area in a musician’s motor cortex (Herholz,
Zatorre, 2012).
Besides for music affecting the cerebrum, musical training also
affects the cerebellum. The cerebellum is used for fine motor
skills. Playing an instrument requires these skills, and, therefore,
learning to play them leads to more synapse connections, bigger
capillaries to supply blood to these cells, and more glial cells to
create a more effective support for the frequently used neurons
in the cerebellum. Musicians’ cerebellums are larger than those
of non-musicians because of the extra stimulation (Iusca, 2011).
Musicians can process simultaneous information more accurately than non-musicians can. When fifteen non-musicians
were told to report their touch sensations while simultaneously listening to two sounds, they had a hard time distinguishing
between the auditory and sensory information and generally
reported feeling two touches rather than one. However, musicians who underwent the same test were more than twice as
accurate at differentiating between the two stimuli. One reason
for increased accuracy in musicians is that musicians are accustomed to reading sheet music, feeling their instruments and
responding to the sounds produced. This balance of a combination of different stimuli enables the musician to better ignore
one stimulus in favor of another (Sparks, 2013). In another study,
musicians and non-musicians were presented with audio-visually
incongruent stimuli. The non-musicians tended to react more
to the visual stimulus, while the musicians relied on their auditory perception. The likelihood of musicians relying on audio
information is dependent on the length of time the musician
has trained in his craft. (Abel, et al., 2016). Although the results
of this experiment seem incongruent with first study, in which
musicians relied on touch rather than sound to determine how
many stimuli were before them, the studies are demonstrating
different aspects of musicians’ skills. The first experiment aimed
at establishing the accuracy of musicians’ sensory perception
when coupled with incongruent auditory input. The musicians
were successful in distinguishing between the two stimuli and,
therefore, were able to accurately state the number of stimuli
they touched. The second study, on the other hand, was not attempting to determine accuracy. Rather, the goal was to discover
which stimulus the musician would rely on when presented with
two incongruent stimuli. Because the musician was not attempting to determine a specific stimulus, he was able to respond to
whichever stimulus he perceived. This study proved that, given
the option of two conflicting stimuli, musicians are more prone
to relying on auditory perception than visual perception.
One reason that musicians rely more on auditory than visual stimuli when the two are conflicting is that the musical
training process provides auditory feedback, strengthening the
sensorimotor associations between the auditory and motor
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systems. Because of this continual strengthening, when the
musician encounters inconsistent visual information, he has an
easier time blocking it out and relying solely on his auditory
perception. A non-musician, who never had such training, has
poorer auditory perception, and therefore compensates with
his visual perception (Abel, et al., 2016). Although this argument
is compelling, the possibility remains that music does not, in
fact, change perception preferences from visual to auditory in
musicians. Perhaps people who naturally are inclined towards
using auditory information, rather than visual, are inherently
more disposed to becoming musicians, and that is the reason
for the trend observed (Abel, et al., 2016, Banai, Ahissar, 2013).

Effects of Beginning Musical Training Young
Although musical training can affect the brain at any age, it has an
extra impact when started at a young age. String instrument musicians who began training early have a greater representation of
their left fingers in their motor cortex (Herholz, Zatorre, 2012).
Another neuroanatomical change found in musicians who began
training before the age of six or seven is found in the corpus callosum. Because these children are practicing complex sequences daily, their brains need to accommodate a large transfer of
information efficiently. This continual stimulation leads to an
enlarged anterior corpus callosum (Iusca, 2011).
When studying the brains of forty-eight young adults who had
at least one year of musical training in their youth, a researcher
found that those who had begun training before the age seven
had more developed brain areas connected to language and executive function (Sparks, 2013).
Starting musical training young seems to lead to improved visuomotor and auditory-motor synchrony, (Herholz, Zatorre, 2012). It
is possible, however, that the children had exemplary visuomotor
or auditory-motor coordination, which led them to begin music
training young. If this is the case, the auditory-motor synchrony is
the cause for early music training, rather than the reverse.

Music Facilitates Learning
Music can facilitate learning in numerous ways. Firstly, music affects the limbic system and subcortical regions, the areas that
control long-term memory. Areas such as the hippocampus and
cingulate cortex are stimulated through music.These areas convert short-term memory into long-term memory. When learning while listening to music, the long-term memory areas are
already stimulated, and the learning will become part of longterm memory as an association of the music heard (Koelsch,
2014, Wilkins, et al., 2014).
Listening to music seems to improve other cognitive tasks
as well. A music director in North Carolina arranged for a
woodwind quintet to play music three times a week to first
grade, then first and second, and finally, first, second and third.
Although the average IQ score for this school’s first through
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fifth graders had been below the national grade level, after the
three years of listening to music the third-grade’s academic
performance increased tremendously. Eighty-five percent of
the students were above grade level for reading and 89% for
math. The improved math skills received from music is understandable. Music is inherently related to math because music
measures beat and rhythm which are mathematical concepts
(Bennet, Bennet, 2008).
Although relatively little musical training can improve basic perceptional skills, especially among the originally poor performers,
the larger population of musicians do not overall show improved
verbal and cognitive skills. When children were given one year of
after school music lessons, they did not show improved non-auditory skills. In other words, the students had better pitch discrimination, but the training did not generalize into verbal memory.
The learning did not extend past the auditory perception the
students gained directly from their music training. Possibly, with
more time, other skills, such as verbal and cognitive skills, could
emerge. Perhaps had the children had three years of music training, like the students from the previous study, the boost in reading
and math skills would be evident as well.
Word decoding and reading comprehension were studied in
six to nine-year-old musicians. The evidence showed no association between length of training and word decoding, however,
there was a close association between reading comprehension and musical training. Possibly, the reason that there was
no significant difference between those with musical training
and those without it with respect to word decoding is that the
children in the control group were old enough that they cognitively caught up on word decoding. If the children had been
studied at a younger age, evidence may have shown a difference
in word decoding ability. If musical training does in fact facilitate
word decoding in younger children, perhaps the reason that the
musical children tested had superior reading comprehension
was because they had earlier and more proficient reading comprehension. According to this theory, the children did have a
superior word decoding ability when they were younger, which
led to an earlier reading comprehension. Because the musical
children have been reading and effectively decoding, they show
a higher reading comprehension than the non-musical children
(Corrigall, Trainor, 2011).
In addition to reading comprehension, musical training facilitates improved reading skills in general, as well as the discrimination of small pitch variations in speech. Because pitch differentiation is an important part of music, learning to play an instrument
will improve pitch discrimination for both the instrument being
learned and speech in general (Moreno, et al., 2009).
Since music training affects the motor cortex, which enables the musician to play more complex pieces with greater
dexterity, learning that involves the motor cortex is easier for
musicians. Long-term musical training, specifically, augments

short-term plasticity in the motor cortex. This is the reason
that musicians have an easier time learning a nonsensical finger
tapping sequence. Overall, motor performance and coordination are improved and, therefore, any learning that involves the
motor cortex will be facilitated by musical training (Herholz,
Zatorre, 2012).
Besides for the anatomical changes music effects, listening to
music produces psychological benefits. Listening to music puts
one in a good mood. When in a good mood, people are more
productive and generate a higher quality of work. A study of
employees listening to music in the workplace demonstrated
that the weeks that the employees listened to music, higher
quality of work was reported. However, it is possible that the
higher review was an effect of the employees’ improved mood,
and the quality of work was unchanged (Lesiuk, 2010).

The Mozart Effect
In the first study that correlated music and learning ability, participants were placed into three groups and told to work out a
spatial reasoning problem. The first group listened to Mozart’s
music, the second practiced various relaxation techniques, and
the third, the control group, did no preparation. The results
showed that the group listening to Mozart performed the best.
The phenomenon was coined the “Mozart Effect.” However, the
benefit from the music lasted for a very short time, ten to fifteen minutes.Also, similar studies later showed that other music
can achieve the same results. Therefore, it is possible that the
result was not exclusively related to Mozart’s music but that
music with an even tempo or rhythm may temporarily improve
spatial relations (Bennet, Bennet, 2008).

Length of Training Needed to Effect a Change
Music training affects the brain’s structure. Some learning changes are evident almost immediately, while others take longer.
Temporarily improved auditory-motor coordination is evident
after twenty minutes of instrument practice. However, the effects
do not last long. More permanent improvement in this area happens after five weeks of training (Herholz, Zatorre, 2012).
Besides for length of training, the age that the musician begins his lessons determines the extent of his brain’s structural
changes. For example, string instrument musicians who began
training young have a greater representation of their motor
cortex dedicated to their fingers (Herholz, Zatorre, 2012). Also,
musicians who began training before the age of seven had a larger corpua callosum than musicians who began later in life. For
example, the change in the corpus collosum of a six-year-old
child would begin after about fifteen months of training (Iusca,
2011, Herholz, Zatorre, 2012). The phenomenon is logical; the
brain goes through the most changes during childhood, discovering which areas require more synapses based on frequency of
use. The younger the child begins music training, the earlier the
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brain learns to accommodate the varying complexities needed,
and the more prominent the resulting structural changes of the
brain will be (Iusca, 2011).

Music Affecting Emotions
Although there is some controversy about whether music can
induce emotions, there are some indications that music does
play a role in stimulating emotion. There are six mechanisms
which can explain the emotions generated by listening to music.
The first is a brain stem reflex. The brain stem reacts to sounds
that are loud and discordant with an arousal mechanism designed to protect the person from possible danger. Listeners
who enjoy arousal will be stimulated by jarring music.
A second mechanism is conditioned response learning.When
music is heard for the first time in an emotional environment
the emotions become connected to the music heard. Later,
when the music is replayed, the emotional feeling is regenerated.
Another mechanism is emotional contagion. The mirror neurons in the brain react by imitating stimuli in the environment.
The tone, frequency or pitch of music will be mirrored by the
listener by eliciting either calm or excitement.
A fourth mechanism through which music stimulates emotions
is visual imagery. Often, while the listener is hearing the music, his
brain conjures up images associated with the sounds he hears.
It is possible for those images to lead to emotions. The images
recalled may or may not be from memory. However, when the
images are from the listener’s episodic memory, a different mechanism provides the emotions associated with the memory.
Finally, momentary surprise or confusion will occur when the
listener anticipates a particular sequence of chords. For example, if a listener hears a C sharp, D sharp, and then E sharp, he
naturally expects the next note to be an F sharp. If the music
breaks the rhythm, the listener is temporarily put off balance
and may be confused. Although this will not lead to emotions
such as joy or sadness, it can cause brief surprise or confusion
(Juslin,Västfjäll, 2008).
Besides for these mechanisms, specific areas of the brain related to emotion are stimulated by music. One area activated
by music is the amygdala. Because the amygdala controls the
processing of emotions, stimulation to that area leads to feeling emotion. Joyful music stimulates the superficial amygdala,
leading to happiness. Both happy and sad music stimulate the
latero-basal amygdala, which is associated with positive and negative reinforcement. This reinforcement can activate the mesolimbic reward system in both musicians and non-musicians
(Koelsch, 2014).
Pleasant music activates the nucleus accumbens and ventral
tegmental area, which controls motivation through reward.
The “reward” feeling is in the form of dopamine being released
into the brain. Performing an action that leads to reward is
enjoyable. Because listening to music stimulates the nucleus
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accumbens and ventral tegmentum which send the dopamine
reward as a response, the listener appreciates the music
(Koelsch, 2014, Schlaug, et al., 2010, Boso, et al., 2006, Menon,
Levitin, 2005, Pereira, et al., 2011). Reward feelings are enjoyable,
and therefore, improve the listener’s mood and affect his emotions. Besides for activating the dopaminergic reward system,
listening to music causes the release of endorphins into the
blood stream. Endorphins reduce pain and stress and can lead
to feelings of happiness (Koelsch, 2014, Herholz, Zatorre, 2012,
Boso, et al., 2006).

Conclusion
Music affects a variety of areas in the brain, including areas that
control cognitive learning, coordination and emotion. Not all
music affects the brain in the same way. Different genres of
music cause different size “hubs” of activation in the auditory
cortex. Similarly, music that the listener likes is processed in a
different way from music that he dislikes. Based on areas of activation in the brain, music therapy can be a useful tool for treating neurological disorders, such as stroke, cerebral palsy, and
fronto-temporal dementia, as well as calming stress. Because
musicians practice playing their instrument, and in general have
more exposure to music, there are distinct differences in the
structural anatomy of a musician’s brain, as opposed to that of
a non-musician. Musicians tend to have a larger anterior corpus
callosum, as well as greater representation of their fingers in
the motor cortex, especially when musical training had been
started at a young age and continued for at least fifteen months.
Because playing an instrument requires complex multitasking,
musicians develop superior multitasking skills, such as the ability
to distinguish between conflicting auditory and visual stimuli.
Additionally, since music affects areas of the brain connected
to learning, people who listen to music or train in music show
higher reading comprehension and math ability compared to
non-listeners and non-musicians. Listening to music can be an
emotional experience, in addition to the learning benefits, because of specific mechanisms associated with emotion which
are stimulated by listening to music, as well as activation in areas
which control underlying emotions, such as the amygdala and
the mesolimbic reward system. Music is more than just sounds
strung together. The effects of music are broad and should continue to be studied to determine the full extent of the benefits.
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Abstract
There is a clear correlation between excessive sun exposure and the development of skin cancer. UVB radiation from the sun
is potent, and as the ozone layer gets depleted, more UVB can reach Earth and cause cell damage. UV radiation causes DNA
lesions, such as 6-4 photoproducts and cyclobutane pyrimidine dimers. Cyclobutane pyrimidine dimers are more abundant and
take longer to be repaired and therefore are responsible for most of the mutation and DNA damage.These DNA lesions lead to
mutation of the p53 gene. The signature mutation on p53 from UV radiation is a CC to TT mutation, which generally occurs at
the binding site of p53. As a result, of the mutation, p53 is inactivated and can no longer perform its tumor suppressive functions.
As a result, cancerous or damaged cells in the skin can proliferate and form tumors. P53 is an early step in skin carcinogenesis,
and p53 mutation is found in abundance in actinic keratosis, a precancerous lesion of Squamous Cell Carcinoma. Experiments
conducted on mice prove the effectiveness of sunscreen. Mice treated with UVB blocking sunscreen had significantly decreased
percentage of mutation, compared to mice without the sunscreen.
Introduction
When summer comes around, it is quite challenging to find a
place to sit at the beach. The sands are covered with people sunbathing and basking in the sunlight. Although it is widely known
that excessive sun exposure directly correlates to the onset of
skin cancer, many people feel that they are immune to the sun’s
harmful rays and therefore will not develop skin cancer. However,
this is not the case, and as they lie there, in denial of the harmful
effects of the sun’s radiation, they are hurting their bodies.Tanning
may cause a more appealing appearance , but in just a few years
the harmful effects can emerge and cause a quite dangerous condition, long after the beauty wears away. Sitting directly in the sun,
especially without sunscreen, is understandably harmful, but what
many people do not realize is that even in cloudy weather eighty
percent of the sun’s rays can penetrate through the clouds and
can still affect the skin (Bowes, 2012). No matter the weather,
spending too much time outdoors without the proper protection
is detrimental to a person’s skin.
In the United States alone there are approximately 500,000
cases of basal cell carcinoma (BCC) and 100,00 to 150,000 cases
if squamous cell carcinoma (SCC) reported every year (Kanjilal
et al., 1995). Sun exposure proves to be the major factor in the
formation of these cancers. Melanoma generally is caused by
short incidents of high intensity ultraviolet (UV) radiation. On
the other hand, BCC and SCC, known as the non-melanoma
skin cancers (NMSC) are generally caused by incidents of exposure to UV radiation which gradually build up. Since NMSC
is a result of the collective UV radiation absorption, it is more
commonly found in older people (Armstrong and Cust, 2017).
Generally skin cancer is more prevalent among fair skinned
people, who have less melanin, pigment, which acts as a barrier
to UV radiation. Moreover, people who live close to the equator
are also at a greater risk for solar UV induced skin cancer, as the
sun’s rays hit Earth most directly at equator.
No matter the skin tone, too much sun exposure can lead
to various issues, such as inflammation, photoaging, erythema,
sunburn, eye damage, DNA damage and skin cancer (Benjamin
et al., 2007). UV radiation causes damage to DNA, specifically
on the p53 gene, a gene with tumor suppressive functions. Once

this gene is mutated, it can no longer act as an anti-oncogene,
and cancerous skin cells can metastasize.

Methods
The research discussed in this paper was obtained from various
published articles from the Touro Library and Google Scholar.
Most of the articles present original information from studies
and experiments of tissue and DNA

Discussion: Ultraviolet Radiation
The electromagnetic spectrum is a range of all forms of light,
based in their frequency and wavelength. Visible light has wavelengths between 400 and 750 nanometers. UV radiation has
shorter wavelengths and therefore higher frequency than visible
light. Wavelengths of UV rays are 100 to 400 nanometers (US
EPA, 2018). UV radiation is divided into 3 categories, UVA, UVB,
and UVC. UVA has wavelengths between 320 to 400 nanometers,
and can penetrate through the ozone layer, a protective layer of
gas that surrounds earth and protects from harmful UV rays. UVB
ranges from 290 to 320 nanometers, and is mostly blocked by the
ozone layer, but some rays do come through the ozone and reach
Earth. UVC ranges from 100 to 290 nanometers, and is almost
entirely blocked by the ozone (Chouinard et al., 2001).
Although UVB is mostly blocked by the ozone, as the stratospheric ozone layer is depleted, UV radiation is more potent
and can raise the instances of skin cancer (Nakazawa et al.,
1994). UVB has been proven to be the major factor to induce
DNA damage, because that specific wavelength can be absorbed
by the nucleotide bases that make up DNA (Ichihashi et al.,
2003).Wavelengths below 290 nanometers usually get absorbed
on the surface of the epidermis, and thus do not cause BCC and
SCC (Radosevich, 2014).
Only ten percent of sunlight is UV radiation, as the rest
comes from visible and infrared light. Of the ten percent, ninety
five percent of it is UVA radiation, and only five percent is UVB
(Bowes, 2012). A little bit of UVB is essential for the production of Vitamin D, however, excessive exposure to it can cause
erythema, cataracts, or skin cancer (Radosevich, 2014). Even
small amounts of UVB exposure can be dangerous if there are
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repeated incidents, as it will affect the cell formation in the skin
by attenuating the basement membrane structure (Chouinard
et al., 2001). The weakened membrane allows the UV radiation
to reach a person’s DNA, specifically that of the p53 gene, a
gene with tumor suppressive functions. Once this gene is mutated, it can no longer act as an anti-oncogene.

Function of p53
The p53 protein is made from a 20 Kb gene on the short arm
of chromosome 17, which codes for a phosphoprotein involved
in transcription and regulation in the cell cycle (Benjamin
and Ananthaswamy, 2007). It has been dubbed the name “the
guardian of the genome” and “the cellular gatekeeper” (Zilfou
and Lowe, 2009). P53 is known this way because of its tumor
suppressive functions. P53 gets activated via phosphorylation
at a serine residue, at either the amino or carboxyl terminus
(Benjamin et al., 2007). Then, it can inhibit the growth of cancerous causing cell cycle arrest, apoptosis, and DNA repair (Ouhtit
et al., 1998). Cell cycle arrest gives the cell the opportunity to
correct DNA complications before the DNA gets replicated.
Since the cell is not continuing mitosis at that point, no new
cells will be formed with the incorrect DNA. On the other
hand, when p53 causes apoptosis, the cancerous cell gets killed
and destroyed, and therefore cannot proliferate and become a
cancerous growth(Benjamin et al., 2007). Moreover, it can preserve the correct form of the DNA (Einspahr et al., 1999). This
is accomplished by “negative growth regulation,” which essentially means that p53 stops cell division and proliferation of cells
with abnormal DNA (Benjamin and Ananthaswamy, 2007).
Mutation of p53 is usually a missense mutation, a mutation
which switches nucleotide in the DNA sequence.Therefore, the
codon in the DNA will code for a different amino acid. Such a
change affects the protein’s function if the mutation results in
an amino acid change in the binding site of the protein, which is
the case in the p53 missense mutations (Einspahr et al., 1999).
When p53 is mutated it loses its ability to act as an anti-oncogene and suppress tumors, so growth of tumors are then able
to grow and form. Tumorigenesis gets inhibited when p53 binds
DNA and triggers a different gene to make p21. Once p21 is
made, it reacts with a cell division stimulating protein(cdk2), and
forms a complex with it. As a result, cdk2 is inactivated and the
cell cannot continue with cell division. By stopping cell division,
the cells cannot multiply and grow to form a tumor. However,
when p53 gets mutated, it can no longer interact with DNA
the same way, so p21 is not produced, cdk2 is not inhibited
and cancerous cells can continue multiplying and form a tumor
(National Center for Biotechnology Information (US), 1998).

UV Damage Adducts: Cyclobutane Pyrimidine
dimers and 6-4 Photoproducts
BCC and SCC are mainly caused by UV radiation(You et al., 2001).
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Studies have shown that 58% of SCC has a mutation on the p53
gene(Benjamin et al., 2007).UVB specifically causes bulky linkages
between pyrimidine dimers(Sarasin and Giglia-Mari, 2002). DNA
is made up of nucleic acid, which is a linear polymer of nucleotides. Each nucleotide contains a ribose sugar, phosphate group
and a nitrogen base.There are four different nitrogen bases found
in DNA: adenine, guanine, cytosine and thymine. Adenine and
guanine have similar ring structures and are classified as purines.
Cytosine (C) and thymine (T) have a similar ring structure (different than that of the purines) and are classified as pyrimidines. A
pyrimidine dimer can form when two pyrimidine nucleotides are
adjacent to each other on a DNA strand.
These pyrimidine dimer linkages can mainly be corrected
by nucleotide excision repair. (Sarasin and Giglia-Mari, 2002).
Nucleotide excision repair can repair UV induced pyrimidine
dimer linkages before DNA replication, or after replication by
using a specific DNA polymerase which corrects DNA. The repair process begins with recognizing the damage on the DNA
.The DNA is then cut on either side of the lesion on a single
strand of DNA, and the damaged area is extracted. Next, the
removed segment is replaced with new nucleotides to recreate
the DNA properly. The process is complete when ligation occurs, and the newly formed DNA segment is linked to rest of
the strand. Two approaches to nucleotide excision repair are
transcription coupled repair, which is done on DNA strands that
are actively transcribed, and global genome repair which occurs
on the non-transcribed strand of DNA. Transcription coupled
repair requires is generally faster than global genome repair in
DNA repair (de Gruijl and Rebel, 2008). Global genome repair
deals with damage recognition and correction of pyrimidine
dimer linkages. The damage recognition stage takes some time,
depending on the effect of the damage on the structure of the
DNA helix, and is the rate limiting aspect in repair, which makes
global genome repair slower than transcription coupled repair
(Ichihashi et al., 2003).The significance of nucleotide excision
repair can be understood by studying patients with Xeroderma
Pigmentosum, a genetic disease in which DNA repair from UV
radiation, nucleotide excision repair, is impaired. Individuals with
this disorder have a much higher rate of developing skin cancer,
since they have more uncorrected pyrimidine dimer linkages
that lead to mutation (de Gruijl and Rebel, 2008). Early growth
of skin cancer is noted in Xeroderma Pigmentosum patients
with a frequency of approximately 4000 more than regular people (Sarasin and Giglia-Mari, 2002).
UVB can cause two types of DNA lesions on the p53 protein,
cyclobutane pyrimidine dimers (CPD) and pyrimidine 6-4 pyrimidone photoproducts (6-4PP). Both of these linkages lead to C
to T or CC to TT mutations, known as “signature mutations,” on
gene p53 in DNA (You et al., 2001). In a study of tissue with
different levels of sun exposure and sun damage, it was noted that
74% of the mutation of p53 occurred at dipyrimidine sites, and
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54% were C to T, or CC to TT mutations (Einspahr et al., 1999).
CPDs are the cause of 80% of the DNA mutations, since 6-4
PP can be repaired more efficiently (You et al., 2001). The repair
of 6-4PP can occur within less than 24 hours of the UV exposure
(de Gruijl and Rebel, 2008). In fact, 56% of keratinocytes corrected the 6-4 PP within 24 hours. Conversely, only 11% of CPDs
were remedied within the first 24 hours after UVB exposure
(Chouinard et al., 2001). CPDs are less effectively repaired and
can lead to mutation of p53 and then skin cancer. Moreover, there
are generally CPDs are 3 to 4 times more commonly formed
than 6-4 PP (de Gruijl and Rebel, 2008). Experimentally it has
been observed that 6-4 PP were formed significantly less often
than CPD overall, and even more rare in experiments with solar
UV simulation.Therefore, in natural sunlight, 6-4 PP are found at a
much lower percentage than CPDs (You et al., 2001).
UVB from sunlight will cause CPD formation, especially at
pyrimidine dimers which have methylated cytosine nucleotides
(You, 2000). A CCG sequence with a methylated cytosine is a
common place for mutation, since a methylated cytosine is less
stable than regular cytosine and can be deaminated easily. The
deamination of a methyl cytosine yields a thymine nucleotide, a
DNA mutation (Sarasin and Giglia-Mari, 2002). CPDs only can
cause mutations to develop after the deamination of a methylcytosine in adduct (You et al., 2001). The CCG sequence codes
for the amino acid arginine, and when the cytosine nucleotide
gets converted to thymine, the sequence now codes for tryptophan. This switch of amino acids is extremely important to
the p53 gene since that arginine is found at p53’s binding site
(Sarasin and Giglia-Mari, 2002). Since arginine and tryptophan
have different side chains they react differently and thus will
affect the binding of p53 to the target DNA. Arginine contains
a second amino group on its side chain, which can act as a base
and get protonated.Tryptophan side chain is two fused aromatic
rings, and the nitrogen in its side chain is an extremely weak
base, as it loses its aromaticity when protonated.Therefore, mutation and transition of the nucleotide at this sequence greatly
affects the function and capabilities of p53.

Mutation of p53 and Carcinogenesis
Genetic mutations of p53 have clear correlations with the
growth of cancer. When p53 is inactivated or mutated, the skin
becomes more vulnerable to carcinogenesis (de Gruijl and
Rebel, 2008). UV radiation provokes the growth of skin tumors,
mostly SCC and BCC(You et al., 2001). Basal cells are on the
bottom layer of the epidermis and rise slowly as new layers
grow beneath them. As a result, these cells stay in the epidermis
the longest, until the rise from the bottom layer until they eventually reach the top and die,Therefore UV damage to these cells
has a long term capability to cause cancer, since they are in the
skin for the longest time (de Gruijl, 2002).
P53 mutation is found in about 50% of all types of cancer. UV

radiation causes specific mutations in p53 which can result in
skin cancer. It causes cancerous growths by stimulating different
growth factors and activating their receptors. Moreover, each
instance of UV exposure helps mutated cells reproduce and
take over healthy epidermal cells, even if it does not induce new
mutations. Although the cell has protective mechanisms against
DNA mutation, UV sometimes can still cause DNA damage.
Buildup of mutations on critical genes leads to carcinogenesis
of the skin. Many mutations of p53 are even noted in normal
looking skin which has been exposed to the sun (Benjamin and
Ananthaswamy, 2007). Most of the mutations found in p53 in
people with skin cancer, prove to have UV radiation as the cause.
Once p53 is mutated, it affects the availability for apoptosis to
occur in keratinocytes, as a response to UV radiation. Apoptosis
is a programmed cell death. In tissues that are constantly renewing, apoptosis is involved in homeostasis , as more cells are
reproducing, others are destroyed through apoptosis. When a
gene which deals with apoptosis is mutated, it can result in too
much growth, since cells are not dying as new cells are being
formed. Moreover, p53 maintains “genomic integrity” by repairing the DNA or causing apoptosis in a cell with mutant DNA.
However, when p53 is mutated, it can no longer function in this
way. In cancer, generally the mutation of p53 occurs further into
the tumorigenic process. In contrast, in NMSC the mutation
in p53 is an early step in carcinogenesis (Einspahr et al., 1999).
Mutated cells have overexpression of the p53 protein and form
“p53 patches.” Most p53 patches had signature UVB damage.The
mutation spectrum observed is quite similar to the mutation
spectrum of SCC. As a result of the damage, the functions of p53,
like apoptosis and cell cycle arrest, are interrupted. Since these
processes generally occur to prevent cancerous growth, UV induced damage which impacts them likely occurs early in cancer
development.Although all p53 have the potential to become SCC,
only a few do actually become cancerous. Approximately 8000 to
40000 p53 patches are around by the time the first tumorous
growth begins (de Gruijl and Rebel, 2008).
UV induced mutations in p53 most likely occur as an early
step in the process of skin carcinogenesis. However in other
cancers, like colon cancer p53 mutations generally occur
later in the development of the cancer, particularly related to
the change from an adenoma to a carcinoma (Benjamin and
Ananthaswamy, 2007). This phase of cancer is much later in the
development as cancer progresses from normal epithelium, to
abnormal epithelium, to a small adenoma, to larger adenoma,
and finally to a carcinoma.
Actinic keratosis (AK) is a precancerous lesion which can lead
to SCC. The frequency of a p53 mutation has been studied with
different conditions of skin. In a particular study, the frequency
of a p53 mutation in SCC was 53.8%, in AK it was 62.5%, in sun
damaged skin it was 38.5%, and in normal skin it was 14.3%.
The mutation is observed to have a higher frequency in skin
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from an AK lesion. This could be because the tissue samples
obtained from AK lesions are closer to the surface of the skin,
and the tissue samples of SCC are deeper in the skin and could
be contaminated from the stromal tissue(Einspahr et al., 1999).
Approximately 89% of the mutations found in AK, were UV
signature mutations. Therefore, it is believed that AK is the
growth of mutated, cancerous cells. Moreover, the UV does not
only cause great increase in reproduction of the mutated cells,
but also causes apoptosis of normal cells in the area of hyperproliferation (Benjamin and Ananthaswamy, 2007). Various studies of skin have found a lot of p53 mutations in BCC and SCC.
Samples of 342 tissues from patients with aggressive and nonaggressive cases of SCC and BCC were studied for p53 changes. In
BCC, 66% of the aggressive cases and 38% of the non-aggressive
cases had p53 changes. In SCC, p53 mutations were observed
in 35% of the aggressive cases and 50% of non-aggressive cases
(Benjamin and Ananthaswamy, 2007).
In a study of eight samples of NMSC, from the head and neck,
7 of the samples (88%) had p53 mutation. Six of the tissues had
at least two amino acid changes as a result of the mutation, which
were mainly at the binding site of p53 (Kanjilal et al., 1995).
In Approximately 38-50% of patients with NMSC, a second
tumor grows within five years of the first one. A patient with
skin cancer needs a lot of medical intervention, surgical procedures, and sometimes radiotherapy (Kanjilal et al., 1995).

Prevention
Since NMSC can be caused by UVB from sunlight, protection
from the sun’s powerful rays would be a great means of prevention. DNA damage and mutation of p53 are the beginning
steps of the development of skin cancer, by preventing them
skin cancer can be prevented as well (El-Deiry, 2007). Sunscreen
can effectively protect the skin from UV induced DNA damage
and p53 mutation, since it can absorb or reflect the harmful
UV rays so they do not penetrate the cells (Radosevich, 2014).
Sunscreens have been proven to protect against DNA damage,
skin aging, sunburn, immunosuppression, and skin carcinogenesis. Although it can be obviously observed that sunscreen prevents erythema and sunburn, experiments and studies must be
conducted to see if it is useful in preventing deeper damage, like
p53 mutation (Benjamin et al., 2007).
The effectiveness of sunscreen in preventing mutations, can
be proven based on a murine experiment. After conducting
experiments to prove that UV radiation causes p53 mutation,
another experiment was conducted to understand if sunscreen
can prevent the p53 mutations from happening. Both sunscreens
used in this experiment had an SPF (sunburn protection factor)
of 15. One sunscreen had only UVB protection, and the other
had protection for UVB as well as protection from UVA. The
mice who had the UVB sunscreen, developed p53 mutations
88% less than mice without sun protection, and those with UVB
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+UVA sunscreen had 92% less mutations. Therefore, this experiment clearly displayed the capability of sunscreen to inhibit p53
mutation. Since p53 mutation is an integral step in carcinogenesis, if mutation is prevented, skin cancer is less likely to develop
(Ananthaswamy, Ullrich and Kripke, 2002).
Another strategic tactic to avoid or delay carcinogenesis is
to minimize sun exposure. Some UV exposure is necessary for
the body, as it plays an important role in the synthesis of vitamin
D , excess exposure can cause skin cancer (Radosevich, 2014).
Studies have proven that p53 patches grow more when exposed
to additional UV exposure. Although reducing UV exposure
cannot eliminate the possibility of skin cancer, it can delay its
progression and development(Benjamin et al., 2007).
The Environmental Protection Agency (EPA) notes that at noon
the sun’s rays are most powerful as they travel the least distance
to reach Earth. Therefore, it would be wise to avoid unnecessary
UV exposure at that time. The EPA also recommends applying
sunscreen, seeking shade when possible, keeping aware the UV
index, and being exceptionally cautious around areas that can reflect the sun’s rays, such as water, snow, and sand (US EPA, 2018).

Conclusion
UVB induced mutation of p53 leads to the development of skin
cancer. UV radiation causes the formation of pyrimidine dimers
on the p53 protein. P53 is an anti-oncogene, which prevents tumorigenesis by causing cell cycle arrest or apoptosis. When p53
is damaged by UV mutation it can longer function and cancerous
basal and squamous cells can proliferate and grow. Cancerous
areas show overexpression of p53 and are referred to as “p53
patches.” These patches will grow more when exposed to more
UV radiation, even if the radiation will not cause a new mutation
to form in that instance. Sunscreen usage and minimization of
sun exposure are affective approaches to prevent UV damage of
p53 and skin carcinogenesis.
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